<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004464.pub3" GROUP_ID="INCONT" ID="705303071514250698" MERGED_FROM="" MODIFIED="2015-08-17 14:30:53 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-08-17 13:59:04 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-08-17 14:30:53 +0100" MODIFIED_BY="Muhammad Imran Omar">
<TITLE>Sacral nerve stimulation for faecal incontinence and constipation in adults</TITLE>
<CONTACT MODIFIED="2015-08-17 14:30:53 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="B871B22482E26AA200CD32E501948933" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Mohamed</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Thaha</LAST_NAME><SUFFIX>PhD, FRCS(Gen Surg), PG Cert Hlt Econ, MBBS</SUFFIX><POSITION>Senior Lecturer &amp; Consultant in Colorectal Surgery</POSITION><EMAIL_1>m.a.thaha@qmul.ac.uk</EMAIL_1><EMAIL_2>mathaha@doctors.org.uk</EMAIL_2><URL>http://www.icms.qmul.ac.uk/centres/digestivediseases/index.html</URL><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building, 2 Newark Street</ADDRESS_1><ADDRESS_2>The Royal London Hospital, Whitechapel</ADDRESS_2><CITY>London</CITY><ZIP>E1 2AT</ZIP><REGION>England</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0044 (0) 207 882 8747 Ext: 8747</PHONE_1><PHONE_2>0044 (0) 207 882 8755</PHONE_2><FAX_1>0044 (0) 207 377 7283</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-08-17 14:30:53 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="B871B22482E26AA200CD32E501948933" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Mohamed</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Thaha</LAST_NAME><SUFFIX>PhD, FRCS(Gen Surg), PG Cert Hlt Econ, MBBS</SUFFIX><POSITION>Senior Lecturer &amp; Consultant in Colorectal Surgery</POSITION><EMAIL_1>m.a.thaha@qmul.ac.uk</EMAIL_1><EMAIL_2>mathaha@doctors.org.uk</EMAIL_2><URL>http://www.icms.qmul.ac.uk/centres/digestivediseases/index.html</URL><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building, 2 Newark Street</ADDRESS_1><ADDRESS_2>The Royal London Hospital, Whitechapel</ADDRESS_2><CITY>London</CITY><ZIP>E1 2AT</ZIP><REGION>England</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0044 (0) 207 882 8747 Ext: 8747</PHONE_1><PHONE_2>0044 (0) 207 882 8755</PHONE_2><FAX_1>0044 (0) 207 377 7283</FAX_1></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="z1401221147514536836646375889454" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Amin</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Abukar</LAST_NAME><POSITION>Research Assistant/Final year medical student</POSITION><EMAIL_1>bt06013@qmul.ac.uk</EMAIL_1><EMAIL_2>amin_abukar@hotmail.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building, 2 Newark Street</ADDRESS_1><CITY>London</CITY><ZIP>E1 2AT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44(0) 20 7882 8747</PHONE_1><FAX_1>44(0) 20 7377 7283</FAX_1></ADDRESS><FOOTNOTE>These authors contributed equally to this work.</FOOTNOTE></PERSON><PERSON ID="z1403121559282337859459658600331" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Noel</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Thin</LAST_NAME><SUFFIX>MBBS</SUFFIX><POSITION>Surgical Registrar</POSITION><EMAIL_1>n.thin@qmul.ac.uk</EMAIL_1><EMAIL_2>noelthin@gmail.com</EMAIL_2><MOBILE_PHONE>07779803291</MOBILE_PHONE><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building</ADDRESS_1><ADDRESS_2>2 Newark Street</ADDRESS_2><CITY>London</CITY><ZIP>E1 2AT</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1403121645529671355049229055686" ROLE="AUTHOR"><FIRST_NAME>Anthony</FIRST_NAME><LAST_NAME>Ramsanahie</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Laparoscopic Colorectal Fellow</POSITION><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building</ADDRESS_1><ADDRESS_2>2 Newark Street</ADDRESS_2><CITY>London</CITY><ZIP>E1 2AT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0044 (0) 207 882 8747 Ext: 8747</PHONE_1></ADDRESS></PERSON><PERSON ID="z1403121655008927312821385006861" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Charles</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Knowles</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Professor of Surgical Research and Hon Consultant Colorectal Surgeon</POSITION><EMAIL_1>c.h.knowles@qmul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Surgical Unit, National Centre for Bowel Research &amp; Surgical Innovation, Centre for Digestive Diseases, Blizard Institute</DEPARTMENT><ORGANISATION>Barts &amp; The London School of Medicine &amp; Dentistry, Queen Mary University London</ORGANISATION><ADDRESS_1>1st Floor, Abernethy Building</ADDRESS_1><ADDRESS_2>2 Newark Street</ADDRESS_2><CITY>London</CITY><ZIP>E1 2AT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0207 882 8757</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-07-21 13:32:12 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="2" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="2" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="2" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-17 13:52:31 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-08-17 13:52:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Five new trials were added in this update (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>;<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>). Risk of bias assessment was redone of all included trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-08-17 13:52:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Five new trials were added in this update (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>;<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>). Risk of bias assessment was redone of all included trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-11-07 15:43:55 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-11-07 15:43:55 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-22 14:58:18 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-08-17 13:46:48 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-08-17 13:46:48 +0100" MODIFIED_BY="[Empty name]"/>
<EXTERNAL_SOURCES MODIFIED="2015-07-21 13:42:29 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-07-21 13:42:29 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to the Incontinence Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-08-17 13:59:04 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-08-17 13:58:55 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Sacral nerve stimulation for treating faecal incontinence and constipation in adults</TITLE>
<SUMMARY_BODY MODIFIED="2015-08-17 13:58:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Importance of the review/Background: </B>Faecal incontinence occurs when a person passes stools without the usual control. Constipation is harder to define but generally describes a situation in which a person feels that their bowel opening is unsatisfactory (usually a combination of difficulty or infrequency of passing stools). Both conditions can severely affect people's quality of life. There are many non-surgical treatments for both conditions but occasionally surgery is required when other options fail. Sacral nerve stimulation (SNS) is a relatively new treatment for these conditions. It involves implanting a battery-powered stimulator unit in the buttock. This is connected to electrodes which rest on the nerves in the lower spine. The stimulator then continuously sends impulses to the nerves and muscles that control the bowel and anus. Initially, a temporary electrode lead is connected to a portable battery unit outside the body. If symptoms are improved enough, this is replaced by the implanted battery.</P>
<P>
<B>Main findings: </B>This review evaluated the published evidence for the use of SNS for patients with faecal incontinence or constipation from six trials of SNS for faecal incontinence (219 participants) and two trials of SNS for constipation (61 participants). Two of the faecal incontinence trials had a 'parallel group design', which means that one group of participants received SNS and the other control group did not receive SNS throughout the trial. The remaining six trials had a 'crossover design', in which the participants experienced equal periods with stimulation 'off' then 'on', or vice versa. The level of stimulation was such that participants could not tell whether the system was 'on' or 'off'.</P>
<P>
<B>SNS for faecal incontinence: </B>In the two 'parallel group' trials, 53 and 15 participants with faecal incontinence who were in the SNS group experienced fewer episodes of faecal incontinence compared to the control group at 3 and 12 months. In the first crossover trial, 24 participants who completed the trial chose the period of stimulation they had preferred while still unaware whether this was 'on' or 'off'. Nineteen participants who preferred the 'on' period experienced 59% fewer episodes of FI per week during the 'on' period, and 5 participants who preferred the 'off' period experienced 118% more episodes of FI per week. In the second crossover trial, the participants did not experience episodes of FI during either the 'on' or the 'off' periods. In the third trial, participants experienced 83% fewer episodes of faecal incontinence during the 'on' compared with the 'off' period. In the fourth crossover trial participants experienced 88% fewer episodes of faecal incontinence during the 'on' period compared with the 'off' period.</P>
<P>
<B>SNS for faecal incontinence</B>&#8212;<B>adverse effects:</B> Not all trials reported adverse effects after SNS. The two 'parallel group' trials reported only minor complications, in 10% of SNS participants in the first study, and in 3 participants in the second study. In the first crossover study 7 out of 34 participants were excluded from crossover due mainly to complications. Four out of 27 participants with an implanted system in this study experienced a problem that led to the device being removed. The participants in the fourth crossover trial experienced some complications with the SNS implanted electrode such as pain (one person), misplacement of the tined lead (one person) and haematoma (swelling containing blood) (three people).</P>
<P>
<B>SNS for constipation: </B>In one trial assessing SNS for constipation, two participants reported an increase of 150% in the frequency of passing stools per week, and time with abdominal pain and swelling went down from 79% during the 'off' period to 33% during the 'on' period. However, in the much larger second trial assessing SNS for constipation, in 59 participants SNS did not improve frequency of bowel movements.</P>
<P>
<B>Limitations of the review: </B>The limited evidence suggests that SNS can improve continence in some people with faecal incontinence. SNS did not improve symptoms in patients with constipation. Larger, good-quality trials are needed to provide more reliable evidence on the effectiveness of SNS for these two conditions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-08-14 15:51:47 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-07-10 10:06:27 +0100" MODIFIED_BY="[Empty name]">
<P>Faecal incontinence (FI) and constipation are both socially-embarrassing and physically-disabling conditions that impair quality of life. For both, surgery may be required in a minority of people when more conservative measures fail. However, the invasiveness and irreversible nature of direct surgery on bowel and sphincter muscles, poor long-term outcomes and well-established compIications makes such procedures unappealing for these benign conditions. A less-invasive surgical option to treat faecal incontinence and constipation is direct, low-voltage stimulation of the sacral nerve roots, termed sacral nerve stimulation (SNS). SNS has become the first line surgical treatment for FI in people failing conservative therapies. Its value in the treatment of constipation is less clear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-08-14 15:50:03 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-08-14 15:50:08 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, ClinicalTrials.gov, the World Health Organization (WHO) ICTRP and handsearched journals and conference proceedings (searched 5 February 2015), EMBASE (1 January 1947 to 2015 Week 5), and the reference lists of retrieved relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-randomised trials assessing the effects of SNS for faecal incontinence or constipation in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-08-10 20:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened the search results, assessed the methodological quality of the included trials, and undertook data extraction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-08-14 15:51:47 +0100" MODIFIED_BY="[Empty name]">
<P>Six crossover trials and two parallel group trials were included.</P>
<P>Six trials assessed the effects of SNS for FI. In the parallel group trial conducted by Tjandra, 53 participants with severe FI in the SNS group experienced fewer episodes of faecal incontinence compared to the control group who received optimal medical therapy (mean difference (MD) &#8722;5.20, 95% confidence interval (CI) &#8722;9.15 to &#8722;1.25 at 3 months; MD &#8722;6.30, 95% CI &#8722;10.34 to &#8722;2.26 at 12 months). Adverse events were reported in a proportion of participants: pain at implant site (6%), seroma (2%) and excessive tingling in the vaginal region (9%).</P>
<P>In the parallel group trial carried out by Thin, 15 participants with FI in the SNS group experienced fewer episodes of FI compared with the percutaneous tibial nerve stimulation (PTNS) group (MD &#8722;3.00, 95% CI &#8722;6.61 to 0.61 at 3 months; MD &#8722;3.20, 95% CI &#8722;7.14 to 0.74 at 12 months). Adverse events were reported in three participants: mild ipsilateral leg pain during temporary testing (n = 1); and stimulator-site pain following insertion of neurostimulator (n = 2).</P>
<P>In the crossover trial by Leroi 7 of 34 recruited participants were excluded from the crossover due mainly to complications or immediate device failure. Twenty-four of the remaining 27 participants while still blinded chose the period of stimulation they had preferred. Outcomes were reported separately for 19 participants who preferred the 'on' and five who preferred the 'off' period. For the group of 19, the median (range) episodes of faecal incontinence per week fell from 1.7 (0 to 9) during the 'off' period to 0.7 (0 to 5) during the 'on' period; for the group of five, however, the median (range) rose from 1.7 (0 to 11) during the 'off' period compared with 3.7 (0 to 11) during the 'on' period. Four of 27 participants experienced an adverse event resulting in removal of the stimulator.</P>
<P>In the crossover trial by Sørensen and colleagues, participants did not experience any FI episodes in either the one-week &#8216;on&#8217; or &#8216;off&#8217; periods.</P>
<P>In the crossover trial by Vaizey, participants reported an average of six, and one, episodes of faecal incontinence per week during the 'off' and 'on' periods respectively in two participants with FI. Neither study reported adverse events.</P>
<P>In the crossover trial by Kahlke, 14 participants with FI experienced significantly lower episodes of FI per week during the stimulator 'on' (1 (SD, 1.7)) compared with the 'off' period (8.4 (SD, 8.7)). Adverse events reported include: haematoma formation (n = 3); misplacement of tined lead (1); and pain at stimulator site (n = 1).</P>
<P>Two trials assessed SNS for constipation. In the Kenefick trial, the two participants experienced an average of two bowel movements per week during the 'off' crossover period, compared with five during the 'on' period. Abdominal pain and bloating occurred 79% of the time during the 'off' period compared with 33% during the 'on' period. No adverse events occurred. In contrast, in the trial by Dinning with 59 participants, SNS did not improve frequency of bowel movements and 73 adverse events were reported, which included pain at site of the implanted pulse generator (32), wound infection (12), and urological (17) events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-05-19 12:48:45 +0100" MODIFIED_BY="[Empty name]">
<P>The limited evidence from the included trials suggests that SNS can improve continence in a proportion of patients with faecal incontinence. However, SNS did not improve symptoms in patients with constipation. In addition, adverse events occurred in some patients where these were reported. Rigorous high quality randomised trials are needed to allow the effects of SNS for these conditions to be assessed with more certainty.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-08-17 13:59:04 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-08-14 15:53:57 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-08-14 15:53:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-07-04 18:12:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;W&lt;/span&gt;&lt;span modified=&quot;2015-07-04 18:13:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;e would prefer to keep the original sentence where the details of these new interventions are given in the cited reference rather than part of the text for better flow of the sentence. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2015-07-04 18:13:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;If that is not acceptable, I've added the interventions in the text.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-08-14 15:53:31 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>The act of defaecation is dependent on the co-ordinated functions of the colon, rectum and anus. Considering the complexity of neuromuscular (sensory and motor) functions required to achieve planned, conscious, and effective defaecation (<LINK REF="REF-Scott-2011" TYPE="REFERENCE">Scott 2011</LINK>), it is no surprise that disturbances to perceived &#8216;normal&#8217; function occur commonly at all stages of life. Clinically, such problems principally encompass presentations with faecal incontinence or constipation. Although usually described separately (as in this review), it should be noted that considerable overlap between these symptoms occurs at all ages of presentation (<LINK REF="REF-Burgell-2012" TYPE="REFERENCE">Burgell 2012</LINK>; <LINK REF="REF-Rao-2004a" TYPE="REFERENCE">Rao 2004a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Faecal incontinence</HEADING>
<P>Faecal incontinence (FI) is a socially-embarrassing and physically-disabling condition. It may be defined as the uncontrolled loss of faeces (liquid or solid) from the bowel. It may occur passively (without the person affected being aware of passing faeces); or be preceded by urgency (a sense of an urgent need to defaecate); or both, commonly termed 'mixed faecal incontinence'. A further term&#8212;&#8216;post-defaecatory seepage or leakage&#8217;&#8212;is also sometimes used to denote passive loss of small amounts of faeces retained after incomplete evacuation (<LINK REF="REF-Rao-2004b" TYPE="REFERENCE">Rao 2004b</LINK>).</P>
<P>Faecal incontinence is a common problem, although the true prevalence is hard to determine due to under-reporting (<LINK REF="REF-Johanson-1996" TYPE="REFERENCE">Johanson 1996</LINK>; <LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). US population surveys suggest the prevalence of FI ranges anywhere from 2% to 17% affecting both men and women (<LINK REF="REF-Nelson-2004" TYPE="REFERENCE">Nelson 2004</LINK>; <LINK REF="REF-Peery-2012" TYPE="REFERENCE">Peery 2012</LINK>; <LINK REF="REF-Whitehead-2009" TYPE="REFERENCE">Whitehead 2009</LINK>). In the UK, it is estimated that up to 10% of adults experience involuntary loss of solid or liquid stool causing physical, psychological and social disability; 0.5% to 1% of adults experience regular faecal incontinence that severely affects their quality of life (<LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>; <LINK REF="REF-Norton-2007" TYPE="REFERENCE">Norton 2007</LINK>). Although awareness of the health burden from faecal incontinence has increased in recent years, it still largely remains a taboo problem (<LINK REF="REF-Johanson-1996" TYPE="REFERENCE">Johanson 1996</LINK>). Considering the higher prevalence with advancing age (<LINK REF="REF-Brown-2010" TYPE="REFERENCE">Brown 2010</LINK>), FI may be an even greater problem in the future. The prevalence of FI approaches 50% in nursing homes (<LINK REF="REF-Nelson-1998" TYPE="REFERENCE">Nelson 1998</LINK>).</P>
<P>Faecal incontinence may result from:</P>
<UL>
<LI>damage to the anal sphincter mechanism (either from direct trauma or damage to its nerve supply);</LI>
<LI>age-related degeneration of the sphincter;</LI>
<LI>spinal injury;</LI>
<LI>other neurological causes; or</LI>
<LI>non-sphincter causes (e.g. diarrhoea, dementia) (<LINK REF="REF-Lunniss-2004" TYPE="REFERENCE">Lunniss 2004</LINK>).</LI>
</UL>
<P>The well-documented association between FI and birth injuries has led to the belief that pudendal nerve injury or direct damage to the anal sphincter complex is the main pathophysiology (<LINK REF="REF-Sultan-1993" TYPE="REFERENCE">Sultan 1993</LINK>; <LINK REF="REF-Sultan-1997a" TYPE="REFERENCE">Sultan 1997a</LINK>; <LINK REF="REF-Sultan-1997b" TYPE="REFERENCE">Sultan 1997b</LINK>). In truth, most FI is caused by a complex interplay of pathophysiological factors including aberrant anorectal sensation and colorectal motility, as well as structural changes or damage to the pelvic floor and sphincter complex. Indeed, women who sustain obstetric trauma often do not present with symptoms of FI until up to 30 years postpartum (<LINK REF="REF-Lunniss-2004" TYPE="REFERENCE">Lunniss 2004</LINK>; <LINK REF="REF-Rao-2004a" TYPE="REFERENCE">Rao 2004a</LINK>).</P>
<P>With such aetiological and pathophysiological heterogeneity, FI remains a challenging condition to directly address by any single treatment. Conservative measures include:</P>
<UL>
<LI>dietary modification;</LI>
<LI>bowel retraining;</LI>
<LI>anti-diarrhoeal medication (<LINK REF="REF-Ehrenpreis-2007" TYPE="REFERENCE">Ehrenpreis 2007</LINK>; <LINK REF="REF-Omar-2013" TYPE="REFERENCE">Omar 2013</LINK>);</LI>
<LI>biofeedback (<LINK REF="REF-Enck-2009" TYPE="REFERENCE">Enck 2009</LINK>; <LINK REF="REF-Norton-2003" TYPE="REFERENCE">Norton 2003</LINK>; <LINK REF="REF-Norton-2004" TYPE="REFERENCE">Norton 2004</LINK>); and</LI>
<LI>supportive devices such as absorbent padding or plugs.</LI>
</UL>
<P>However, such measures have, at best, a lasting success in only approximately 50% of patients (<LINK REF="REF-Otto-2010" TYPE="REFERENCE">Otto 2010</LINK>); thus surgical treatment is often considered. The latter may include:</P>
<UL>
<LI>bulking agents (<LINK REF="REF-Graf-2011" TYPE="REFERENCE">Graf 2011</LINK>);</LI>
<LI>direct anal sphincter repair (<LINK REF="REF-Malouf-2000" TYPE="REFERENCE">Malouf 2000</LINK>);</LI>
<LI>artificial bowel sphincter (<LINK REF="REF-Altomare-2004" TYPE="REFERENCE">Altomare 2004</LINK>); and</LI>
<LI>dynamic graciloplasty (<LINK REF="REF-Baeten-1991" TYPE="REFERENCE">Baeten 1991</LINK>).</LI>
</UL>
<P>All of these operations have well-established complications and high long-term failure rates (<LINK REF="REF-Altomare-2004" TYPE="REFERENCE">Altomare 2004</LINK>; <LINK REF="REF-Malouf-2000" TYPE="REFERENCE">Malouf 2000</LINK>). While several newer treatments, such as autologous muscle cell therapy, magnetic sphincter augmentation and sphincter bulking agents, are at an early clinical evaluation stage (<LINK REF="REF-Carr-2013" TYPE="REFERENCE">Carr 2013</LINK>; <LINK REF="REF-Lehur-2010" TYPE="REFERENCE">Lehur 2010</LINK>; <LINK REF="REF-Ratto-2011" TYPE="REFERENCE">Ratto 2011</LINK>), many patients may still resort to a stoma (usually colostomy) for significant intractable symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Constipation</HEADING>
<P>Constipation is common in adults and children and up to 20% of the population report this symptom depending on definitions used (2% to 28% adults; 0.7% to 30% children) (<LINK REF="REF-Sonnenberg-1989" TYPE="REFERENCE">Sonnenberg 1989</LINK>; <LINK REF="REF-Stewart-1999" TYPE="REFERENCE">Stewart 1999</LINK>; <LINK REF="REF-van-den-Berg-2006" TYPE="REFERENCE">van den Berg 2006</LINK>), with a higher prevalence in women (<LINK REF="REF-McCrea-2009" TYPE="REFERENCE">McCrea 2009</LINK>; <LINK REF="REF-Mugie-2011" TYPE="REFERENCE">Mugie 2011</LINK>; <LINK REF="REF-Sonnenberg-1989" TYPE="REFERENCE">Sonnenberg 1989</LINK>), and the elderly (<LINK REF="REF-Gallegos_x002d_Orozco-2012" TYPE="REFERENCE">Gallegos-Orozco 2012</LINK>; <LINK REF="REF-Norton-2006" TYPE="REFERENCE">Norton 2006</LINK>). Chronic constipation (CC), usually defined as more than six months of symptoms, is less common (<LINK REF="REF-Probert-1995" TYPE="REFERENCE">Probert 1995</LINK>), but results in half a million UK GP consultations per annum. A proportion of the population suffer symptoms which are both chronic and more disabling (probably about 1% to 2% of the population) (<LINK REF="REF-Cook-2009" TYPE="REFERENCE">Cook 2009</LINK>). Such patients, who are most often female (<LINK REF="REF-Knowles-2003" TYPE="REFERENCE">Knowles 2003</LINK>), are usually referred to secondary care with many progressing to tertiary specialist investigation. Patient dissatisfaction is high in this group: nearly 80% feel that laxative therapy is unsatisfactory (<LINK REF="REF-Wald-2008" TYPE="REFERENCE">Wald 2008</LINK>), and the effect of symptoms on measured QOL is significant (<LINK REF="REF-Irvine-2002" TYPE="REFERENCE">Irvine 2002</LINK>). Chronic constipation consumes significant healthcare resources: in the US in 2012, a primary complaint of constipation was responsible for 3.2 million physician visits (<LINK REF="REF-Peery-2012" TYPE="REFERENCE">Peery 2012</LINK>), resulting in (direct and indirect) costs of $1.7 billion. In the UK, it is estimated that 10% of district nursing time is spent on constipation (<LINK REF="REF-Poulton-1999" TYPE="REFERENCE">Poulton 1999</LINK>), and the annual spend on laxatives exceeds £80 million, with £17.4 million prescribed in 2012 (<LINK REF="REF-HSCIC-2013" TYPE="REFERENCE">HSCIC 2013</LINK>).</P>
<P>Management of chronic constipation is a major problem due to its high prevalence and lack of widespread specialist expertise. In general, a step-wise approach is undertaken, with first-line conservative treatment such as lifestyle advice and laxatives (<LINK REF="REF-NHS-2012" TYPE="REFERENCE">NHS 2012</LINK>), followed by nurse-led bowel retraining programs, often including focused biofeedback (<LINK REF="REF-Woodward-2014" TYPE="REFERENCE">Woodward 2014</LINK>), and psychosocial support. Although these treatments may improve symptoms in more than half of patients, they are very poorly standardised and are not universally successful. While some hope has been offered by a range of new prokinetic and pro-secretory drugs (<LINK REF="REF-Camilleri-2008" TYPE="REFERENCE">Camilleri 2008</LINK>; <LINK REF="REF-Johanson-2008" TYPE="REFERENCE">Johanson 2008</LINK>), patients with intractable symptoms and impaired QOL may be offered a range of costly, irreversible surgical interventions with unpredictable results (<LINK REF="REF-Knowles-1999" TYPE="REFERENCE">Knowles 1999</LINK>; <LINK REF="REF-Knowles-2009" TYPE="REFERENCE">Knowles 2009</LINK>), sometimes resulting in major adverse events or a permanent stoma.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-08-14 15:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Neuromodulation is one of the fastest growing areas of medicine and may be defined as a technology that impacts upon neural interfaces to produce benefit. The concept of electrical stimulation of the pelvic floor may be traced back to the early 19<SUP>th</SUP> century with several methods of direct neuromuscular stimulation developed subsequently (<LINK REF="REF-Hopkinson-1966" TYPE="REFERENCE">Hopkinson 1966</LINK>). In the last 20 years, a group of treatments have been developed that employ chronic, low-voltage electrical stimulation to recruit residual function of pelvic organs by direct or indirect stimulation of the sacral spinal nerves (<LINK REF="REF-Matzel-1995" TYPE="REFERENCE">Matzel 1995</LINK>; <LINK REF="REF-Matzel-1990" TYPE="REFERENCE">Matzel 1990</LINK>). Such developments, which in general have evolved from the urology field (<LINK REF="REF-Brindley-1974" TYPE="REFERENCE">Brindley 1974</LINK>; <LINK REF="REF-Tanagho-1989" TYPE="REFERENCE">Tanagho 1989</LINK>), have the potential to bridge the gap between conservative treatments and potentially hazardous direct surgery to the bowel or anal sphincter. An attraction of these treatments is that, unlike direct surgery to the sphincter or colon, they have the potential to modify all aspects of the co-ordinated neuromuscular functions required for defaecation (<LINK REF="REF-Carrington-2011" TYPE="REFERENCE">Carrington 2011</LINK>), and on this basis may benefit both FI and chronic constipation. Further, neuromodulation has the intrinsic qualities of dose variation and reversibility which are rarely possible with other surgical therapies. The most established of these treatments is Sacral Nerve Stimulation (SNS).</P>
<P>SNS involves direct, chronic, low-voltage electrical stimulation of the sacral nerve roots by the siting of an electrode via a sacral foramen (S3 is the optimal site for most patients). Whilst there has been an evolution of systems over time (<LINK REF="REF-MacDonagh-1990" TYPE="REFERENCE">MacDonagh 1990</LINK>; <LINK REF="REF-Matzel-1990" TYPE="REFERENCE">Matzel 1990</LINK>), in its most common current form SNS utilises a percutaneously-sited, commercially-manufactured quadripolar electrode lead system connected to an implanted pulse generator (InterStim® Therapy, Medtronic, Inc., Minneapolis, US) buried in the subcutaneous fat of the buttock. The Medtronic system also allows for a temporary percutaneous nerve evaluation (PNE) phase which allows the patient to trial the impact of sacral nerve stimulation on their lifestyle and test the feasibility of success before the more expensive permanent stimulator is implanted.</P>
<P>SNS techniques are well described in the literature, with agreement that this can be carried out effectively and safely under both general anaesthetic, and local anaesthetic with or without sedation (<LINK REF="REF-Mitchell-2011" TYPE="REFERENCE">Mitchell 2011</LINK>); with minimal reported morbidity (overall complications rates of 5% to 26% (<LINK REF="REF-Tjandra-2004" TYPE="REFERENCE">Tjandra 2004</LINK>)); and no reported mortality (<LINK REF="REF-Wong-2011" TYPE="REFERENCE">Wong 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-08-14 15:53:47 +0100" MODIFIED_BY="[Empty name]">
<P>Understanding of the mechanism of action of SNS is universally acknowledged to be an important knowledge gap limiting potential for patient selection, technology and procedural optimisation that could focus therapy, improve outcomes and reduce healthcare costs (<LINK REF="REF-Carrington-2014" TYPE="REFERENCE">Carrington 2014</LINK>). Traditional understanding of the pathophysiology and surgical management of FI held that sphincter &#8216;barrier&#8217; had primacy. It is now clear that whilst sphincter disruption (resulting from, for example, obstetric injuries) is still relevant to the development of FI, it is only one factor in complex defaecatory dysfunction that involves alteration in unconscious anorectal and pelvic reflexes and conscious modulation by the central nervous system.</P>
<P>The importance of sensory dysfunction on both urinary and bowel control is being increasingly appreciated and there is strong evolving evidence (in man (<LINK REF="STD-Knowles-2012" TYPE="STUDY">Knowles 2012</LINK>); and experimental animals (<LINK REF="REF-Evers-2014" TYPE="REFERENCE">Evers 2014</LINK>; <LINK REF="REF-Griffin-2011" TYPE="REFERENCE">Griffin 2011</LINK>)) that the mechanism of action of SNS results primarily from modulation of afferent nerve activity rather than motor effects on the anal sphincter itself (<LINK REF="REF-Carrington-2014" TYPE="REFERENCE">Carrington 2014</LINK>; <LINK REF="REF-Duelund_x002d_Jakobsen-2013" TYPE="REFERENCE">Duelund-Jakobsen 2013</LINK>; <LINK REF="REF-Patton-2013" TYPE="REFERENCE">Patton 2013</LINK>). The effects of SNS on colonic motor activity have also been studied. Data suggest that SNS, but not sham stimulation, increased the frequency of retrograde propagated sequences throughout the colon in participants with FI (<LINK REF="REF-Patton-2013" TYPE="REFERENCE">Patton 2013</LINK>) i.e. effects anticipated to delay colonic transit. In contrast SNS also increased colonic propagating sequences in participants with slow-transit constipation (<LINK REF="REF-Dinning-2012" TYPE="REFERENCE">Dinning 2012</LINK>). This disparity of effect may reflect baseline differences of colonic motor activity, however further study is required to explain these seemingly counter-intuitive findings.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-08-14 15:53:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;i&gt;&lt;span class=&quot;marker&quot;&gt;Yes, we wish to keep that sentence as it is. &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;span class=&quot;marker&quot;&gt;Although rare, occasionally in intractable cases one has to consider segmental colectomy and very rarely even total colectomy, the good old Arbuthnots total colectomy. In addition, for complex cases depending on the predominance of aetiology serveral options of pelvic floor surgery could beconsidered either alone or in combination with other treatment)&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-08-14 15:53:57 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>SNS is now considered the first-line surgical intervention for people with FI for whom conservative treatments have failed (<LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). Over 100 published case series (of over 2000 participants), including some quite large prospective studies (<LINK REF="REF-Melenhorst-2007" TYPE="REFERENCE">Melenhorst 2007</LINK>; <LINK REF="REF-Wexner-2010" TYPE="REFERENCE">Wexner 2010</LINK>), attest to the general success of this approach, and SNS has regulatory approval in most major health systems (<LINK REF="REF-NHS-2013" TYPE="REFERENCE">NHS 2013</LINK>; <LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). Recent systematic review data show favourable mid- and long-term positive outcomes for SNS of approximately 80% based on a greater than 50% reduction in FI episodes, although this figure is reduced to approximately 60% when results are reanalysed using all available participants who start therapy as the denominator (comparable with intention-to-treat principles) (<LINK REF="REF-Thin-2013" TYPE="REFERENCE">Thin 2013</LINK>).</P>
<P>In comparison with FI, the role of SNS in treating chronic constipation is less well established. However, it carries the same attractions: namely the avoidance of potentially hazardous direct surgery to the colon or pelvic floor. Unfortunately, favourable results of a European experience of SNS on 62 participants (63% successful) with chronic constipation, (of mixed or specific pathophysiology (<LINK REF="REF-Kamm-2010" TYPE="REFERENCE">Kamm 2010</LINK> and <LINK REF="STD-Knowles-2012" TYPE="STUDY">Knowles 2012</LINK> respectively)) have not been replicated by others (<LINK REF="REF-Holzer-2008" TYPE="REFERENCE">Holzer 2008</LINK>; <LINK REF="REF-Maeda-2010" TYPE="REFERENCE">Maeda 2010</LINK>; <LINK REF="REF-Vitton-2009" TYPE="REFERENCE">Vitton 2009</LINK>). On this basis SNS has not yet, in general, been commissioned as a treatment for constipation in most health systems.</P>
<P>Despite the implicit advantages and reported success of SNS over the last 20 years (especially for FI), one major drawback remains: the initial costs of SNS are still considerable both in terms of direct equipment cost and indirect hospital admission costs (<LINK REF="REF-Dudding-2008" TYPE="REFERENCE">Dudding 2008</LINK>). On this basis, health practitioners need to be reassured of the efficacy of SNS therapy. This systematic review updates the available evidence from randomised controlled trials.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-08-14 15:53:59 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation in adults.</P>
<P>The following comparisons were made:</P>
<OL>
<LI>Sacral nerve stimulation (implanted) versus control or sham stimulation</LI>
<LI>Sacral nerve stimulation (implanted) versus another active treatment</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2015-08-14 15:54:17 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-08-14 15:54:08 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-08-14 15:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised, quasi-randomised and crossover trials. Crossover trials have been identified with the suffix '#'.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-10 21:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with faecal incontinence or constipation, including functional, structural and neurological causes. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-08-14 15:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>One arm of the trial had to use a surgically implanted device to provide sacral nerve stimulation.</P>
<P>Comparators considered included:</P>
<OL>
<LI>mock, sham or placebo treatment; and</LI>
<LI>any alternative active intervention considered appropriate by the trialists, such as dynamic graciloplasty, artificial bowel sphincter implants, stoma formation, absorbent pads, anal plugs, and physical or behavioural therapies.</LI>
</OL>
<P>Trials in which both arms used active implanted sacral nerve stimulation were not included in this review. Newer treatment modalities including magnetic and transcutaneous stimulation were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-08-14 15:54:08 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-12-11 09:34:32 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence</HEADING>
<P>The primary outcomes were: (a) cure or improvement of incontinence; and (b) quality of life. Outcomes were considered in the following categories:</P>
<P>(1) Faecal incontinence (number cured or improved, episodes of faecal incontinence, urgency, ability to defer defaecation, use of pads, use of anal plugs, incontinence score, and need for further treatment such as medication or surgery).</P>
<P>(2) Quality of life (generic and condition-specific).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Constipation</HEADING>
<P>The primary outcomes were: (a) cure or improvement of constipation; and (b) quality of life. Outcomes were considered in the following categories:</P>
<P>(1) Constipation (number cured or improved, frequency of bowel movements, abdominal pain/bloating, constipation score, and need for further treatment such as medication or surgery).</P>
<P>(2) Quality of life (generic and condition-specific).</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-08-14 15:54:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence</HEADING>
<P>Outcomes were considered in the following categories:</P>
<P>(1) Surrogate measures, such as anorectal manometry (resting pressure, maximum squeeze pressure, rectal sensory threshold to balloon distention, sensation of urgency to balloon distention, and maximum tolerated rectal volume to balloon distention).</P>
<P>(2) Adverse effects (infection or pain or both at the implantation site; displacement of the electrodes; technical failure requiring removal or change in urinary function, or both).</P>
<P>(3) Health economics (costs, resource implications and cost-effectiveness or cost utility evaluation).</P>
<P>(4) Other outcomes (other outcome measures quoted by trial authors and judged to be important by the authors of this review).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Constipation</HEADING>
<P>Outcomes were considered in the following categories:</P>
<P>(1) Surrogate measures, such as anorectal manometry (resting pressure, maximum squeeze pressure, rectal sensory threshold to balloon distention, sensation of urgency to balloon distention, and maximum tolerated rectal volume to balloon distention).</P>
<P>(2) Adverse effects (infection or pain or both at the implantation site; displacement of the electrodes; technical failure requiring removal or change in urinary function, or both).</P>
<P>(3) Health economics (costs, resource implications, and cost-effectiveness or cost utility evaluation).</P>
<P>(4) Other outcomes (other outcome measures quoted by trial authors and judged to be important by the authors of this review).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-08-14 15:54:10 +0100" MODIFIED_BY="[Empty name]">
<P>We did not impose any language or other limitations on the searches described below.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-08-14 15:54:10 +0100" MODIFIED_BY="[Empty name]">
<P>This review drew on the search strategy developed for the Incontinence Group as a whole. Relevant trials were identified from the Cochrane Incontinence Group Specialised Trials Register. The methods used to derive this, including the search strategy, are described under the Group's <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/INCONT/frame.html">module</A> in the Cochrane Library. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, ClinicalTrials.gov, WHO ICTRP and hand searching of journals and conference proceedings.<BR/>The Incontinence Group Specialised Register was searched using the Group's own keyword system; the search terms used are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Date of the most recent search of the register for this review: 5 February 2015.</P>
<P>The majority of the trials in the Incontinence Group's Specialised Register are also contained in CENTRAL.</P>
<P>Also Embase (1 January 1947 to 2015 Week 5) was searched on 5 February 2015 using the search strategy given in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. Only the years 2010 to 2015 (inclusive) were searched as these years were not covered by the Cochrane Collaboration's centralised search of Embase for CENTRAL at this time.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-03-03 23:28:27 +0000" MODIFIED_BY="Amin A Abukar">
<P>All reference lists of identified trials were searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-08-14 15:54:17 +0100" MODIFIED_BY="[Empty name]">
<P>Analyses of crossover trials were based on data available from included relevant trials. Meta-analysis could not be performed because of variation in reported outcomes.</P>
<STUDY_SELECTION MODIFIED="2015-05-07 10:00:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2015-04-26 09:33:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Not sure wh&lt;/span&gt;&lt;span modified=&quot;2015-04-26 09:34:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;y this yellow highlighting is for?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-05-07 10:00:58 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, MAT) independently evaluated reports of all potentially eligible studies for inclusion. Any disagreements were resolved by discussion or arbitration by the review group at consensus meetings.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-08-14 15:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, MAT) independently undertook data extraction for the five new trials that were added (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>); and checked and updated the information from the previously included trials, in particular 'Risk of bias' assessment. We planned to seek clarification from the trialists where data were collected but not reported, or reported in a form unsuitable for the review. Included data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (http://www.cochrane.org/resources/handbook/hbook.htm) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreements were resolved by discussion or arbitration by the review authors. Data from crossover were entered into Other Data Tables.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-05-07 10:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, MAT) independently assessed the methodological quality of all the included trials using the Cochrane Incontinence Group's assessment criteria. Studies were not excluded from the review on the basis of methodological quality. Any disagreements were resolved by discussion or arbitration by all the review authors.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-03-03 23:46:14 +0000" MODIFIED_BY="Amin A Abukar">
<P>We planned to combine data, if this was considered appropriate, by applying fixed-effect methods, with relative risk used for dichotomous outcomes and weighted mean difference used for continuous outcomes.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-12-11 09:35:23 +0000" MODIFIED_BY="[Empty name]">
<P>We sought clarification on missing data from the trialists and, when available, they were included in the final abstraction and analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-12-11 09:35:26 +0000" MODIFIED_BY="[Empty name]">
<P>If visual inspection or the Chi² test had suggested heterogeneity at the 10% level then we planned to explore the reasons for this. If the level of heterogeneity was serious enough to affect the validity of the results then applying a random-effects method would be considered. Alternatively, if it was considered inappropriate to combine data from the included trials we planned instead to present a narrative synthesis of the results of the primary studies. In the event it was not possible to find any data suitable for meta-analyses, and all the data are presented in 'Other Data' tables.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-08-14 15:54:17 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials were formally assessed for methodological quality, including for selective reporting using appropriate tools in Cochrane's Review Manager (RevMan) software. The methodological quality of included trials are reported in 'Risk of bias' figure and summary.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-04-17 17:23:51 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to combine data by applying fixed-effect methods when appropriate. </P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-05-07 10:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>If the evidence had allowed, we planned to undertake sub-group analysis on the following categories of participants:<BR/>(1) participants with faecal urgency;<BR/>(2) participants with structural defects of the anal sphincter;<BR/>(3) participants with partial spinal cord injury; and<BR/>(4) participants with central neurological disease.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-05-07 10:04:26 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use sensitivity analysis to test the effects of included studies of poor methodological quality, if appropriate.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-08-17 13:59:04 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-08-17 13:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>Please see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables for further details.</P>
<SEARCH_RESULTS MODIFIED="2015-08-14 15:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 197 records, identified by the literature search, were screened and 16 full-text articles of potentially eligible studies were obtained. There were 10 reports of 8 included studies and 3 reports of 3 excluded studies. Additionally there were three reports of three ongoing studies, details of which can be found in the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> table. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> illustrates the process of the literature search and selection of studies for the update of this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-08-17 13:59:02 +0100" MODIFIED_BY="[Empty name]">
<P>Eight potentially relevant trials identified by the search strategy were included (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>).</P>
<P>Six trials assessed the effects of sacral nerve stimulation (SNS) for faecal incontinence (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>).</P>
<P>Two trials assessed the effects of SNS for constipation (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Design</HEADING>
<P>Six trials had a crossover design (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), while two had a parallel-group design (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>).</P>
<P>In the study carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> patients were allocated to receive either SNS or percutaneous tibial nerve stimulation (PTNS). In the SNS group participants underwent a trial with temporary SNS for two weeks; those who exhibited a good response (at least 50% reduction in FI) had permanent SNS implantation. In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> all participants attended multidisciplinary pelvic floor clinic and were randomised to sacral nerve stimulation (SNS group) or optimal medical therapy (control group). In the SNS group all participants were tested for a minimum of seven days and participants who exhibited a good response underwent permanent implantation with a quadripolar electrode for the 12 months of follow up. The electrode combination with best perception of muscle contraction of perineum and anal sphincter with least voltage was selected for permanent stimulation.</P>
<P>Moreover, in the trials conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> and <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>, participants underwent two two-week intervals with subsensory stimulation either 'on' or 'off'. There was no interval between the treatment periods.</P>
<P>Similarly, in the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, participants underwent two one-week intervals with stimulation either &#8216;on&#8217; or &#8216;off&#8217;. There was no interval between the treatment periods.</P>
<P>In the trial carried out by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>, participants underwent three weeks of temporary peripheral nerve stimulation, then all patients underwent permanent SNS electrode implantation. Participants were then randomised to receive subsensory stimulation or sham for three weeks; and after a two-week washout period the group that received sham stimulation now received subsensory stimulation for three weeks and vice versa. Then, following a further two-week washout period, participants were re-randomised to receive either sham or suprasensory stimulation for three weeks. Participants then underwent a further two-week washout period, after which participants who received sham stimulation now underwent suprasensory stimulation for three weeks and vice versa.</P>
<P>In the trial conducted by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, after permanent implantation 31 patients had a minimum of 3 months with the stimulator turned on. Then participants were invited to take part in the crossover study. Sixteen participants were enrolled, who were subsequently randomised in a crossover design to 'on' or 'off' stimulation, each period lasting three weeks. At the end of each three-week period the stimulator was programmed to the opposite mode ('off' or 'on'). While still blinded at the end of the crossover period participants selected the period of stimulation they had preferred ('off' or 'on'). The mode of stimulation corresponding to the preferred period ('off' or 'on') was continued for a further three months.</P>
<P>In the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, after definitive 'permanent' implantation each participants had a one- to three-month phase when the stimulator was turned 'on' (postimplantation period), to optimise the effectiveness of stimulation by determining the most effective parameters of stimulation (choice of stimulation electrodes and intensity of stimulation). At the end of the postimplantation period, participants were randomised in a crossover design to 'on' or 'off' stimulation for a two-month period. At the end of the first month, the neurostimulator was programmed to the opposite mode ('off' or 'on'), and monitoring continued for a second month. There was no interval between the two treatment periods. At the end of the crossover period, while still blinded, the participants chose the period of stimulation ('on' or 'off') they had preferred. The mode of stimulation corresponding to the selected period ('on' or 'off') was then continued for a three-month follow-up period. If the participant could not choose between one of the two periods, the stimulator was turned 'on'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sample sizes</HEADING>
<P>In total the trials enrolled 280 people, of whom 177 received a definitive implant. The trials included:</P>
<SUBSECTION>
<HEADING LEVEL="4">Faecal incontinence:</HEADING>
<UL>
<LI>
<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> included two participants;</LI>
<LI>
<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> enrolled 16 participants, all received a permanent SNS implant;</LI>
<LI>
<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> enrolled 34 participants, of whom 27 went on to receive a permanent implant;</LI>
<LI>
<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> enrolled 7 participants;</LI>
<LI>
<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> enrolled 40 participants, of whom 16 received a permanent SNS implant;</LI>
<LI>
<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> enrolled 120 participants, of whom 53 received a permanent implant.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Constipation</HEADING>
<UL>
<LI>
<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> enrolled 59 participants of whom 55 had permanent implant; and</LI>
<LI>
<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> included two participants;</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Setting</HEADING>
<P>Two trials were carried out in the same hospital centre (St. Mark's Hospital, Harrow); neither reported the time period during which the trial was undertaken (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). The third trial was carried out in a single centre located in Germany (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>). The fourth trial was a multicentre trial (number of centres not stated), set in France, which took place during the period February 2000 to February 2003 (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>). The fifth trial was a single-centre trial set in Denmark (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>). The sixth trial was a two-centre trial set in two London hospitals (Royal London Hospital and University College London Hospital, UK) (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>). The seventh trial was a single-centre trial set in Australia (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). The eighth trial was a two-centre trial conducted in Australia (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Of 280 participants enrolled, 246 (87.9%) were women.</P>
<SUBSECTION>
<HEADING LEVEL="4">Compliance and treatment received</HEADING>
<P>In the trial carried out by Thin and colleagues, 8 of the 23 participants in the SNS group did not receive permanent implantation (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>). The reasons cited include: intercurrent illness requiring urgent medical management (n = 1); symptoms resolved (n = 1); declined further participation (n = 2); failed temporary SNS (n = 3); withdrawn from treatment for urgent investigation of a new pararectal cyst (n = 1). In the trial conducted by Tjandra and colleagues 7 of the 60 participants in the SNS arm did not receive permanent implantation (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). The reasons were: cannulation of foramen with electrode was not achieved due to previous back surgery, which required bone graft from the sacral area (n = 1); insufficient therapeutic response with peripheral nerve evaluation (n = 5); and concern participants might require magnetic resonance imaging of brain post excision of meningioma (n = 1).</P>
<P>In the trial carried out by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, out of the 16 participants enrolled, 2 discontinued; the reasons were (i) participant turned stimulator 'on' with handheld device because she had become completely incontinent (n = 1); (ii) participant fell on lower back leading to breakage of permanent lead (n = 1).</P>
<P>In the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> 10 of 34 participants prematurely discontinued the trial. The reasons for discontinuation were: device-related adverse events (n = 4); protocol violation (n = 3); insufficient therapeutic response (n = 1); no return to follow-up (n = 1); and adverse event (stroke) not related to SNS (n = 1).</P>
<P>In the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> four participants did not receive permanent SNS implant due to depression (n = 1); too far to travel (n = 2); and could not commit (n = 1). Of those who received permanent implant 2 participants discontinued the study due to pregnancy (n = 1); and severe wound infection (n = 1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Age</HEADING>
<P>The age of both participants in the trial conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> was 36 years, while in the trial conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> the participants were aged 65 and 61 years. The mean age of the participants in the trial carried out by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> was 55.5 years (standard deviation (SD) = 11.8). The median age of the participants in the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> was 57 years (range 33 to 73 years). In the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> the median age of participants was 67 years (range 60 to 87 years). In the trial conducted by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> the mean age of participants was 59 years (SD = 13 in the SNS group and 11 in the PTNS group). In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> the median age of the participants was 63.9 years (SD = 13.2) in the SNS arm and 63 years (SD = 12.1) in the control group. In the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> the median age was 42 years (range 19 to 74 years).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cause/type of faecal incontinence or constipation</HEADING>
<P>The causes of faecal incontinence in the two participants in Vaizey's trial were, respectively, scleroderma and idiopathic degeneration of the internal anal sphincter (<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). The cause of faecal incontinence cited in the trial conducted by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> were idiopathic (n = 8), anorectal surgery (n = 4), and neurogenic (n = 4). In the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> the majority of participants (22 of 34, 65%) suffered from urge incontinence, while four suffered from passive incontinence and eight from mixed incontinence. The causes of incontinence were reported as idiopathic (n = 18); pudendal neuropathy (n = 14); postoperative internal anal sphincter fragmentation (n = 1); and primary internal anal sphincter degeneration (n = 1) (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>). In the trial conducted by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> participants suffered from urge and passive incontinence. In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> all participants had both passive and urge incontinence. The participants in the trial conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> suffered from severe resistant idiopathic constipation that had failed maximal conservative treatment. The participants in the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> suffered severe refractory idiopathic slow transit constipation. The cause of faecal incontinence in the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> was not stated. (See '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for details of the inclusion/exclusion criteria applied by each trial).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>The intervention in all eight trials consisted of SNS via a permanently-implanted stimulator (Medtronic InterStim®).</P>
<P>In the trials conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, and <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>, the participants had received permanent implants respectively 12 months, 12 months and 9 months previously.</P>
<UL>
<LI>
<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> reported that prior to permanent implantation, both participants had undergone a successful three-week trial of temporary percutaneous stimulation; whereas <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>, and <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported that before permanent implantation, participants underwent temporary percutaneous stimulation for, on average, 14 days, 10 days and between 8 and 15 days respectively to assess their response to treatment.</LI>
<LI>Similarly, <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> reported that before permanent implantation, participants underwent temporary percutaneous stimulation for a period between 14 and 20 days to assess their response to treatment.</LI>
<LI>In the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>, following 3 weeks of temporary peripheral nerve evaluation all participants underwent permanent SNS electrode implantation.</LI>
<LI>In the trial conducted by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, participants underwent a trial of temporary SNS and participants with a good response (at least 50% reduction in episodes of FI) progressed to permanent stimulation.</LI>
<LI>Also, in the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, the decision to progress from temporary to permanent stimulation was made on the basis of at least a 50% reduction in the number of episodes of incontinence per week, or a 50% reduction in the number of faecal urgency episodes per week, or both.</LI>
<LI>Similarly, in the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> the decision to progress to permanent stimulation was based on a good response, defined as a 50% or greater reduction in faecal incontinence episodes per week or a 50% or greater reduction in number of days with faecal incontinence per week.</LI>
</UL>
<P>In the trial conducted by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> and <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> the permanent pulse generator was placed in the upper outer part of the buttocks. Similarly, in the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> and <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> the permanent pulse generator was placed in the gluteal area. In the trial conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> it was placed in the abdominal wall. <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> and <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> did not report the location of the pulse generator.</P>
<SUBSECTION>
<HEADING LEVEL="4">Duration of treatment and follow up</HEADING>
<P>The length of time between the participants receiving a permanently-implanted stimulator and the start of the crossover period varied from 3 weeks (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>), around 3 months (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>), through 9 months (<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), to 12 months (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>). In the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> the follow-up time for the SNS and PTNS groups was six months. In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>, the follow up time for the SNS group and the control group was 12 months.</P>
<P>In two trials the crossover period consisted of two two-week periods when the stimulator was either 'on' or 'off', with no follow-up (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). Similarly, in the third trial the crossover period consisted of two one-week periods when the stimulator was either 'on' or 'off' with no follow-up (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>); while in the fourth, larger, trial the crossover period consisted of two one-month periods when the stimulator was 'on' or 'off', with a three-month follow-up (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>). In the fifth trial (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>), the crossover period consisted of two three-week periods when the stimulator was 'off' or 'on', with a three-month follow-up. In the sixth trial (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>), the crossover period consisted, in the suprasensory phase, of two three-week periods where the stimulator was on (suprasensory) or off (sham); long-term follow-up is still ongoing.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The trials reported a variety of outcome measures.</P>
<P>
<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> reported that participants used a diary to record episodes of faecal incontinence for liquid or solid stool; anal manometry was undertaken; and health status was assessed both before permanent implantation and again at the beginning of the trial, using an SF-36 questionnaire. In terms of anal manometry, a stationary pull-through method was used with an eight-channel perfused system, and the squeeze pressure was measured as the incremental rise. Rectal sensation was tested using balloon distension with air (<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>).</P>
<P>
<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported that participants also used a diary, recording episodes of faecal incontinence, faecal urgency, delay in postponing defaecation, and bowel movements. Severity of incontinence was graded by the Cleveland Clinic Incontinence Scoring System, while quality of life was assessed with the French version of the American Society of Colon and Rectal Surgeons' (ASCRS) Fecal Incontinence Quality of Life Scale (FIQL). Anal manometry was also undertaken (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>). Measurements of maximum resting pressure and maximum squeeze pressure were recorded at baseline, at the end of each crossover period, and at follow-up; while rectal sensation to balloon distension with air was recorded at baseline and at the end of the follow-up period (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>).</P>
<P>
<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> reported outcomes that included frequency of bowel movements, frequency of faecal incontinence, and the Cleveland Clinic Incontinence Score (CCIS).</P>
<P>In the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> participants used a bowel diary (stool frequency per week; bowel motion per week; feeling of complete evacuation per week; straining per week; laxative-free days per week; soft stool per week; normal stool per week; hard stool per week; pain score weekly average; bloating score weekly average; weekly global satisfaction score; weekly bothersome score). Quality of life was documented using the SF-36 questionnaire.</P>
<P>Also, in the trial conducted by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> participants utilised a bowel diary to document the number and type of incontinence episodes per week. Additionally, symptom severity was assessed through the use of Cleveland Clinic Incontinence Score and quality of life was measured through use of Faecal Incontinence Quality of Life Scale (FIQL), Short Form 36 (SF-36) and EQ-5D.</P>
<P>Similarly, in the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> participants used a bowel diary to record the number of incontinent episodes per week; days with incontinence per week; days with staining per week; and days with pads per week. Severity was scored by the Wexner incontinence score (Cleveland Clinic Incontinence Scoring System); and quality of life was evaluated by ASCRS's FIQL, and the standard Short Form-12 health survey quality of life questionnaire (SF-12) (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). Measurements of anal manometry (resting and squeeze pressure) were undertaken at baseline for both SNS and control group, while further anal manometry measurements were only carried out for the SNS group during peripheral nerve evaluation and at 3-, 6- and 12-month follow-up (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>).</P>
<P>In the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, outcomes were reported using bowel diaries and anal manometry.</P>
<P>In the trial conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, outcomes included diary-recorded bowel movements; the Wexner Constipation Score; a symptom analogue score; anal manometry; and quality of life. In terms of anal manometry, resting pressure was the maximal anal resting pressure using a stationary pull-through technique, and squeeze pressure was the maximal increment above resting pressure. Threshold, urge and maximal tolerated volume were to rectal balloon distension with air. Anal and rectal electrosensation measured threshold sensation with increasing amplitude of stimulation, recorded with a 1 cm bipolar ring electrode (5 Hz, 0.1 ms and 10 Hz, 0.5 ms respectively) (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Timing of outcome measures</HEADING>
<P>Four trials reported results at the end of the crossover period (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), while the trials by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> and <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> also reported results at the end of a three-month follow-up after the crossover period ended. The trial by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> reported results at baseline prior to intervention, at 3 months and 6 months follow up. <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> reported results at the end of a 12-month follow-up.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-12-11 09:45:32 +0000" MODIFIED_BY="[Empty name]">
<P>See '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-08-17 13:51:31 +0100" MODIFIED_BY="[Empty name]">
<P>The results of the methodological quality assessment along with justifications are covered in the 'Risk of bias' tables (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table) for each trial and are illustrated in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-08-17 13:51:31 +0100" MODIFIED_BY="[Empty name]">
<P>The information is provided in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table and presented visually in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Random number generation</HEADING>
<P>The method of randomisation was unclear in the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>. <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> randomised patients remotely using a statistician uninvolved in recruitment: requests were made by and actioned by email. <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> utilised an off-site (NHMRC) clinical trials centre automated phone link. <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> and <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> randomised participants by using a random numbers table. Similarly, <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> randomised participants using shuffling of envelopes but did not indicate how the envelopes were filled. <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> and <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> provided no details of the method for deciding which participants were initially allocated to stimulator 'off' or 'on'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concealment of allocation</HEADING>
<P>Five of the trials did not explicitly state that allocation was concealed (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). In the trial by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> and <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> randomisation and allocation was made remotely, hence low risk of bias. The <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> trial, which used sealed envelopes, reported that the quality of allocation concealment was at low risk of bias.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-08-17 11:46:06 +0100" MODIFIED_BY="[Empty name]">
<P>In the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, the outcome assessor was blinded to participant allocation. The participants and the outcome assessor were not blinded to the allocation in the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>. In the remaining six trials the participants and outcome assessors were blinded to the allocation (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-08-17 11:46:16 +0100" MODIFIED_BY="[Empty name]">
<P>There were no withdrawals in three trials (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). However, in the trial conducted by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, 9 participants out of the 40 enrolled withdrew from the trial. Likewise, in the trial carried out by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, 10 people out of the 34 enrolled prematurely discontinued the trial. Furthermore, in the trial conducted by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, 2 participants out of the 16 enrolled discontinued the trial. Similarly, in the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> seven participants in the SNS group prematurely discontinued. In the trials conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> and <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>, most of the outcome results were reported for everyone who entered the trials. As the participants were analysed in the groups to which they were originally allocated, the analysis was effectively intention-to-treat. In the trial carried out by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>, out of the 59 participants enrolled, 6 withdrew. The reasons for discontinuation were depression (n = 1), too far to travel (n = 2), could not commit (n = 1), pregnancy (n = 1) and severe wound infection (n = 1).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-08-17 11:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials were at low risk of bias as they reported all outcomes for everyone (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>); the others trials were unclear (see 'Risk of bias' tables <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-08-10 20:40:25 +0100" MODIFIED_BY="[Empty name]">
<P>None of the trials reported other sources of bias and so were judged to be at low risk on this domain. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-08-17 13:59:04 +0100" MODIFIED_BY="[Empty name]">
<P>The eight trials, which comprised two parallel group trials (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> and <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>) and six crossover trials (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>, <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, and <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), included 280 participants, of whom 177 received a permanently-implanted stimulator.</P>
<SUBSECTION>
<HEADING LEVEL="3">Faecal incontinence</HEADING>
<P>Six of these trials investigated the effects of SNS for faecal incontinence (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical outcomes (number cured and improved, episodes of faecal incontinence, ability to defer defaecation, urgency, incontinence score)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">SNS versus control (medical therapy)</HEADING>
<P>In the trial by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> the SNS group experienced fewer episodes of faecal incontinence compared to the control group who received optimal medical therapy</P>
<UL>
<LI>both at 3 months (MD &#8722;5.20, 95% CI &#8722;9.15 to &#8722;1.25, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1)</LI>
<LI>and 12 months (MD &#8722;6.30, 95% CI &#8722;10.34 to &#8722;2.26, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2),</LI>
</UL>
<P>In addition, SNS was better than control in terms of:</P>
<UL>
<LI>Number of days of pad use per week (MD &#8722;1.40, 95% CI &#8722;2.59 to &#8722;0.21 at 3 months, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1; though this was no longer statistically significant at 12 months, MD &#8722;1, 95% CI &#8722;2.13 to 0.13, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.2);</LI>
<LI>Cleveland Clinic Incontinence Score (MD &#8722;11, 95% CI &#8722;11.60 to &#8722;10.40 at 3 months; and MD &#8722;12.90 to &#8722;13.58 to &#8722;12.22, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</LI>
</UL>
<P>Additionally, none of the participants in the SNS group had worsening of faecal incontinence, with 25 participants (47.2%) achieving continence, but the data for the control group were not reported (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SNS versus PTNS</HEADING>
<P>In the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> the SNS group experienced fewer episodes of faecal incontinence compared to the PTNS group:</P>
<UL>
<LI>both at 3 months (MD &#8722;3.00, 95% CI &#8722;6.61 to 0.61, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1)</LI>
<LI>and 6 months (MD &#8722;3.20, 95% CI &#8722;7.14 to 0.74, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2).</LI>
</UL>
<P>Additionally, SNS was better than PTNS with regards to Cleveland Clinic Incontinence Score:</P>
<UL>
<LI>both at 3 months (MD &#8722;1.70, 95% CI &#8722;5.14 to 1.74, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.1)</LI>
<LI>and 6 months (MD &#8722;3.00, 95% CI &#8722;6.74 to 0.74, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.2).</LI>
</UL>
<P>Additionally, at the six months follow-up three participants in the SNS group and PTNS group reported no episodes of faecal incontinence. Moreover, in the SNS group 10 participants had a 50% or greater reduction in episodes of faecal incontinence compared with 7 participants in the PTNS group (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence: crossover trials</HEADING>
<P>In the trial conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>, during the period when the stimulator was 'off' the participants experienced an average of six episodes of faecal incontinence per week, compared with an average of one episode per week when the stimulator was 'on' (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). SNS resulted in one participant being cured and the other experiencing a reduction in the number of episodes of faecal incontinence per week from 10 when the stimulator was 'off' to one when it was 'on' (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>In the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, at the end of the crossover period and while still blinded, the participants chose the period of stimulation ('on' or 'off') they had preferred and the mode of stimulation corresponding to the selected period ('on' or 'off') was then continued for the three-month follow-up period. Most outcomes at baseline, prior to the crossover, during the 'on' and 'off' periods of the crossover and at follow-up were reported separately for the group of 19 participants who preferred the 'on' period and for the group of 5 participants who preferred the 'off' period once the crossover period had ended. For the group of 19 participants, during the one-month period when the stimulator was 'off' the median (range) number of episodes of faecal incontinence per week was 1.7 (0 to 9) compared with 0.7 (0 to 5) during the 'on' period (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; P &lt; 0.05), with 0.5 (0 to 11) episodes per week during the three-month follow-up period. During the follow-up period 5 (26%) of the 19 participants were cured (no episodes of faecal incontinence) and 17 (89%) felt they had improved (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The median (range) minutes delay in postponing defaecation was 1.4 (1 to 3) during the 'off' period, compared with 1.8 (1 to 3) during the 'on' period, and 1.9 (1 to 3) during the follow-up period (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The median (range) episodes of urgency per week were 1.4 (0 to 19) during the 'off' period compared with 1 (0 to 16) during the 'on' period and 1 (0 to 24) during the follow-up period (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
<P>The group of five participants who chose the 'off' period once the crossover period had ended actually experienced an increase in the number of episodes of faecal incontinence when the stimulator was 'on' compared with when it was 'off'. For this group, the median (range) number of episodes of faecal incontinence per week was 1.7 (0 to 11) during the one-month 'off' period compared with 3.7 (0 to 11) during the one-month 'on' period and 3.5 (0 to 10) during the three-month follow-up period (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The median (range) minutes delay in postponing defaecation remained relatively unchanged at 1 (1 to 3) during the 'off' period compared with 1 (1 to 2) during the 'on' period, and 1.2 (1 to 1.8) during the follow-up period (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The median (range) episodes of urgency per week were 4.5 (3 to 10) during the 'off' period compared with 8.2 (2 to 19) during the 'on' period and 5.2 (0 to 20) during the follow-up period(<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>).</P>
<P>The Cleveland Clinic Incontinence Score ranges from 0 (normal continence) to 20 (total incontinence). In the trial conducted by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, for the whole group of participants the median (range) Cleveland Clinic Incontinence Score was 10.5 (4 to 17) during the 'off' period compared with 8.5 (3 to 18) during the 'on' period (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). For the follow-up period, the Cleveland Clinic Incontinence Score was not reported for the whole group, but separately for the group of 19 who had chosen the 'on' period and for the group of 5 who had chosen the 'off' period following the crossover. For the group of 19, the median score for the follow-up period was 10 (3 to 17) while for the group of 5 it was 13 (11 to 18) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>) (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>).</P>
<P>In the trial carried out by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, at the end of the crossover while still blinded all patients (n = 14) elected to continue with 'on' as their preferred intervention for the final 3 months (final period). FI episodes per week were at a low level (average of 1 (SD = 1.7)) during the 'on' period, but increased significantly (P &lt; 0.05) on average to 8.4 (SD = 8.7) during the 'off' period. During the final period FI episodes per week remained low 0.3 (SD = 0.5) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The CCIS was significantly higher (P &lt; 0.05) during the 'off' period (14.6 (SD = 4.6)) compared with the 'on' period (8.7 (SD = 3.6)). During the final period the CCIS was 6.4 (SD = 3.3) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). The overall number of defaecations per week also declined significantly (P &lt; 0.05) in the crossover 'on' period (10.9 (SD = 4.1)) compared with the 'off' period (18.2 (SD = 8.7)). Furthermore, during the final period the number of defaecations per week was 9.4 (SD = 2.6) (<LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>).</P>
<P>In the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> there were no faecal incontinence episodes per week in both the 'on' and 'off' periods (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The mean episodes of urgency per week was 4.14 (&#8722;0.16 to 8.44) during the 'off' period and reduced to 2.43 (&#8722;0.23 to 5.1) during the 'on' period (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>).</P>
<P>
<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008 </LINK>did not report urgency or use of anal plugs. <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> did not report urgency, the ability to defer defaecation, or incontinence score. <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> did not report number cured or improved, ability to defer defaecation, and incontinence score. Of the <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>, <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, and <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> trials, none reported the use of pads, anal plugs or the need for further treatment during follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Quality of life outcomes</HEADING>
<P>
<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> used the SF-12 and ASCRS FIQL quality of life indexes. SF-12 is developed from the longer SF-36 and generates eight scale scores which can be summarised into a physical and mental summary score. Both of these physical and mental scores have a range from 0 to 100, higher scores indicating better quality of life. ASCRS FIQL index comprises 29 questions that are grouped into four sections: lifestyle; coping/behaviour; depression/self-perception; and embarrassment. The ASCRS FIQL scores range from one (worst) to five (best). <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> used the SF-36 tool, while <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> used the French version of the ASCRS FIQL. <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> used the ASCRS FIQL, SF-36 and EQ-5D. EQ-5D, a standardised instrument for use as a measure of health outcome, provides a descriptive profile and a single index value for health status.</P>
<SUBSECTION>
<HEADING LEVEL="5">SNS versus medical treatment</HEADING>
<P>In the trial by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> the SNS group reported better quality of life on FIQL index scores in all four scales compared to the control group in terms of:</P>
<P>1. Lifestyle</P>
<UL>
<LI>3 months (MD &#8722;1.22, 95% CI &#8722;1.52 to &#8722;0.92)</LI>
<LI>12 months (MD &#8722;1.00, 95% CI &#8722;1.30 to &#8722;0.70, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>)</LI>
</UL>
<P>2. Coping behaviour</P>
<UL>
<LI>3 months (MD, &#8722;1.02, 95% CI &#8722;1.34 to &#8722;0.70)</LI>
<LI>12 months (MD, &#8722;0.82, 95% CI &#8722;1.14 to &#8722;0.50, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>)</LI>
</UL>
<P>3. Depression/self-perception</P>
<UL>
<LI>3 months (MD, &#8722;0.63, 95% CI &#8722;0.89 to &#8722;0.37)</LI>
<LI>12 months (MD, &#8722;0.61, 95% CI &#8722;0.91 to &#8722;0.31, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>)</LI>
</UL>
<P>4. Embarrassment</P>
<UL>
<LI>3 months (MD, &#8722;1.19, 95% CI &#8722;1.47 to &#8722;0.91)</LI>
<LI>12 months (MD, &#8722;0.98, 95% CI &#8722;1.28 to &#8722;0.68, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>)</LI>
</UL>
<P>However, there were no significant differences between the two groups on the generic quality-of-life scores at 3 or 12 months for either the SF-12 Physical health scale (MD, &#8722;1.68, 95% CI &#8722;5.70 to 2.34 at 3 months; MD, &#8722;1.72, 95% CI &#8722;5.31 to 1.87 at 12 months, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>); or SF-12 Mental health scale (MD, &#8722;2.34, 95% CI &#8722;6.23 to 1.55 at 3 months; MD, &#8722;1.00, 95% CI &#8722;4.89 to 2.89 at 12 months, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SNS versus PTNS</HEADING>
<P>In the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> the SNS group reported no statistically significant differences in quality of life FIQL index scores in all four domains compared with the PTNS group in terms of:</P>
<P>1. Lifestyle</P>
<UL>
<LI>3 months (MD, &#8722;0.20, 95% CI &#8722;0.82 to 0.42)</LI>
<LI>6 months (MD, &#8722;0.20, 95% CI &#8722;0.82 to 0.42, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)</LI>
</UL>
<P>2. Coping</P>
<UL>
<LI>3 months (MD, &#8722;0.20, 95% CI &#8722;0.72 to 0.32)</LI>
<LI>6 months (MD, &#8722;0.50, 95% CI &#8722;1.09 to 0.09, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>)</LI>
</UL>
<P>3. Depression</P>
<UL>
<LI>3 months (MD, 0.10, 95% CI &#8722;0.46 to 0.66)</LI>
<LI>6 months (MD, &#8722;0.10, 95% CI &#8722;0.66 to 0.46, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>)</LI>
</UL>
<P>4. Embarrassment</P>
<UL>
<LI>3 months (MD, &#8722;0.30, 95% CI &#8722;0.82 to 0.22)</LI>
<LI>6 months (MD, &#8722;0.60, 95% CI &#8722;1.16 to &#8722;0.04, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>)</LI>
</UL>
<P>However, EQ-5D scores were not significantly different between the two groups (at three months MD, 0.06, 95% CI &#8722;0.17 to 0.29; at six months MD, 0.13, 95% CI &#8722;0.08 to 0.34, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence: crossover trials</HEADING>
<P>Raw data for the SF-36 was unavailable, but was reported as within patient changes (from baseline to three months and six months respectively). Increases in physical role was seen for SNS (at six months: 25.0 versus 0.0, SNS and PTNS respectively, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK> ), while modest increases were observed for emotional role (at six months: 17.8 versus 16.7, SNS and PTNS respectively, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK> ) and social functioning (at six months: 17.5 versus 10.9, SNS and PTNS respectively, <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) for both interventions.</P>
<P>
<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> reported quality of life before implantation of the stimulator and nine months after implantation, prior to the crossover period. There was an overall improvement in both participants but especially so in one participant in terms of the domains of bodily pain (30 versus 100); role-physical (0 versus 100); social function (12 versus 100); and vitality (10 versus 80) <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>. <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> recorded quality of life using the French version of the FIQL instrument at baseline and again during the final three-month follow-up period, noting a statistically significant (P &lt; 0.05) improvement in the median scores for all domains: lifestyle (1.7 versus 3.2); coping/behaviour (1.5 versus 2.7); depression/self-perception (2.2 versus 3.6); and embarrassment (1.3 versus 2.3) <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>.</P>
<P>
<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> and <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> did not report quality of life of participants.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Surrogate measures (anorectal manometry)</HEADING>
<P>
<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> reported anal manometry for both groups at base line and only the SNS group during the follow-up period. There was a non-significant (P &gt; 0.05) change in the two parameters reported. In the SNS group the mean resting pressure (cm H&#8322;O) was 40.4 (SD = 15.9) at baseline and 40.9 (SD = 21.9) at 12 months, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. Similarly, in the SNS group the mean squeeze pressure (cm H&#8322;O) was 83.2 (SD = 39.6) at baseline and 90.2 (SD = 54.9) at 12 months (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>Moreover, in the trial conducted by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>, the mean (95% CI for mean) resting anal pressure (cm H&#8322;O) decreased from 84.2 (70.4 to 98.3) when the stimulator was 'on' to 106.2 (71.1 to 141.4) when the stimulator was 'off', <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. However, the mean values for squeeze pressure remained the same during the 'on' and 'off' periods: 223.0 (159.1 to 287.0) and 223.0 (153.7 to 292.4) respectively, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. With regards to rectal sensory threshold (ml), the mean (95% CI for mean) threshold sensation was 50.0 (34.6 to 65.4) during the 'off' period which decreased to 27.1 (17.8 to 36.4) when 'on'; with corresponding values for urge of 82.9 (64.8 to 101) and 60 (48.7 to 71.3), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. Contrastingly, mean maximum-tolerated volume (ml) remained the same during the 'off' and 'on' periods: 124 (106 to 142) and 124 (82.4 to 165.6) respectively (<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>In the trial conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> the mean (range) resting anal pressure (cm H&#8322;O) improved from 43 (35 to 50) when the stimulator was 'off' to 58 (45 to 70) when it was 'on'; with the corresponding values for squeeze pressure also improving from 65 (60 to 70) to 95 (90 to 100), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. In terms of rectal sensation to distention (ml), the mean (range) threshold sensation was 38 (25 to 50) during the 'off' period compared with 68 (45 to 90) during the 'on' period, with corresponding values for urge of 85 (70 to 100) and 103 (85 to 120); and, for maximum-tolerated volume, 135 (120 to 150) during the 'off' period compared with 140 (130 to 150) during the 'on' period, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>
<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported anorectal manometry measures separately for the group of 19 participants who preferred the 'on' period and for the group of five participants who preferred the 'off' period following the crossover. For the group of 19, the median (range) maximum resting pressure (cm H&#8322;O) improved from 37 (26 to 100) during the one-month period when the stimulator was 'off' to 50 (27 to 155) when it was 'on,' <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. The median (range) maximum squeeze pressures improved from 49 (10 to 98) during the 'off' period to 53 (6 to 326) during the 'on' period, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. The median (range) threshold, constant sensation volume and maximum tolerated volume (all ml) were reported only for baseline and the final three-month follow-up period following crossover. Threshold values were 25 (10 to 120) at baseline compared with 30 (10 to 120) during the follow-up period, with the corresponding values for constant sensation volume of 100 (40 to 230) and 85 (30 to 300), while maximum tolerated volume was 185 (80 to 350) at baseline compared with 170 (40 to 275) at follow-up, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>For the group of five participants who preferred the 'off' period following the crossover period, the median (range) maximum resting pressure (cm H&#8322;0) improved from 50 (39 to 98) during the 'off' period to 64 (37 to 98) during the 'on' period (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. However, the median (range) maximum squeeze pressures (cm H&#8322;0) decreased from 54 (37 to 110) during the 'off' period to 30 (21 to 90) during the 'on' period, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. The median (range) rectal volume sensation values (ml) remained relatively unchanged between baseline and follow-up, with threshold values 10 (10 to 40) at baseline and 10 (10 to 50) during follow-up; constant sensation volume 50 (20 to 90) at baseline and 50 (20 to 95) at follow-up; and maximum tolerated volume 200 (80 to 300) at baseline compared with 195 (100 to 300) at follow-up (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>), <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>
<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> and <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> did not report anorectal manometry outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence: SNS versus medical treatment</HEADING>
<P>In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>, adverse events reported for the SNS group consisted of implantation site pain (6%), particularly in slimmer participants; seroma (2%), which required percutaneous aspiration; and excessive tingling in the vaginal region (9%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence: SNS versus PTNS</HEADING>
<P>In the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, adverse events reported for the SNS group include mild ipsilateral leg pain during temporary testing (n = 1) and stimulator-site pain following insertion of neurostimulator (n = 2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Faecal incontinence: crossover trials</HEADING>
<P>
<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported that, of 27 participants receiving a permanent implant, 4 (15%) experienced adverse events prior to the commencement of the crossover period, resulting in explantation of the stimulator. Three of the explantations were due to unresolved pain and one was for recurrent infection. Another participant suffered an adverse event (stroke), not related to SNS, prior to the crossover period. <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> did not report whether there had been any adverse events during the crossover period or three-month follow-up period. <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> and <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> did not report whether any adverse events had occurred during the course of the trial.</P>
<P>In the trial carried out by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, adverse events reported for the enrolled participants after implantations included: haematoma formation (n = 3), misplacement of tined lead (1), and pain at stimulator site (n = 1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Health economics</HEADING>
<P>None of the trials (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>) provided any information on costs within the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Other outcomes quoted by trial authors and judged to be important</HEADING>
<P>
<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported bowel movements per week; and regarding anorectal manometry, reported squeeze pressure duration (seconds) and constant sensation volume (ml). For the 19 participants who preferred the 'on' period once the crossover period had ended, during the one-month period when the stimulator was 'off' the number of bowel movements per week was 10.6 (6 to 33) compared with 10.2 (5 to 26) during the 'on' period, and 10.6 (7 to 37) during the follow-up period, <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>. For the group of five participants who preferred the 'off' period once the crossover period had ended, the number of bowel movements per week during the 'off' period was 12.7 (8 to 19) compared with 11.2 (7 to 32) during the 'on' period, and 11.7 (7 to 32) during the follow-up period, <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>. For the group of 19 participants, squeeze pressure duration was 21 (4 to 32) seconds during the 'off' period compared with 18 (6 to 92) during the 'on' period; the corresponding values for the group of five participants were 40 (5 to 40) during the 'off' period compared with 32 (23 to 38) during the 'on' period, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>. For the group of 19 participants, the median (range) constant sensation volume values for baseline were 100 (40 to 230) compared with 85 (30 to 300) during the follow-up period; the corresponding values for the group of five participants remained relatively unchanged at 50 (20 to 90) at baseline and 50 (20 to 95) at follow-up, <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>.</P>
<P>
<LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> reported mean (95% CI for mean) soiling per week for the participants which decreased from 1.86 (0.29 to 3.43) during the 'off' period to 0.71 (&#8722;0.69 to 2.11) during the 'on' period, <LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>. <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> also reported mean (95% CI for mean) bowel movements per week which reduced from 12.1 (6.32 to 17.9) during the 'off' period to 8.86 (6.21 to 11.5) during the 'on' period, <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>. Similarly, the mean (95% CI for mean) passive leakage per week reduced from 0.43 (&#8722;0.41 to 1.27) during the 'off' period to 0 during the 'on' period, <LINK REF="CMP-003.16" TYPE="ANALYSIS">Analysis 3.16</LINK>.</P>
<P>Moreover, <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> reported days with incontinence and days with staining per week. SNS was better than control in terms of:</P>
<UL>
<LI>Number of days with faecal incontinence per week (MD &#8722;1.90, 95% CI &#8722;2.66 to &#8722;1.14 at 3 months; and MD &#8722;2.10, 95% CI &#8722;3.01 to &#8722;1.19 at 12 months, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>);</LI>
<LI>Number of days with faecal staining per week (MD &#8722;3.20, 95% CI &#8722;3.90 to &#8722;2.50 at 3 months; and MD &#8722;3.10, 95% CI &#8722;3.89 to &#8722;2.31 at 12 months, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>);</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Constipation</HEADING>
<P>Two crossover trials investigated the effects of SNS for constipation (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Number improved, bowel movements, percentage time with abdominal pain and bloating, constipation score</HEADING>
<P>In the trial conducted by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>, during the period when the stimulator was turned off (sham) the participants on average had stool frequency of 6.4 compared with an average of 6.6 when the stimulator was turned on (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). With regards to bowel movements per week, this was on average 4.0 during the off period compared with 4.3 during the on period, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>. Furthermore, on average the pain score per week was 1.0 during the on period compared with 0.9 during the off period, <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>. Bloating score on average per week was 1.2 in both the 'off' and 'on' periods, <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.</P>
<P>In the trial conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, both participants experienced an improvement, both in terms of bowel movements per week and the percentage of time with abdominal pain and bloating, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>. During the period when the stimulator was 'off' the participants experienced an average of two bowel movements (episodes of defaecation) per week, compared with five when the stimulator was 'on', an increase of 150% (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>), <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>. The average percentage of time with abdominal pain and bloating was 79% during the 'off' period compared with 33% during the 'on' period, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.</P>
<P>The Wexner constipation score ranges from 0 (normal) to 30 (severe constipation). The mean (range) scores for the participants improved from 14 (13 to 15) during the 'off' period to 9 (5 to 13) during the 'on' period, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>. <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> also noted an improvement in symptoms with the Symptom Analogue Score, with mean (range) scores during the 'off' period of 32 (30 to 33), compared with scores of 74 (60 to 88) during the 'on' period, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>. <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> did not report constipation scores.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Quality of life</HEADING>
<P>
<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, using the SF-36 tool, reported a marked improvement in both participants after a year of chronic stimulation compared with baseline, although no data were provided. <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> utilised the SF-36 tool; however no significant changes in the quality-of-life scores were reported, <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Surrogate measures (anorectal manometry)</HEADING>
<P>In the trial conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>, the mean (range) maximal resting pressures (cm H&#8322;0) improved from 51 (39 to 63) when the stimulator was 'off' to 76 (68 to 84) when it was 'on', with the corresponding values for maximal squeeze pressures also improving from 54 (51 to 57) during the 'off' period to 93 (41 to 145) during the 'on' period, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>. In terms of threshold sensation (ml air), the mean (range) values were 35 (30 to 40) during the 'off' period compared with 18 (15 to 20) during the 'on' period; while the corresponding figures for urgency were 70 (60 to 80) compared with 34 (33 to 35); and for maximum-tolerated volumes, 103 (85 to 120) during the 'off' period compared with 68 (65 to 70) during the 'on' period, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>. <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> did not report anal manometry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Adverse effects</HEADING>
<P>
<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> reported that there were no adverse events during the course of the trial. <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> reported 73 adverse events, which includes pain at site of the implanted pulse generator (32), wound infection (12) and urological symptoms (17), <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Health economics</HEADING>
<P>
<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> and <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> provided no information on costs.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-08-17 11:53:24 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-08-17 11:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>The finding of this review is that SNS for faecal incontinence can significantly improve faecal continence in some selected people, bearing in mind the limited evidence from randomised controlled trials.</P>
<P>On the other hand, we found that SNS did not seem to improve symptoms in people with constipation, but there were only two randomised trials providing evidence, of which one trial had only two participants.</P>
<P>Only eight trials, comprising two parallel group trials (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>), and six small crossover trials were identified that met our inclusion criteria (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>). Six of these trials focused on SNS for faecal incontinence (FI) (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), while two assessed the effects of SNS for constipation (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>). Two of the trials each contained only two participants (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>); while the trial by <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> enrolled seven participants, and <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> enrolled 16 participants. Although still relatively small, the trial by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> enrolled 34 participants; and <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> enrolled 40 participants. For constipation, <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> enrolled 59 participants; whilst for FI, <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> enrolled 120 participants, making them the largest of the trials that were included.</P>
<SUBSECTION>
<HEADING LEVEL="3">Faecal incontinence</HEADING>
<P>The trials conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> and <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> suggest that for some selected participants, SNS can reduce episodes of faecal incontinence and urgency and improve the ability to defer defaecation, leading to a better quality of life. However, a minority may get worse despite apparently successful testing before permanent implantation. <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> found that SNS can reduce number of defaecations, urgency episodes, soiling and passive leakage, while increasing first sensation of content in the rectum. Similarly, <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK> found that SNS significantly reduces faecal incontinence episodes and bowel movements and improves CCIS scores. Furthermore, the trial by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> suggests that sacral nerve stimulation in selected participants with severe faecal incontinence can significantly reduce episodes of faecal incontinence as well as improving the ability to defer defaecation but this did not quite result in measurable improvement in quality of life. Additionally, the trial by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> found that in the short term SNS provides some clinical benefit to patients with FI.</P>
<P>In the trial by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, at the end of the crossover period and while still blinded, the participants chose the period of stimulation ('on' or 'off') they had preferred and the mode of stimulation corresponding to the selected period ('on' or 'off') was then continued for the 3-month follow-up. Rather than reporting outcomes for the trial group as a whole, <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported most outcomes (at baseline; prior to the crossover period; during the 'on' and 'off' crossover periods; and at follow-up) separately for the group of 19 participants who preferred the 'on' period and the group of 5 who preferred the 'off' period. The characteristics of the two groups differed somewhat in terms of type and duration of faecal incontinence. The two groups responded differently to SNS, with the group of 19 reporting a 59% reduction in episodes of faecal incontinence per week, from a median of 1.7 during the 'off' period to 0.7 during the 'on' period. In contrast, the group of five experienced a 118% increase in episodes of faecal incontinence per week: from a median of 1.7 during the 'off' period to 3.7 during the 'on' period.</P>
<P>If results for the 'on' and 'off' periods of the crossover had been reported for the trial group as a whole then in terms of episodes of faecal incontinence per week, ability to defer defaecation, and episodes of urgency, SNS would have been shown to be less effective compared with the results for the group of 19 participants who preferred the 'on' period. The fact that five participants chose the mode of stimulation corresponding to the 'off' period at the end of the crossover emphasises the fact that SNS for faecal incontinence is not an effective treatment for all patients eligible for the procedure, even taking into account that temporary percutaneous stimulation for a two- to three-week period prior to permanent implantation allows selection of those for whom permanent SNS is likely to be effective. Despite having met the criteria to progress from temporary to permanent stimulation (at least a 50% reduction in the number of episodes of faecal incontinence per week or a 50% reduction in the number of episodes of faecal urgency per week, or both) these five participants actually experienced an increase rather than a reduction in episodes of faecal incontinence during the 'on' period compared with the 'off' period.</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>
<LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK> and <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK> did not report adverse effects. However, the other four trials did (<LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> reported a relatively high adverse event rate, with 4 (15%) of the 27 participants who received a permanent implant experiencing an adverse event requiring removal (explantation) of the stimulator, all prior to the crossover period. Three of the explantations were because of unresolved pain, while the fourth was because of recurrent infection. These adverse events were resolvable through removal of the device, and no adverse events appeared to have occurred during the second crossover period or follow-up period. In the trial conducted by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>, adverse events included pain at the site of implantation, seroma which required percutaneous aspiration, and excessive tingling in the vaginal region. However, no septic complication requiring explantation or urinary/sexual function-related adverse events were reported (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). Also, in the trial carried out by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>, adverse effects included mild ipsilateral leg pain during temporary testing which resolved after removal of the temporary lead and insertion of the permanent implant. Other adverse events experienced include stimulator-site pain following insertion of the neurostimulator, which resolved with adjustment of stimulator settings (<LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>). Finally, in the trial conducted by <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>, adverse events reported for the enrolled participants after implantations included: haematoma formation (n = 3), misplacement of tined lead (n = 1) and pain at stimulator site (n = 1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Constipation</HEADING>
<P>In the trial of only two participants conducted by <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> assessing the effects of SNS for constipation, bowel movements per week were increased by 150%, while the time with abdominal pain and bloating decreased from 79% during the 'off' period to 33% during the 'on' period; the Wexner constipation score showed an improvement of 36%. The much larger RCT of 59 participants carried out by <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> found that in patients with refractory slow transit constipation, SNS did not improve the frequency of complete bowel movements per week.</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>
<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK> reported 73 adverse events which included pain at the site of the implanted pulse generator (32), wound infection (12), and urological symptoms (17). <LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK> reported that no adverse effects had occurred.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-08-17 11:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review includes eight trials, all of which are RCTs. Six assessed SNS for faecal incontinence (219 participants enrolled overall) while two trials assessed SNS for constipation (61 participants enrolled). In the interval since the first Cochrane review on this subject (<LINK REF="REF-Mowatt-2007" TYPE="REFERENCE">Mowatt 2007</LINK>), SNS has become well established as first-line minimally-invasive treatment for patients with FI failing conservative measures, with recognition of this fact by regulatory agencies (<LINK REF="REF-FDA-1998" TYPE="REFERENCE">FDA 1998</LINK>; <LINK REF="REF-NICE-2007" TYPE="REFERENCE">NICE 2007</LINK>). Such widespread acceptance has been based almost exclusively on post-registration data published in the form of numerous case series, including some large well-designed prospective non-randomised studies (<LINK REF="REF-Wexner-2010" TYPE="REFERENCE">Wexner 2010</LINK>).</P>
<P>The availability of data from randomised trials has progressed slightly with five new trials being added to this update (<LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>; <LINK REF="STD-Kahlke-2015_x0023_" TYPE="STUDY">Kahlke 2015#</LINK>; <LINK REF="STD-S_x00f8_rensen-2010_x0023_" TYPE="STUDY">Sørensen 2010#</LINK>; <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK>; <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>). Within the included trials, potentially relevant primary outcome measures (such as the proportion of participants either cured or improved, having urgency, and using pads/plugs) were not reported consistently. Other primary outcome measures such as incontinence scores and quality-of-life scores were also not consistently reported. This variation has made comparison between the trials problematic. The addition of these trials does not change the conclusions reached in the previous review and provides further evidence for a reduction in episodes of faecal incontinence and urgency, and improvement in the ability to defer defaecation.</P>
<SUBSECTION>
<HEADING LEVEL="3">Surrogate outcome measures</HEADING>
<P>Anorectal manometry measurements, although commonly reported in trials, does not appear to provide information that can be used to determine which patients will benefit from SNS, and so does not appear to provide clinically useful information.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-06-23 23:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>In terms of methodological quality, the main uncertainty in judging trial bias stemmed from lack of clarity around randomisation techniques and allocation concealment. Additionally, participant blinding in the trials is complicated by the widely-acknowledged preference of the majority of participants for suprasensory stimulation (meaning that the current needs to be so high to be effective that the patient is aware of it) which makes allocation concealment and use of valid sham therapy problematic. Hence the observed effect may have been overestimated due to a placebo effect.</P>
<P>Moreover, some trials had little or no wash-out period between the two crossover periods with short treatment duration, thus carry-over effects when the device was used first in the 'on' position may exist.</P>
<P>Another methodological limitation is the heterogeneity in the collection of data and method of analysis: some trials reported outcomes at specific time points whereas others reported average outcome for the whole cohort with an average follow-up period. Hence formal statistical synthesis was generally not possible due to the heterogeneity in reported outcomes and styles of reporting, as well as differences in the populations, interventions and trial designs.</P>
<P>Some of the trials included in this review had a small sample of participants which would affect estimates of treatment differences. Furthermore, follow-up period was generally inadequate and needs to be longer to further evaluate long-term effects of SNS.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2015-08-17 11:53:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Faecal incontinence</HEADING>
<P>Our findings that SNS for faecal incontinence can significantly improve faecal continence in some selected patients is in agreement with an earlier systematic review conducted in the UK of the efficacy and safety of SNS for faecal incontinence by <LINK REF="REF-Fraser-2004" TYPE="REFERENCE">Fraser 2004</LINK>. This was submitted to the National Institute for Health and Clinical Excellence (NICE) Interventional Procedures Programme in 2004 as part of NICE's consideration of this topic (<LINK REF="REF-Fraser-2004" TYPE="REFERENCE">Fraser 2004</LINK>). The systematic review conducted by <LINK REF="REF-Fraser-2004" TYPE="REFERENCE">Fraser 2004</LINK> included one trial that is also included in this review (the crossover trial conducted by <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), a non-randomised multicentre trial involving 37 participants, and six case series enrolling 266 participants, of whom 149 received permanent implants. The review reported that 41% to 75% of participants achieved complete faecal continence and 75% to 100% experienced an improvement of 50% or more in the number of faecal incontinence episodes. In the multicentre trial and all six case series, SNS resulted in a decrease in the number of episodes of faecal incontinence per week (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) (<LINK REF="REF-Fraser-2004" TYPE="REFERENCE">Fraser 2004</LINK>). The review also noted a relatively high adverse event rate: amongst 149 participants receiving permanent implants in the case series, 19 (13%) adverse events were reported, although these resulted in the explantation of only four devices. Amongst 34 participants receiving permanent implants in the multicentre trial, 15 (44%) adverse events were reported, resulting in the removal of two devices.</P>
<P>Our findings that SNS for faecal incontinence can significantly improve faecal continence in some selected patients is also in agreement with a systematic review conducted in the UK of clinical effectiveness of neuromodulation in the treatment of faecal incontinence by <LINK REF="REF-Thin-2013" TYPE="REFERENCE">Thin 2013</LINK>. This systematic review for SNS included 61 eligible studies of which the majority were prospective case series (n = 50) and only two were randomised clinical trials. The two randomised trials were the parallel-group study by <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK> and the crossover study by <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>, both included in our current systematic review. The review reported the success rates for SNS (based on at least 50% improvement in FI episodes per week) were 63% (range 33% to 36%), 58% (range 52% to 81%) and 54% (range 50% to 58%) in the short, medium and long term respectively. Furthermore, 36% (range 8% to 68%), 32% (range 4% to 74%) and 20% (range 2% to 48%) of participants achieved complete faecal continence.</P>
<P>Similarly, a meta-analysis conducted by <LINK REF="REF-Tan-2011" TYPE="REFERENCE">Tan 2011</LINK> was in agreement with our findings. In their review 34 studies were included of which the majority (n = 28) were prospective non-randomised trials (<LINK REF="REF-Tan-2011" TYPE="REFERENCE">Tan 2011</LINK>). The remaining studies included three randomised control trials. Two of the RCTs were crossover trials (<LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK>; <LINK REF="STD-Vaizey-2000_x0023_" TYPE="STUDY">Vaizey 2000#</LINK>), while the third was a parallel-group trial (<LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>): all are included in the current review. Tan and colleagues found SNS significantly improved the faecal incontinence episodes per week (weighted mean difference &#8722;6.83; 95% confidence interval &#8722;8.05 to &#8722;5.60; P &lt; 0.001) compared with maximal conservative therapy (<LINK REF="REF-Tan-2011" TYPE="REFERENCE">Tan 2011</LINK>). Additionally, the adverse events rate reported was 15% for permanent SNS, 3% resulting in permanent explantation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Constipation</HEADING>
<P>The systematic review by <LINK REF="REF-Jarrett-2004" TYPE="REFERENCE">Jarrett 2004</LINK> included two case series involving 20 participants and concluded that SNS improved evacuation difficulty, increased the frequency of defaecation, and decreased the time with abdominal pain and bloating. Furthermore, a systematic review by <LINK REF="REF-Sharma-2013" TYPE="REFERENCE">Sharma 2013</LINK> of SNS for constipation included 10 studies of which one was a double-blind, placebo-controlled crossover study (<LINK REF="STD-Kenefick-2002_x0023_" TYPE="STUDY">Kenefick 2002#</LINK>). This study found that SNS can improve bowel frequency and reduce constipation symptoms (<LINK REF="REF-Sharma-2013" TYPE="REFERENCE">Sharma 2013</LINK>). However, our current review which included two randomised controlled trials involving 61 participants does not concur with the review by <LINK REF="REF-Jarrett-2004" TYPE="REFERENCE">Jarrett 2004</LINK> and <LINK REF="REF-Sharma-2013" TYPE="REFERENCE">Sharma 2013</LINK>. We found that SNS does not improve symptoms in patients with constipation but the number of participants was too small to be conclusive.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-08-17 11:53:30 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-08-17 11:53:30 +0100" MODIFIED_BY="[Empty name]">
<P>It remains true that SNS is not effective for all patients with severe faecal incontinence and even some of those who meet the criteria to progress from temporary to permanent stimulation may then go on to experience an increase rather than a reduction in episodes of faecal incontinence. The practice of employing temporary, percutaneous stimulation for a two- to three-week period may identify those most likely to respond positively to a permanent implant but does not identify all those for whom a permanent implant will be beneficial. Further, it must be noted that the failure to implant patients who have not benefited from a testing phase means that the true utility of this extra procedure (based on standard statistical measures of diagnostic accuracy) has not been studied. The adverse event rate leading to removal of the permanent stimulator was high at 15% in the <LINK REF="STD-Leroi-2005_x0023_" TYPE="STUDY">Leroi 2005#</LINK> trial but less (6%) in the larger trial of <LINK REF="STD-Tjandra-2008" TYPE="STUDY">Tjandra 2008</LINK>, and less also in the trials by <LINK REF="STD-Thin-2015" TYPE="STUDY">Thin 2015</LINK> and <LINK REF="STD-Dinning-2015_x0023_" TYPE="STUDY">Dinning 2015#</LINK>.</P>
<P>In summary, this review supports the view that SNS has an important role for selected patients with FI failing conservative therapies thus reserving direct surgery to the anal sphincter for particular highly-selected patients or perhaps those failing SNS: such surgery carries a high risk of serious morbidity and is not always successful (<LINK REF="REF-Baeten-1995" TYPE="REFERENCE">Baeten 1995</LINK>; <LINK REF="REF-Lehur-1998" TYPE="REFERENCE">Lehur 1998</LINK>; <LINK REF="REF-Malouf-2000" TYPE="REFERENCE">Malouf 2000</LINK>). This position may change with further potentially-disruptive technologies at various stages of trial evaluation (<LINK REF="REF-Hotouras-2014" TYPE="REFERENCE">Hotouras 2014</LINK>; <LINK REF="REF-Lehur-2010" TYPE="REFERENCE">Lehur 2010</LINK>; <LINK REF="REF-Ratto-2011" TYPE="REFERENCE">Ratto 2011</LINK>).</P>
<P>Although there have been considerably fewer published case series for patients with chronic constipation, available prospective case series data support a beneficial effect in most, including in the relatively large European study (<LINK REF="REF-Kamm-2010" TYPE="REFERENCE">Kamm 2010</LINK>). Despite this the current clinical view is that the overall results are less good than for FI (<LINK REF="REF-Knowles-2009" TYPE="REFERENCE">Knowles 2009</LINK>; <LINK REF="REF-Maeda-2010" TYPE="REFERENCE">Maeda 2010</LINK>); and that adverse events are more common (<LINK REF="REF-Maeda-2010" TYPE="REFERENCE">Maeda 2010</LINK>). The data in the current review involving two crossover trials of 61 participants do not show any beneficial effect for SNS when treating patients with constipation but the information is limited by the small number of participants.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-23 23:32:42 +0100" MODIFIED_BY="[Empty name]">
<P>The current literature base in respect of controlled trials must surely be considered inadequate for an invasive and expensive therapy which, for urinary and faecal incontinence, has now been implanted in 145,000 patients worldwide. The proof of effectiveness, and indeed efficacy, of SNS is currently based almost entirely on post-registration (phase IV) data presented by enthusiastic individuals in ad hoc case series. To date, there has been no definitive phase III study of effectiveness of SNS versus sham stimulation nor, importantly, any phase II study designed to combine efficacy with proof of mechanism. This latter point is important for the reasons outlined above, i.e. that a proportion of seemingly well-selected patients fail therapy over time. In the absence of knowledge of mechanism, valid biomarkers for patient selection will be difficult to determine. Further trials will also need to compare SNS with other therapies which fall into the minimally-invasive therapy cluster, i.e. between conservative approaches and drugs versus major reconstructive surgery.</P>
<P>The design of all future trials will need to address the deficiencies of current trials but this will not be easy. Design points that should be considered are:</P>
<P>(1) the inadequacy of current outcome measures, especially the dependency on bowel diaries (<LINK REF="REF-Vaizey-2014" TYPE="REFERENCE">Vaizey 2014</LINK>);</P>
<P>(2) the need for meaningful follow-up (at least one year and ideally two years or more);</P>
<P>(3) the avoidance of crossover designs with short treatment durations and lack of wash-out periods. (It is accepted that parallel arm trials require greater recruitment numbers to mitigate against baseline variances. However, it will be important to assess primary efficacy in treatment of naïve patients rather than switching the device on or off in patients who have already been selected on the basis of successful therapy progression);</P>
<P>(4) attention to participant blinding as well as observer blinding. (This is complicated by the widespread acknowledgement that some patients require suprasensory stimulation thus making allocation concealment and selection of a valid sham therapy difficult);</P>
<P>(5) interpretation of the temporary testing phase as a diagnostic test or rather as part of the therapy itself (this has implications for presenting data as intent-to-treat). As noted above, the validity of this testing phase has in any case been questioned for discriminant-value and health-economic reasons.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-12-11 09:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>We thank Sheila Wallace for searching the Cochrane Incontinence Group Specialised Trials Register.</P>
<P>We also acknowledge the authors (G Mowatt, C Glazener, and M Jarrett) of the original review (<LINK REF="REF-Mowatt-2007" TYPE="REFERENCE">Mowatt 2007</LINK>) for their contribution.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-12-11 09:52:42 +0000" MODIFIED_BY="[Empty name]">
<P>Some members of the review author group (NNT, MAT, CHK) are authors of a recently-published overview on the wider topic of neuromodulation including SNS (<LINK REF="REF-Thin-2013" TYPE="REFERENCE">Thin 2013</LINK>). The Royal London Hospital's team under Professor Knowles heads many original clinical and methodological studies on neuromodulation, including SNS and PTNS.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-12-11 09:52:31 +0000" MODIFIED_BY="[Empty name]">
<P>Amin Abukar and Mohamed A Thaha screened the search results, assessed full text studies for inclusion, and undertook data abstraction and quality assessment. Amin Abukar, Mohamed A Thaha and Charles Knowles drafted the review. Mohamed A Thaha, Noel Thin, Anthony Ramsanahie, and Charles Knowles provided advice on analysis and interpretation of data and commented on drafts of the review. Mohamed A Thaha and Charles Knowles provided clinical advice on aspects of the SNS procedure.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-19 12:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>The current review is an update of the previous publication in 2007 (<LINK REF="REF-Mowatt-2007" TYPE="REFERENCE">Mowatt 2007</LINK>) and has included five extra trials.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-08-17 13:46:11 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-07-21 13:35:03 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-07-21 13:35:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Dinning-2015_x0023_" MODIFIED="2015-07-21 13:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Dinning 2015#" YEAR="2015">
<REFERENCE MODIFIED="2015-07-21 13:34:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinning PG, Hunt L, Patton V, Tzang T, Szczesniak M, Gebski V, et al</AU>
<TI>Treatment efficacy of sacral nerve stimulation in slow transit constipation: A two phase, double blind randomized controlled crossover study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2015</YR>
<VL>110</VL>
<NO>5</NO>
<PG>733-40</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:34:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:34:08 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont67952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-25 14:13:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-25 14:13:54 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12611001192976"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahlke-2015_x0023_" MODIFIED="2015-07-21 13:34:58 +0100" MODIFIED_BY="[Empty name]" NAME="Kahlke 2015#" YEAR="2015">
<REFERENCE MODIFIED="2015-07-21 13:34:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahlke V, Topic H, Peleikis HG, Jongen J</AU>
<TI>Sacral nerve modulation for fecal incontinence: results of a prospective single-center randomized crossover study</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2015</YR>
<VL>58</VL>
<PG>235-40</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:36:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:36:34 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont66462"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenefick-2002_x0023_" MODIFIED="2015-06-24 13:52:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kenefick 2002#" YEAR="2002">
<REFERENCE MODIFIED="2015-06-24 13:52:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kenefick NJ, Vaizey CJ, Cohen CR, Nicholls RJ, Kamm MA</AU>
<TI>Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation</TI>
<SO>British Journal of Surgery</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>12</NO>
<PG>1570-1</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:52:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:52:52 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont16145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-11 09:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenefick NJ</AU>
<TI>Sacral nerve neuromodulation for the treatment of lower bowel motility disorders</TI>
<SO>Annals of The Royal College of Surgeons of England</SO>
<YR>2006</YR>
<VL>88</VL>
<NO>7</NO>
<PG>617-23</PG>
<IDENTIFIERS MODIFIED="2008-10-29 15:59:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-29 15:59:19 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="22235"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leroi-2005_x0023_" MODIFIED="2015-06-24 13:53:18 +0100" MODIFIED_BY="[Empty name]" NAME="Leroi 2005#" YEAR="2005">
<REFERENCE MODIFIED="2015-06-24 13:53:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leroi AM, Parc Y, Lehur PA, Mion F, Barth X, Rullier E et al</AU>
<TI>Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study</TI>
<SO>Annals of Surgery</SO>
<YR>2005</YR>
<VL>242</VL>
<NO>5</NO>
<PG>662-9</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:53:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:53:18 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont21269"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-S_x00f8_rensen-2010_x0023_" MODIFIED="2015-06-23 13:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="Sørensen 2010#" YEAR="2010">
<REFERENCE MODIFIED="2014-12-11 09:54:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sørensen M, Thomsen F</AU>
<TI>Sacral nerve stimulation increases rectal sensitivity in patients with faecal incontinence: results of a randomised double-blinded crossover study (Abstract number 437)</TI>
<SO>Proceedings of the Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association, 2010 Aug 23-27, Toronto, Canada</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2014-06-18 17:28:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-18 17:28:39 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont40174"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thin-2015" MODIFIED="2015-07-21 13:35:03 +0100" MODIFIED_BY="[Empty name]" NAME="Thin 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-07-21 13:35:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thin NN, Taylor SJC, Bremner SA, Emmanuel AV, Hounsome N, Williams NS, et al</AU>
<TI>Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence</TI>
<SO>British Journal of Surgery</SO>
<YR>2015</YR>
<VL>102</VL>
<NO>4</NO>
<PG>349-58</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:55:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:55:05 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont66403"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-24 13:55:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:55:31 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="EUCTR2010-018728-15"/>
<IDENTIFIER MODIFIED="2015-06-24 13:55:54 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="UKCRN10479"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tjandra-2008" MODIFIED="2014-06-19 10:18:07 +0100" MODIFIED_BY="[Empty name]" NAME="Tjandra 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-06-19 10:18:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tjandra J, Lim J, Green C, Carey M</AU>
<TI>Sacral neuromodulation in patients with faecal incontinence: a randomized controlled study on efficacy and quality of life (Abstract number 090)</TI>
<SO>Colorectal Disease</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>31</PG>
<IDENTIFIERS MODIFIED="2014-06-19 10:18:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-19 10:18:07 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont24001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-18 17:29:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tjandra JJ, Chan MKY, Yeh CH, Murray-Green C</AU>
<TI>Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: A randomized, controlled study</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>5</NO>
<PG>494-502</PG>
<IDENTIFIERS MODIFIED="2014-06-18 17:29:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-18 17:29:36 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont27640"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaizey-2000_x0023_" MODIFIED="2015-06-24 13:57:08 +0100" MODIFIED_BY="[Empty name]" NAME="Vaizey 2000#" YEAR="2000">
<REFERENCE MODIFIED="2015-06-24 13:57:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaizey CJ, Kamm MA, Roy AJ, Nicholls RJ</AU>
<TI>Double-blind crossover study of sacral nerve stimulation for fecal incontinence</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>3</NO>
<PG>298-302</PG>
<IDENTIFIERS MODIFIED="2015-06-24 13:57:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 13:57:08 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont11184"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-06-24 14:07:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dinning-2007" MODIFIED="2015-06-24 14:03:40 +0100" MODIFIED_BY="[Empty name]" NAME="Dinning 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-06-24 14:03:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinning PG, Fuentealba SE, Kennedy ML, Lubowski DZ, Cook IJ</AU>
<TI>Sacral nerve stimulation induces pan-colonic propagating pressure waves and increases defecation frequency in patients with slow-transit constipation</TI>
<SO>Colorectal Disease</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>2</NO>
<PG>123-32</PG>
<IDENTIFIERS MODIFIED="2015-06-24 14:03:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:03:40 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont22557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinning-2013" MODIFIED="2015-06-24 14:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Dinning 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-24 14:05:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinning P, Patton V, Hunt L, Gebski V, Jones M, Stewart P, Lubowski D, Cook I</AU>
<TI>Efficacy of sacral nerve stimulation for severe slow transit constipation: A randomised, double-blind, placebo-controlled, crossover study</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2013</YR>
<VL>56</VL>
<NO>4</NO>
<PG>e116</PG>
<IDENTIFIERS MODIFIED="2015-06-24 14:05:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:05:07 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-24 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:05:30 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12611001192976"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knowles-2012" MODIFIED="2015-06-24 14:07:08 +0100" MODIFIED_BY="[Empty name]" NAME="Knowles 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-06-24 14:06:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knowles CH, Thin N, Gill K, Bhan C, Grimmer K, Lunniss PJ, et al</AU>
<TI>Prospective randomized double-blind study of temporary sacral nerve stimulation in patients with rectal evacuatory dysfunction and rectal hyposensitivity</TI>
<SO>Annals of Surgery</SO>
<YR>2012</YR>
<VL>255</VL>
<NO>4</NO>
<PG>643-9</PG>
<IDENTIFIERS MODIFIED="2015-06-24 14:06:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:06:30 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45223"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-24 14:07:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:07:08 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN25945941"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-06-24 14:57:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Borjesson-2013" MODIFIED="2015-06-24 14:08:22 +0100" MODIFIED_BY="[Empty name]" NAME="Borjesson 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-24 14:08:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Borjesson L</AU>
<TI>Sacral nerve stimulation vs anal bulking for faecal incontinence - a randomised controlled trial</TI>
<SO>http://isrctn.org/ISRCTN00247992</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2015-06-24 14:08:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:08:22 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont64540"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-17 13:08:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-17 13:08:34 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN00247992"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jayne-2014" MODIFIED="2015-06-24 14:57:15 +0100" MODIFIED_BY="[Empty name]" NAME="Jayne 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-06-24 14:09:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jayne D</AU>
<TI>Safari: Sacral nerve stimulation versus the FENIX TM magnetic sphincter augmentation for adult faecal incontinence: a prospective, UK multi-site, parallel-group, randomised clinical study investigating the safety and efficacy of the FENIX TM magnetic sphincter augmentation (MSA) compared to sacral nerve stimulation (SNS) for adult FI</TI>
<SO>http://isrctn.org/ISRCTN16077538</SO>
<YR>2014</YR>
<IDENTIFIERS MODIFIED="2015-06-24 14:09:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:09:10 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont64510"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-24 14:57:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-17 13:09:23 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN16077538"/>
<IDENTIFIER MODIFIED="2015-06-24 14:57:15 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.SaFaRI."/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vallance-2014" MODIFIED="2015-06-24 14:57:42 +0100" MODIFIED_BY="[Empty name]" NAME="Vallance 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-06-24 14:14:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal: Conference Abstract&lt;br&gt;English; ABSTRACT LANGUAGE:English&lt;/p&gt;" NOTES_MODIFIED="2015-06-24 14:14:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vallance A, Brown S, Nugent K, Lodge J, Protheroe D, Neville K, et al</AU>
<TI>Study design: Sacral nerve stimulation versus the FENIXTM magnetic anal sphincter for adult faecal incontinence: A randomised investigation (SaFaRI) (Abstract number W191)</TI>
<SO>Colorectal Disease</SO>
<YR>2014</YR>
<VL>16</VL>
<NO>Suppl s2</NO>
<PG>197</PG>
<IDENTIFIERS MODIFIED="2015-06-24 14:14:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:14:46 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont66262"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-06-24 14:57:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 14:15:52 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN16077538"/>
<IDENTIFIER MODIFIED="2015-06-24 14:57:42 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.SaFaRI"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-08-17 13:46:11 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-08-17 13:46:11 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altomare-2004" MODIFIED="2014-04-13 19:54:14 +0100" MODIFIED_BY="[Empty name]" NAME="Altomare 2004" TYPE="JOURNAL_ARTICLE">
<AU>Altomare DF, Binda GA, Dodi G, La Torre F, Romano G, Rinaldi M, et al</AU>
<TI>Disappointing long-term results of the artificial anal sphincter for faecal incontinence</TI>
<SO>The British Journal of Surgery</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>10</NO>
<PG>1352-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baeten-1991" MODIFIED="2014-12-11 09:55:08 +0000" MODIFIED_BY="[Empty name]" NAME="Baeten 1991" TYPE="JOURNAL_ARTICLE">
<AU>Baeten CG, Konsten J, Soeters PB, Spaans F, Visser R, Habets AM, et al</AU>
<TI>Dynamic graciloplasty for treatment of faecal incontinence</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8776</NO>
<PG>1163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baeten-1995" MODIFIED="2014-04-13 22:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Baeten 1995" TYPE="JOURNAL_ARTICLE">
<AU>Baeten CG, Geerdes BP, Adang EM, Heineman E, Konsten J, Engel GL, et al</AU>
<TI>Anal dynamic graciloplasty in the treatment of intractable fecal incontinence</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>24</NO>
<PG>1600-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brindley-1974" MODIFIED="2014-04-13 19:55:14 +0100" MODIFIED_BY="[Empty name]" NAME="Brindley 1974" TYPE="JOURNAL_ARTICLE">
<AU>Brindley GS</AU>
<TI>Emptying the bladder by stimulating sacral ventral roots</TI>
<SO>The Journal of Physiology</SO>
<YR>1974</YR>
<VL>237</VL>
<NO>2</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2010" MODIFIED="2014-05-21 17:57:46 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2010" TYPE="COCHRANE_REVIEW">
<AU>Brown SR, Wadhawan H, Nelson RL</AU>
<TI>Surgery for faecal incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<PG>CD001757</PG>
<ED>Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD001757. DOI: 10.1002/14651858.CD001757.pub4</ED>
<IDENTIFIERS MODIFIED="2014-05-21 17:57:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-21 17:57:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001757.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burgell-2012" MODIFIED="2014-04-13 19:55:34 +0100" MODIFIED_BY="[Empty name]" NAME="Burgell 2012" TYPE="JOURNAL_ARTICLE">
<AU>Burgell RE, Bhan C, Lunniss PJ, Scott SM</AU>
<TI>Fecal incontinence in men: coexistent constipation and impact of rectal hyposensitivity</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2012</YR>
<VL>55</VL>
<NO>1</NO>
<PG>18-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Camilleri-2008" MODIFIED="2014-04-13 19:55:51 +0100" MODIFIED_BY="[Empty name]" NAME="Camilleri 2008" TYPE="JOURNAL_ARTICLE">
<AU>Camilleri M, Kerstens R, Rykx A, Vandeplassche L</AU>
<TI>A placebo-controlled trial of prucalopride for severe chronic constipation</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>22</NO>
<PG>2344-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carr-2013" MODIFIED="2014-04-13 19:56:00 +0100" MODIFIED_BY="[Empty name]" NAME="Carr 2013" TYPE="JOURNAL_ARTICLE">
<AU>Carr LK, Robert M, Kultgen PL, Herschorn S, Birch C, Murphy M, et al</AU>
<TI>Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study</TI>
<SO>The Journal of Urology</SO>
<YR>2013</YR>
<VL>189</VL>
<NO>2</NO>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carrington-2011" MODIFIED="2014-12-11 09:55:22 +0000" MODIFIED_BY="[Empty name]" NAME="Carrington 2011" TYPE="JOURNAL_ARTICLE">
<AU>Carrington EV, Knowles CH</AU>
<TI>The influence of sacral nerve stimulation on anorectal dysfunction</TI>
<SO>Colorectal Disease</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carrington-2014" MODIFIED="2015-08-17 13:45:44 +0100" MODIFIED_BY="[Empty name]" NAME="Carrington 2014" TYPE="JOURNAL_ARTICLE">
<AU>Carrington EV, Evers J, Grossi U, Dinning PG, Scott SM, O'Connell PR, et al</AU>
<TI>A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation</TI>
<SO>Neurogastroenterology &amp; Motility</SO>
<YR>2014</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1222-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-2009" MODIFIED="2014-12-11 09:57:37 +0000" MODIFIED_BY="[Empty name]" NAME="Cook 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cook IJ, Talley NJ, Benninga MA, Rao SS, Scott SM</AU>
<TI>Chronic constipation: overview and challenges</TI>
<SO>Neurogastroenterology &amp; Motility</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>Suppl 2</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dinning-2012" MODIFIED="2015-08-17 13:45:53 +0100" MODIFIED_BY="[Empty name]" NAME="Dinning 2012" TYPE="JOURNAL_ARTICLE">
<AU>Dinning PG, Hunt LM, Arkwright JW, Patton V, Szczesniak MM, Wiklendt L, et al</AU>
<TI>Pancolonic motor response to subsensory and suprasensory sacral nerve stimulation in patients with slow-transit constipation</TI>
<SO>British Journal of Surgery</SO>
<YR>2012</YR>
<VL>99</VL>
<NO>7</NO>
<PG>1002-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dudding-2008" MODIFIED="2014-04-13 19:56:18 +0100" MODIFIED_BY="[Empty name]" NAME="Dudding 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dudding TC, Meng Lee E, Faiz O, Pares D, Vaizey CJ, McGuire A, et al</AU>
<TI>Economic evaluation of sacral nerve stimulation for faecal incontinence</TI>
<SO>The British Journal of Surgery</SO>
<YR>2008</YR>
<VL>95</VL>
<NO>9</NO>
<PG>1155-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duelund_x002d_Jakobsen-2013" MODIFIED="2015-07-21 13:35:30 +0100" MODIFIED_BY="[Empty name]" NAME="Duelund-Jakobsen 2013" TYPE="JOURNAL_ARTICLE">
<AU>Duelund-Jakobsen J, Buntzen S, Lundby L, Laurberg S</AU>
<TI>Sacral nerve stimulation at subsensory threshold does not compromise treatment efficacy: results from a randomized, blinded crossover study</TI>
<SO>Annals of Surgery</SO>
<YR>2013</YR>
<VL>257</VL>
<NO>2</NO>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ehrenpreis-2007" MODIFIED="2014-04-13 19:56:30 +0100" MODIFIED_BY="[Empty name]" NAME="Ehrenpreis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ehrenpreis ED, Chang D, Eichenwald E</AU>
<TI>Pharmacotherapy for fecal incontinence: a review</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2007</YR>
<VL>50</VL>
<NO>5</NO>
<PG>641-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enck-2009" MODIFIED="2014-12-11 09:57:47 +0000" MODIFIED_BY="[Empty name]" NAME="Enck 2009" TYPE="JOURNAL_ARTICLE">
<AU>Enck P, Van der Voort IR, Klosterhalfen S</AU>
<TI>Biofeedback therapy in fecal incontinence and constipation</TI>
<SO>Neurogastroenterology &amp; Motility</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1133-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evers-2014" MODIFIED="2015-08-17 13:46:01 +0100" MODIFIED_BY="[Empty name]" NAME="Evers 2014" TYPE="JOURNAL_ARTICLE">
<AU>Evers J, Devane L, Carrington EV, Scott SM, Knowles CH, O'Connell PR, et al</AU>
<TI>Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model</TI>
<SO>British Journal of Surgery</SO>
<YR>2014</YR>
<VL>101</VL>
<NO>10</NO>
<PG>1317-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1998" MODIFIED="2014-05-21 17:58:55 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 1998" TYPE="JOURNAL_ARTICLE">
<AU>Food and Drug Administration</AU>
<TI>Medtronic, Inc.; premarket approval of the Interstim Sacral Nerve Stimulation (SNS) System--FDA. Notice</TI>
<SO>Federal register</SO>
<YR>1998</YR>
<VL>63</VL>
<NO>19</NO>
<PG>4457</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-2004" MODIFIED="2014-12-12 10:42:52 +0000" MODIFIED_BY="[Empty name]" NAME="Fraser 2004" TYPE="OTHER">
<AU>Fraser C, Glazener C, Grant A, Mowatt G</AU>
<TI>Systematic review of the efficacy and safety of sacral nerve stimulation for faecal incontinence</TI>
<SO>Available at: http://www.nice.org.uk/guidance/ipg99/resources/systematic-review-of-the-efficacy-and-safety-of-sacral-nerve-stimulation-for-faecal-incontinence2 (accessed 12 December 2014)</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallegos_x002d_Orozco-2012" MODIFIED="2014-04-13 19:56:46 +0100" MODIFIED_BY="[Empty name]" NAME="Gallegos-Orozco 2012" TYPE="JOURNAL_ARTICLE">
<AU>Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM</AU>
<TI>Chronic constipation in the elderly</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2012</YR>
<VL>107</VL>
<NO>1</NO>
<PG>18-25; quiz 26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graf-2011" MODIFIED="2014-04-12 23:58:06 +0100" MODIFIED_BY="Amin A Abukar" NAME="Graf 2011" TYPE="JOURNAL_ARTICLE">
<AU>Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M</AU>
<TI>Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>377</VL>
<NO>9770</NO>
<PG>997-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2011" MODIFIED="2015-07-21 13:35:43 +0100" MODIFIED_BY="[Empty name]" NAME="Griffin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Griffin KM, Pickering M, O'Herlihy C, O'Connell PR, Jones JF</AU>
<TI>Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model</TI>
<SO>British Journal of Surgery</SO>
<YR>2011</YR>
<VL>98</VL>
<NO>8</NO>
<PG>1160-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-08-17 13:46:11 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holzer-2008" MODIFIED="2014-12-11 09:57:57 +0000" MODIFIED_BY="[Empty name]" NAME="Holzer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Holzer B, Rosen HR, Novi G, Ausch C, Hölbling N, Hofmann M, et al</AU>
<TI>Sacral nerve stimulation in patients with severe constipation</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>5</NO>
<PG>524-29; discussion 529-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopkinson-1966" MODIFIED="2014-04-13 18:10:15 +0100" MODIFIED_BY="[Empty name]" NAME="Hopkinson 1966" TYPE="JOURNAL_ARTICLE">
<AU>Hopkinson BR, Lightwood R</AU>
<TI>Electrical treatment of anal incontinence</TI>
<SO>Lancet</SO>
<YR>1966</YR>
<VL>1</VL>
<NO>7432</NO>
<PG>297-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hotouras-2014" MODIFIED="2014-12-11 09:58:16 +0000" MODIFIED_BY="[Empty name]" NAME="Hotouras 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hotouras A, Murphy J, Walsh U, Allison M, Curry A, Williams NS, et al</AU>
<TI>Outcome of percutaneous tibial nerve stimulation (PTNS) for fecal incontinence: a prospective cohort study</TI>
<SO>Annals of Surgery</SO>
<YR>2014</YR>
<VL>259</VL>
<NO>5</NO>
<PG>939-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HSCIC-2013" MODIFIED="2014-04-13 17:41:41 +0100" MODIFIED_BY="[Empty name]" NAME="HSCIC 2013" TYPE="OTHER">
<AU>Health and Social Care Information Centre</AU>
<TI>Prescriptions Dispensed in the Community: England 2002-12</TI>
<SO>http://www.hscic.gov.uk/catalogue/PUB11291/pres-disp-com-eng-2002-12-rep.pdf</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irvine-2002" MODIFIED="2014-04-13 19:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Irvine 2002" TYPE="JOURNAL_ARTICLE">
<AU>Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L</AU>
<TI>Health-related quality of life in functional GI disorders: focus on constipation and resource utilization</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>8</NO>
<PG>1986-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jarrett-2004" MODIFIED="2014-12-11 09:58:29 +0000" MODIFIED_BY="[Empty name]" NAME="Jarrett 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jarrett MED, Mowatt G, Glazener CMA, Fraser C, Nicholls RJ, Grant AM et al</AU>
<TI>Systematic review of sacral nerve stimulation for faecal incontinence and constipation</TI>
<SO>British Journal of Surgery</SO>
<YR>2004</YR>
<VL>91(12)</VL>
<PG>1559-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-1996" MODIFIED="2014-04-13 19:57:58 +0100" MODIFIED_BY="[Empty name]" NAME="Johanson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Lafferty J</AU>
<TI>Epidemiology of fecal incontinence: the silent affliction</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>1</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-2008" MODIFIED="2014-04-13 19:58:12 +0100" MODIFIED_BY="[Empty name]" NAME="Johanson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Morton D, Geenen J, Ueno R</AU>
<TI>Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>1</NO>
<PG>170-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamm-2010" MODIFIED="2014-04-13 18:57:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kamm 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kamm MA, Dudding TC, Melenhorst J, Jarrett M, Wang Z, Buntzen S, et al</AU>
<TI>Sacral nerve stimulation for intractable constipation</TI>
<SO>Gut</SO>
<YR>2010</YR>
<VL>59</VL>
<NO>3</NO>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knowles-1999" MODIFIED="2014-04-13 19:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Knowles 1999" TYPE="JOURNAL_ARTICLE">
<AU>Knowles CH, Scott M, Lunniss PJ</AU>
<TI>Outcome of colectomy for slow transit constipation</TI>
<SO>Annals of Surgery</SO>
<YR>1999</YR>
<VL>230</VL>
<NO>5</NO>
<PG>627-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knowles-2003" MODIFIED="2014-04-13 19:58:33 +0100" MODIFIED_BY="[Empty name]" NAME="Knowles 2003" TYPE="JOURNAL_ARTICLE">
<AU>Knowles CH, Scott SM, Rayner C, Glia A, Lindberg G, Kamm MA, et al</AU>
<TI>Idiopathic slow-transit constipation: an almost exclusively female disorder</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2003</YR>
<VL>46</VL>
<NO>12</NO>
<PG>1716-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knowles-2009" MODIFIED="2014-12-11 10:06:02 +0000" MODIFIED_BY="[Empty name]" NAME="Knowles 2009" TYPE="JOURNAL_ARTICLE">
<AU>Knowles CH, Dinning PG, Pescatori M, Rintala R, Rosen H</AU>
<TI>Surgical management of constipation</TI>
<SO>Neurogastroenterology &amp; Motility</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>Suppl 2</NO>
<PG>62-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehur-1998" MODIFIED="2014-12-11 10:06:17 +0000" MODIFIED_BY="[Empty name]" NAME="Lehur 1998" NOTES="&lt;p&gt;5770&lt;/p&gt;" NOTES_MODIFIED="2014-12-11 10:06:17 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lehur PA, Glemain P, Bruley des Varannes S, Buzelin JM, Leborgne J</AU>
<TI>Outcome of patients with an implanted artificial anal sphincter for severe faecal incontinence. A single institution report</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>1998</YR>
<VL>13(2)</VL>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehur-2010" MODIFIED="2014-04-13 19:58:56 +0100" MODIFIED_BY="[Empty name]" NAME="Lehur 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lehur PA, McNevin S, Buntzen S, Mellgren AF, Laurberg S, Madoff RD</AU>
<TI>Magnetic anal sphincter augmentation for the treatment of fecal incontinence: a preliminary report from a feasibility study</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2010</YR>
<VL>53</VL>
<NO>12</NO>
<PG>1604-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lunniss-2004" MODIFIED="2014-04-12 23:21:52 +0100" MODIFIED_BY="Amin A Abukar" NAME="Lunniss 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lunniss PJ, Gladman MA, Hetzer FH, Williams NS, Scott SM</AU>
<TI>Risk factors in acquired faecal incontinence</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>3</NO>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacDonagh-1990" MODIFIED="2014-04-13 18:34:33 +0100" MODIFIED_BY="[Empty name]" NAME="MacDonagh 1990" TYPE="JOURNAL_ARTICLE">
<AU>MacDonagh RP, Sun WM, Smallwood R, Forster D, Read NW</AU>
<TI>Control of defecation in patients with spinal injuries by stimulation of sacral anterior nerve roots</TI>
<SO>British Medical Journal</SO>
<YR>1990</YR>
<VL>300</VL>
<NO>6738</NO>
<PG>1494-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maeda-2010" MODIFIED="2014-04-13 19:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Maeda 2010" TYPE="JOURNAL_ARTICLE">
<AU>Maeda Y, Lundby L, Buntzen S, Laurberg S</AU>
<TI>Sacral nerve stimulation for constipation: suboptimal outcome and adverse events</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2010</YR>
<VL>53</VL>
<NO>7</NO>
<PG>995-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malouf-2000" MODIFIED="2014-04-13 16:08:40 +0100" MODIFIED_BY="[Empty name]" NAME="Malouf 2000" NOTES="&lt;p&gt;11048&lt;/p&gt;" NOTES_MODIFIED="2014-04-13 16:08:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Malouf AJ, Norton CS, Engel AF, Nicholls RJ, Kamm MA</AU>
<TI>Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9200</NO>
<PG>260-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matzel-1990" MODIFIED="2015-04-19 11:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Matzel 1990" TYPE="JOURNAL_ARTICLE">
<AU>Matzel KE, Schmidt RA, Tanagho EA</AU>
<TI>Neuroanatomy of the striated muscular anal continence mechanism. Implication for the use of neurostimulation</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1990</YR>
<VL>33</VL>
<PG>666-673</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matzel-1995" MODIFIED="2014-04-13 18:13:51 +0100" MODIFIED_BY="[Empty name]" NAME="Matzel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP</AU>
<TI>Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<NO>8983</NO>
<PG>1124-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCrea-2009" MODIFIED="2014-04-13 19:59:28 +0100" MODIFIED_BY="[Empty name]" NAME="McCrea 2009" TYPE="JOURNAL_ARTICLE">
<AU>McCrea GL, Miaskowski C, Stotts NA, Macera L, Paul SM, Varma MG</AU>
<TI>Gender differences in self-reported constipation characteristics, symptoms, and bowel and dietary habits among patients attending a specialty clinic for constipation</TI>
<SO>Gender Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>1</NO>
<PG>259-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melenhorst-2007" MODIFIED="2014-12-11 10:06:33 +0000" MODIFIED_BY="[Empty name]" NAME="Melenhorst 2007" TYPE="JOURNAL_ARTICLE">
<AU>Melenhorst J, Koch SM, Uludag O, van Gemert WG, Baeten CG</AU>
<TI>Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations</TI>
<SO>Colorectal Disease</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>8</NO>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-2011" MODIFIED="2014-12-11 10:06:44 +0000" MODIFIED_BY="[Empty name]" NAME="Mitchell 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell PJ, Cattle K, Saravanathan S, Telford KJ, Kiff ES</AU>
<TI>Insertion under local anaesthetic of temporary electrodes for sacral nerve stimulation testing is reliable and cost effective</TI>
<SO>Colorectal Disease</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>4</NO>
<PG>445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mugie-2011" MODIFIED="2014-12-11 10:06:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mugie 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mugie SM, Benninga MA, Di Lorenzo C</AU>
<TI>Epidemiology of constipation in children and adults: a systematic review</TI>
<SO>Best Practice &amp; Research: Clinical Gastroenterology</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>1</NO>
<PG>3-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1998" MODIFIED="2014-04-13 20:00:12 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nelson R, Furner S, Jesudason V</AU>
<TI>Fecal incontinence in Wisconsin nursing homes: prevalence and associations</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>10</NO>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2004" MODIFIED="2014-04-12 23:03:16 +0100" MODIFIED_BY="Amin A Abukar" NAME="Nelson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nelson RL</AU>
<TI>Epidemiology of fecal incontinence</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>1 Suppl1</NO>
<PG>S3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHS-2012" MODIFIED="2014-04-13 20:17:28 +0100" MODIFIED_BY="[Empty name]" NAME="NHS 2012" TYPE="OTHER">
<AU>National Health Service</AU>
<TI>Constipation - suspected</TI>
<SO>http://healthguides.mapofmedicine.com/choices/map/constipation_in_adults_and_the_elderly1.html</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHS-2013" MODIFIED="2014-05-21 17:55:22 +0100" MODIFIED_BY="[Empty name]" NAME="NHS 2013" NOTES="&lt;p&gt;The NHS Commissioning Board is now known as NHS England&lt;/p&gt;" NOTES_MODIFIED="2014-05-21 17:55:22 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>National Health Service (NHS) England</AU>
<TI>A08/S/d 2013/14 NHS standard contract for colorectal: faecal incontinence (adult)</TI>
<SO>Available at: http://www.england.nhs.uk/wp-content/uploads/2013/06/a08-colore-faecal-incon-adult.pdf (accessed 21 May 2014)</SO>
<YR>2013</YR>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2007" MODIFIED="2014-12-11 10:07:25 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2007" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Faecal incontinence: The management of faecal incontinence in adults</TI>
<SO>http://www.nice.org.uk/nicemedia/live/11012/36582/36582.pdf</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norton-2003" MODIFIED="2014-04-12 23:46:32 +0100" MODIFIED_BY="Amin A Abukar" NAME="Norton 2003" TYPE="JOURNAL_ARTICLE">
<AU>Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA</AU>
<TI>Randomized controlled trial of biofeedback for fecal incontinence</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>125</VL>
<NO>5</NO>
<PG>1320-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norton-2004" MODIFIED="2014-04-12 23:43:31 +0100" MODIFIED_BY="Amin A Abukar" NAME="Norton 2004" TYPE="JOURNAL_ARTICLE">
<AU>Norton C</AU>
<TI>Behavioral management of fecal incontinence in adults</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>1 Suppl 1</NO>
<PG>S64-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norton-2006" MODIFIED="2014-04-13 19:37:44 +0100" MODIFIED_BY="[Empty name]" NAME="Norton 2006" TYPE="JOURNAL_ARTICLE">
<AU>Norton C</AU>
<TI>Constipation in older patients: effects on quality of life</TI>
<SO>British Journal of Nursing</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>4</NO>
<PG>188-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norton-2007" MODIFIED="2014-04-13 18:35:59 +0100" MODIFIED_BY="[Empty name]" NAME="Norton 2007" TYPE="JOURNAL_ARTICLE">
<AU>Norton C, Thomas L, Hill J</AU>
<TI>Management of faecal incontinence in adults: summary of NICE guidance</TI>
<SO>British Medical Journal</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>7608</NO>
<PG>1370-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Omar-2013" MODIFIED="2015-07-21 13:35:52 +0100" MODIFIED_BY="[Empty name]" NAME="Omar 2013" TYPE="COCHRANE_REVIEW">
<AU>Omar MI, Edwin C</AU>
<TI>Drug treatment for faecal incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2015-06-24 12:33:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 12:33:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002116.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Otto-2010" MODIFIED="2014-12-11 10:07:37 +0000" MODIFIED_BY="[Empty name]" NAME="Otto 2010" TYPE="JOURNAL_ARTICLE">
<AU>Otto SD, Burmeister S, Buhr HJ, Kroesen A</AU>
<TI>Sacral nerve stimulation induces changes in the pelvic floor and rectum that improve continence and quality of life</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>4</NO>
<PG>636-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patton-2013" MODIFIED="2015-07-21 13:35:59 +0100" MODIFIED_BY="[Empty name]" NAME="Patton 2013" TYPE="JOURNAL_ARTICLE">
<AU>Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG</AU>
<TI>The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence</TI>
<SO>British Journal of Surgery</SO>
<YR>2013</YR>
<VL>100</VL>
<NO>7</NO>
<PG>959-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peery-2012" MODIFIED="2014-04-12 23:00:55 +0100" MODIFIED_BY="Amin A Abukar" NAME="Peery 2012" TYPE="JOURNAL_ARTICLE">
<AU>Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al</AU>
<TI>Burden of gastrointestinal disease in the United States: 2012 update</TI>
<SO>Gastroenterology</SO>
<YR>2012</YR>
<VL>143</VL>
<NO>5</NO>
<PG>1179-87 e1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poulton-1999" MODIFIED="2014-12-12 10:43:49 +0000" MODIFIED_BY="[Empty name]" NAME="Poulton 1999" TYPE="JOURNAL_ARTICLE">
<AU>Poulton B, Thomas S</AU>
<TI>The Nursing Cost of Constipation</TI>
<SO>Primary Health Care</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>9</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Probert-1995" MODIFIED="2014-12-11 10:07:55 +0000" MODIFIED_BY="[Empty name]" NAME="Probert 1995" TYPE="JOURNAL_ARTICLE">
<AU>Probert CS, Emmett PM, Heaton KW</AU>
<TI>Some determinants of whole-gut transit time: a population-based study</TI>
<SO>QJM</SO>
<YR>1995</YR>
<VL>88</VL>
<NO>5</NO>
<PG>311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rao-2004a" MODIFIED="2014-04-12 22:43:44 +0100" MODIFIED_BY="Amin A Abukar" NAME="Rao 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Rao SS</AU>
<TI>Pathophysiology of adult fecal incontinence</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>1 Suppl1</NO>
<PG>S14-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rao-2004b" MODIFIED="2014-12-11 10:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Rao 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Rao SS</AU>
<TI>Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>8</NO>
<PG>1585-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ratto-2011" MODIFIED="2014-04-13 20:02:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ratto 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ratto C, Parello A, Donisi L, Litta F, De Simone V, Spazzafumo L, et al</AU>
<TI>Novel bulking agent for faecal incontinence</TI>
<SO>The British Journal of Surgery</SO>
<YR>2011</YR>
<VL>98</VL>
<NO>11</NO>
<PG>1644-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-Manager-2012" MODIFIED="2015-06-24 12:30:40 +0100" MODIFIED_BY="[Empty name]" NAME="Reference Manager 2012" TYPE="COMPUTER_PROGRAM">
<TI>Reference Manager Professional Edition Version 12</TI>
<YR>2012</YR>
<PB>Thomson Reuters</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-2011" MODIFIED="2014-12-11 10:09:15 +0000" MODIFIED_BY="[Empty name]" NAME="Scott 2011" TYPE="JOURNAL_ARTICLE">
<AU>Scott SM, van den Berg MM, Benninga MA</AU>
<TI>Rectal sensorimotor dysfunction in constipation</TI>
<SO>Best Practice &amp; Research: Clinical Gastroenterology</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>1</NO>
<PG>103-18</PG>
<IDENTIFIERS MODIFIED="2014-04-12 22:30:31 +0100" MODIFIED_BY="Amin A Abukar"/>
</REFERENCE>
<REFERENCE ID="REF-Sharma-2013" MODIFIED="2015-07-21 13:36:04 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2013" TYPE="JOURNAL_ARTICLE">
<AU>Sharma A, Bussen D, Herold A, Jayne D</AU>
<TI>Review of Sacral Neuromodulation for Management of Constipation</TI>
<SO>Surgical Innovation</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>6</NO>
<PG>614-624</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sonnenberg-1989" MODIFIED="2014-04-13 20:14:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sonnenberg 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sonnenberg A, Koch TR</AU>
<TI>Epidemiology of constipation in the United States</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1999" MODIFIED="2014-04-13 20:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Stewart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E, et al</AU>
<TI>Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>12</NO>
<PG>3530-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sultan-1993" MODIFIED="2014-04-13 20:15:01 +0100" MODIFIED_BY="[Empty name]" NAME="Sultan 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sultan AH, Kamm MA, Hudson CN, Thomas JM, Bartram CI</AU>
<TI>Anal-sphincter disruption during vaginal delivery</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>26</NO>
<PG>1905-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sultan-1997a" MODIFIED="2014-04-13 20:15:16 +0100" MODIFIED_BY="[Empty name]" NAME="Sultan 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Sultan AH, Kamm MA</AU>
<TI>Faecal incontinence after childbirth</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>9</NO>
<PG>979-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sultan-1997b" MODIFIED="2014-04-13 20:15:30 +0100" MODIFIED_BY="[Empty name]" NAME="Sultan 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Sultan AH, Monga AK</AU>
<TI>Anal and urinary incontinence in women with obstetric anal sphincter rupture</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>6</NO>
<PG>754-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2011" MODIFIED="2015-07-21 13:36:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tan 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tan E, Ngo NT, Darzi A, Shenouda M, Tekkis PP</AU>
<TI>Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>275-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanagho-1989" MODIFIED="2014-04-13 20:15:37 +0100" MODIFIED_BY="[Empty name]" NAME="Tanagho 1989" TYPE="JOURNAL_ARTICLE">
<AU>Tanagho EA, Schmidt RA, Orvis BR</AU>
<TI>Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders</TI>
<SO>The Journal of Urology</SO>
<YR>1989</YR>
<VL>142</VL>
<NO>2 Pt 1</NO>
<PG>340-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thin-2013" MODIFIED="2014-04-13 18:55:34 +0100" MODIFIED_BY="[Empty name]" NAME="Thin 2013" TYPE="JOURNAL_ARTICLE">
<AU>Thin NN, Horrocks EJ, Hotouras A, Palit S, Thaha MA, Chan CL, et al</AU>
<TI>Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence</TI>
<SO>The British Journal of Surgery</SO>
<YR>2013</YR>
<VL>100</VL>
<NO>11</NO>
<PG>1430-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tjandra-2004" MODIFIED="2014-04-13 20:15:52 +0100" MODIFIED_BY="[Empty name]" NAME="Tjandra 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tjandra JJ, Lim JF, Matzel K</AU>
<TI>Sacral nerve stimulation: an emerging treatment for faecal incontinence</TI>
<SO>ANZ Journal of Surgery</SO>
<YR>2004</YR>
<VL>74</VL>
<NO>12</NO>
<PG>1098-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaizey-2014" MODIFIED="2014-12-11 10:09:47 +0000" MODIFIED_BY="[Empty name]" NAME="Vaizey 2014" TYPE="JOURNAL_ARTICLE">
<AU>Vaizey CJ</AU>
<TI>Faecal incontinence: standardizing outcome measures</TI>
<SO>Colorectal Disease</SO>
<YR>2014</YR>
<VL>16</VL>
<NO>3</NO>
<PG>156-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Berg-2006" MODIFIED="2014-04-13 20:16:04 +0100" MODIFIED_BY="[Empty name]" NAME="van den Berg 2006" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg MM, Benninga MA, Di Lorenzo C</AU>
<TI>Epidemiology of childhood constipation: a systematic review</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>10</NO>
<PG>2401-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vitton-2009" MODIFIED="2014-04-13 20:16:12 +0100" MODIFIED_BY="[Empty name]" NAME="Vitton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Vitton V, Roman S, Damon H, Barth X, Mion F</AU>
<TI>Sacral nerve stimulation and constipation: still a long way to go</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2009</YR>
<VL>52</VL>
<NO>4</NO>
<PG>752-3; author reply 753-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wald-2008" MODIFIED="2014-04-13 20:16:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wald 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wald A, Scarpignato C, Mueller-Lissner S, Kamm MA, Hinkel U, Helfrich I, et al</AU>
<TI>A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>7</NO>
<PG>917-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wexner-2010" MODIFIED="2014-04-13 20:16:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wexner 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wexner SD, Coller JA, Devroede G, Hull T, McCallum R, Chan M, et al</AU>
<TI>Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study</TI>
<SO>Annals of Surgery</SO>
<YR>2010</YR>
<VL>251</VL>
<NO>3</NO>
<PG>441-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-2009" MODIFIED="2014-04-12 23:07:46 +0100" MODIFIED_BY="Amin A Abukar" NAME="Whitehead 2009" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al</AU>
<TI>Fecal incontinence in US adults: epidemiology and risk factors</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>137</VL>
<NO>2</NO>
<PG>512-7, 517 e1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2011" MODIFIED="2014-04-13 20:16:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wong 2011" TYPE="JOURNAL_ARTICLE">
<AU>Wong MT, Meurette G, Rodat F, Regenet N, Wyart V, Lehur PA</AU>
<TI>Outcome and management of patients in whom sacral nerve stimulation for fecal incontinence failed</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>4</NO>
<PG>425-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woodward-2014" MODIFIED="2014-05-21 17:49:18 +0100" MODIFIED_BY="[Empty name]" NAME="Woodward 2014" TYPE="COCHRANE_REVIEW">
<AU>Woodward S, Norton C, Chiarelli P</AU>
<TI>Biofeedback for treatment of chronic idiopathic constipation in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>3</NO>
<PG>CD008486</PG>
<IDENTIFIERS MODIFIED="2014-05-21 17:49:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-21 17:49:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008486.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-21 17:46:45 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mowatt-2007" MODIFIED="2014-05-21 17:46:45 +0100" MODIFIED_BY="[Empty name]" NAME="Mowatt 2007" TYPE="COCHRANE_REVIEW">
<AU>Mowatt G, Glazener C, Jarrett M</AU>
<TI>Sacral nerve stimulation for faecal incontinence and constipation in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<PG>CD004464</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004464.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-08-17 13:51:57 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-08-17 13:51:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-08-17 11:55:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dinning-2015_x0023_">
<CHAR_METHODS MODIFIED="2015-08-17 11:54:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial<BR/>Blinding: participant and investigator.<BR/>Follow-up: 3 weeks (long-term follow-up not reported)<BR/>Setting: two centres in Sydney, Australia.<BR/>Intention-to-treat analysis: yes</P>
<P>Withdrawals: 6 participants</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-17 11:55:15 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled: 59<BR/>Median age (range): 42 (19 to 74)<BR/>Gender: male (4); female (55).<BR/>Duration of symptoms: constipation &gt; 10 years (43), 5 to 10 years (7), and 2 to 5 years (9)<BR/>Received permanent implant: 55<BR/>Lost to follow-up: 2<BR/>Inclusion criteria:</P>
<P>All of the following: i) A complete bowel movement on less than 3 days per week, for at least 2 of 3 weeks of the surveillance phase (determined from daily stool diaries). ii) Aged 18 to 75 yrs; iii) Scintigraphically confirmed slow colonic transit defined as colonic isotope retention &gt; 20% at 96 h (laboratory upper limit of normal = 1% at 96 h; iv) Normal anorectal manometry, with no evidence of dyssynergia and confirmed ability to expel rectal balloon; v) With no radiographic evidence of functional (e.g. pelvic floor dyssynergia) or anatomical (e.g. significant rectocele with retention of contrast, occluding intussusception) impediment to the expulsion of the radio-opaque contrast; vi) Failed symptomatic response to standard therapies including osmotic agents, faecal emollients, laxatives, dietary modification and exercise; and vii) A normal colonoscopy within 5 years</P>
<P>
<BR/>Exclusion criteria:</P>
<P>Any one of the following; i) Metabolic, neurogenic or endocrine disorder(s) known to cause constipation; ii) Drugs listing constipation as a potential side effect; or iii) Non-English speaker or an inability to provide informed consent.</P>
<P>Any one of the following; i) Prior abdominal radiotherapy; ii) Prior abdominal surgery (except cholecystectomy, appendicectomy, inguinal hernia repair, splenectomy, fundoplication; oophorectomy or hysterectomy); iii) Current or planned pregnancy; iv) Co-morbidity considered to put the patient at risk from surgical electrode implantation; or v) History of malignancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>All participants underwent peripheral nerve evaluation. Then participants received permanent electrode implantation. </P>
<P>Intervention: 'suprasensory' stimulation for 3 weeks</P>
<P>Control: Sham stimulator off for 3 weeks. </P>
<P>Wash out period: 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-19 12:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>Bowel diary (stool frequency per week; bowel motion per week; feeling of complete evacuation per week; straining per week; laxative free days per week; soft stool per week; normal stool per week; hard stool per week; pain score weekly average; bloating score weekly average; weekly global satisfaction score; weekly bothersome score). Quality of life SF-36. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-08-17 13:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahlke-2015_x0023_">
<CHAR_METHODS MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial<BR/>Blinding: participant and investigator. Sequence generation by random number table<BR/>Follow-up: 3 months<BR/>Setting: single-centre, Germany</P>
<P>Withdrawals: 2 participants<BR/>
</P>
<P>Intention-to-treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-17 13:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled: 16<BR/>Median age (SD): 55.5 (11.8)<BR/>Gender: female (16)<BR/>Duration of symptoms: mean (SD): 51.9 (42.7)<BR/>Received permanent implant: 16<BR/>Lost to follow-up: 0<BR/>Inclusion criteria: not mentioned<BR/>Exclusion criteria: not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-17 13:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>All patients had sacral nerve modulation through a staged implantation procedure between 2009 and 2011. After 26.8 months (median) following implantation 16 out of the 31 participants agreed to be randomised into a crossover design to stimulation ON or OFF, each period lasted for 3 weeks. After 6 weeks (i.e. the two periods) participants while blinded selected the preferred period (ON or OFF) which was continued for a further 3 months. There was no treatment-free interval.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Frequency of bowel movements, frequency of faecal incontinence, Cleveland Clinic Incontinence Score (CCIS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-08-17 13:43:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kenefick-2002_x0023_">
<CHAR_METHODS MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial<BR/>Blinding: participant and investigator<BR/>Follow-up: the study consisted of two 2-week intervals with subsensory stimulation either 'on' or 'off'<BR/>Setting: single centre UK<BR/>Withdrawals: none<BR/>Intention-to-treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-11 09:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>Enrolled: 2<BR/>Age: both aged 36<BR/>Gender: female (2)<BR/>Duration of symptoms: not stated<BR/>Received permanent implant: 2<BR/>Inclusion criteria: failed maximal conservative treatment; psychologically stable; normal sigmoidoscopy; prolonged whole gut transit time; delayed evacuation<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]">
<P>Both participants had a successful 3-week trial of percutaneous stimulation before one-stage permanent implantation of a stimulator to the S3 foramen.</P>
<P>A Intervention: stimulator On for two weeks with subsensory stimulation</P>
<P>B Control: stimulator Off</P>
<P>No treatment-free period between the weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-17 13:43:36 +0100" MODIFIED_BY="[Empty name]">
<P>Bowel frequency (per 2 weeks); time with pain and bloating (%); Wexner constipation score (0 to 30); Symptom analogue score (0 to 100); anal manometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-13 22:08:59 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-08-17 13:51:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leroi-2005_x0023_">
<CHAR_METHODS MODIFIED="2015-08-17 13:43:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial<BR/>Blinding: participant and investigator. Sequence generation by random number table.<BR/>Follow-up: 3 months<BR/>Setting: multicentre, France<BR/>Intention-to-treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-17 13:43:44 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled: 34<BR/>Median age (range): 57 (33 to 73)<BR/>Gender: male (3); female (31).<BR/>Duration of symptoms: &lt; 1 yr (12); 1 to 5 years (12); 5 to 10 years (4); &gt; 10 years (6)<BR/>Received permanent implant: 27<BR/>Lost to follow-up: 3<BR/>Inclusion criteria: faecal incontinence to solid or liquid stool or incapacitating urgency; failed conservative treatment; demonstrable unilateral bulbo- (or clitorido-) cavernosus reflex; informed consent given. Participants with external anal sphincter damage on ultrasound were included in the study if the defect was not considered to be the main cause of faecal incontinence (i.e. limited defect, &#8805; than 30° or limited to one part, superficial, middle, or deep part of the external anal sphincter).<BR/>Exclusion criteria: extensive external anal sphincter defect (defect that was considered to be the main cause of faecal incontinence).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-17 13:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>Before permanent implantation, participants underwent temporary stimulation, either percutaneously-placed test stimulation lead (Medtronic InterStim 3057) or permanent quadripolar lead (model 3093). Both types of leads were connected to an external pulse generator (model 3625). All participants were tested for 8 to 15 days.</P>
<P>For permanent implantation, participants with temporary test stimulation lead underwent simultaneous implantation of the quadripolar lead and the pulse generator; those with a lead already in place underwent removal of the percutaneous extension (model 3095) before placement of the pulse generator (model 3023) subcutaneously, below the superficial fascia, in the upper parts of buttocks ipsilateral to the permanent electrode. The lead contained four contact electrodes. The electrode combination which allowed the participant to have the best perception of the perineum muscle and anal sphincter contraction was chosen for permanent stimulation. Stimulation was continuous with a pulse width of 210 microseconds, a frequency of 14 pulses per second, and a current amplitude adapted to the participant's perception of perineal and anal sphincter muscle contraction. The stimulator was left on during defaecation and urinary voiding. After a 1- to 3-month optimisation 'on' phase, participants were randomised to:</P>
<P>A Intervention: stimulation 'on' for 1 month or</P>
<P>B Control: stimulation 'off' for 1 month, then crossed over to the alternative.</P>
<P>No treatment-free interval</P>
<P>At the end of the second month, the preferred period ('on' or 'off') was continued for a further 3 months: if neither was preferred, the stimulator was turned on.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Episodes of faecal incontinence; faecal urgency; delay in postponing defaecation; bowel movements; severity of incontinence; quality of life; anal manometry.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-17 13:51:54 +0100" MODIFIED_BY="[Empty name]">
<P>Severity of incontinence was graded by the Cleveland Clinic Incontinence Scoring System. The score ranged from 0 (normal continence) to 20 (maximum incontinence).<BR/>Quality of life was assessed with the French version of the American Society of Colon and Rectal Surgeons' Fecal Incontinence Quality of Life Questionnaire (FIQL). In the questionnaire, four separate QOL domains were explored: lifestyle; coping/behaviour; depression/self-perception; and embarrassment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<CHAR_METHODS MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial<BR/>Blinding: participant and investigator<BR/>Follow-up: 2 weeks<BR/>Setting: single centre, Denmark<BR/>Intention-to-treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-11 09:53:39 +0000" MODIFIED_BY="[Empty name]">
<P>Enrolled: 7<BR/>Age: 67 years (60 to 87)<BR/>Gender: male (1); female (6).<BR/>Duration of symptoms: not stated<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-11 09:53:40 +0000" MODIFIED_BY="[Empty name]">
<P>Sacral nerve stimulation</P>
<P>A Intervention: stimulator 'on' for one week</P>
<P>B Control: stimulator 'off' for one week</P>
<P>No treatment-free period between the weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-11 09:53:41 +0000" MODIFIED_BY="[Empty name]">
<P>Defaecations/week; faecal incontinence episodes/week; urge episodes/week; passive leakage/week; soiling/week; anal manometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-13 22:14:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-08-17 13:51:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thin-2015">
<CHAR_METHODS MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised parallel-arm<BR/>Blinding: Investigator<BR/>Follow-up: 6 months<BR/>Setting: two centres, London, UK<BR/>Intention-to-treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-17 13:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolled: 40<BR/>Age: 59 years (mean age)<BR/>Gender: male (1); female (39).<BR/>Duration of symptoms: not stated<BR/>Inclusion criteria:</P>
<P>Age &gt; 18 years</P>
<P>Meets NICE criteria (2007) for symptom severity and failure of previous conservative therapy</P>
<P>
<BR/>Exclusion criteria:</P>
<P>Inability to provide informed consent for the research study</P>
<P>Severe concomitant medical condition precluding randomization to operative treatment</P>
<P>Neurological diseases, such as diabetic neuropathy, multiple</P>
<P>sclerosis and progressing Parkinson&#8217;s disease</P>
<P>Other medical conditions precluding stimulation, such as bleeding</P>
<P>disorders, certain cardiac pacemakers, peripheral vascular</P>
<P>disease</P>
<P>Congenital anorectal anomalies or absence of native rectum as a</P>
<P>result of surgery</P>
<P>Present evidence of external full-thickness rectal prolapse.</P>
<P>Previous rectal surgery (rectopexy/resection) &lt; 12 months ago</P>
<P>Stoma in situ</P>
<P>Chronic bowel disease, such as inflammatory bowel disease,</P>
<P>chronic uncontrolled diarrhoea</P>
<P>Anatomical limitations that would prevent successful placement of</P>
<P>electrodes</P>
<P>Pregnancy or intention to become pregnant.</P>
<P>Previous experience of SNS or PTNS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>SNS vs percutaenous tibial nerve stimulation (PTNS)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-17 13:51:57 +0100" MODIFIED_BY="[Empty name]">
<P>FI episodes/week (total, urge and passive); symptom severity scoring with Cleveland Clinic Incontinence Score (CCIS); quality of life measurements using EQ-5D, FIQL and SF-36.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-07 10:16:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tjandra-2008">
<CHAR_METHODS MODIFIED="2014-12-11 09:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel groups<BR/>Blinding: no<BR/>Follow-up: 12 months</P>
<P>Withdrawals: 7<BR/>Setting: single centre, Australia<BR/>Intention-to-treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-11 09:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>Enrolled: 120<BR/>Age: 63.9 (±13.2) in SNS group. 63 (±12.1) in the control group.<BR/>Gender: male (9); female (111).<BR/>Duration of symptoms: not mentioned<BR/>Received permanent implant: 53<BR/>Lost to follow-up: none<BR/>Inclusion criteria: involuntary passage of solid or liquid stool at least once per week; refractory to medical therapy and pelvic floor exercises; and aged 35 to 86 years.<BR/>Exclusion criteria: rectal prolapse, inflammatory bowel disease, congenital anorectal malformation, neurologic disorders such as Parkinson&#8217;s disease, multiple sclerosis, spinal cord injury, stoma in situ, pregnancy, external anal sphincter defect of more than 120° of the circumference, bleeding diathesis, and mental or physical disability precluding adherence to study protocol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-07 10:16:28 +0100" MODIFIED_BY="[Empty name]">
<P>A (53): SNS (Peripheral nerve evaluation for at least 7 days; then permanent implantation in participants with &#8805; 50% reduction in faecal incontinence episodes per week or &#8805; 50% reduction in number of days with faecal incontinence per week based on the two-week bowel diary)</P>
<P>B (60): control group (optimal medical therapy). Optimal medical therapy includes bulking agents, pelvic floor exercises with a team of dedicated physiotherapists, and dietary management on fluid and fibre with a team of dieticians.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-13 22:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Anorectal physiology, severity of incontinence, two-week bowel diary (number of incontinent episodes per week, days with incontinence per week, days with staining per week and days with pads per week), faecal incontinence quality of life.</P>
<P>
<I>Continuous data: all mean (SD) N</I>
</P>
<P>Episodes of faecal incontinence per week at 3 months: A 2.9 (6.3) 53, B 8.1 (14.1) 60</P>
<P>Episodes of faecal incontinence per week at 12 months: A 3.1 (10.1) 53, B 9.4 (11.8) 60</P>
<P>Days with pads per week at 3 months: A 1.6 (2.6) 53, B 3 (3.8) 60</P>
<P>Days with pads per week at 12 months: A 2.2 (3) 53, B 3.2 (3.1) 60</P>
<P>Days with incontinence per week at 3 months: A 1 (1.7) 53, B 2.9 (2.4) 60</P>
<P>Days with incontinence per week at 12 months: A 1 (1.7) 53, B 3.1 (3.1) 60</P>
<P>Days with staining per week at 3 months: A 1.3 (1.7) 53, B 4.5 (2.1) 60</P>
<P>Days with staining per week at 12 months: A 1.4 (2) 53, B 4.5 (2.3) 60</P>
<P>Cleveland Clinic Incontinence Score [higher = worse] at 3 months: A 1.1 (1) 53, B 12.1 (2.1) 60</P>
<P>Cleveland Clinic Incontinence Score at 12 months: A 1.2 (1.8)53, B 14.1 (1.9) 60</P>
<P>Quality of Life SF12 [higher = better]:</P>
<P>SF12 Physical at 3 months: A 43.18 (11.68) 53, B 41.5 (9.89) 60</P>
<P>SF12 Physical at 12 months: A 42.22 (9.25) 53, B 40.5 (10.2) 60</P>
<P>SF12 Mental at 3 months: A 50.16 (10.41) 53, B 47.82 (10.66) 60</P>
<P>SF12 Mental at 12 months: A 49.22 (10.88) 53, B 48.22 (10.12) 60</P>
<P>Quality of Life ASCRS Faecal Incontinence Quality of Life Index (FIQL) [higher = better]:</P>
<P>Lifestyle at 3 months: A 3.34 (0.72) 53, B 2.12 (0.91) 60</P>
<P>Lifestyle at 12 months: A3.31 (0.72) 53, B 2.31 (0.89) 60</P>
<P>Coping at 3 months: A 2.87 (0.8) 53, B 1.85 (0.92) 60</P>
<P>Coping at 12 months : A 2.68 (0.87) 53, B 1.86 (0.88) 60</P>
<P>Depression/self perception at 3 months: A 3.31 (0.77) 53, B 2.68 (0.65) 60</P>
<P>Depression/self perception at 12 months: A 3.25 (0.8) 53, B 2.64 (0.84) 60</P>
<P>Embarrassment at 3 months: A 2.89 (0.85) 53, B 1.7 (0.67) 60</P>
<P>Embarrassment at 12 months: A 2.76 (0.94) 53, B 1.78 (0.61) 60</P>
<P>Anal manometry measures only reported in SNS Group A at 3 months</P>
<P>Ability to defer defecation and worsening of faecal incontinence only reported in SNS Group A at 3 months</P>
<P>Adverse effects only reported for SNS group: implantation site pain (6 %) particularly in slimmer participants,</P>
<P>seroma (2%) which required percutaneous aspiration and</P>
<P>excessive tingling in the vaginal region (9%).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-11 09:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>Severity of incontinence was assessed by the Wexner's incontinence score. The score ranged from 0 (normal continence) to 20 (maximum incontinence).<BR/>Quality of life was assessed using Fecal Incontinence Quality of Life index (FIQL) of The American Society of Colon and Rectal Surgeons; and the standard short form-12 health survey quality of life questionnaire (SF-12).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-08-17 13:44:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaizey-2000_x0023_">
<CHAR_METHODS MODIFIED="2015-08-17 13:44:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised crossover trial.<BR/>Blinding: participant and investigator.<BR/>Follow-up: the study consisted of two 2-week intervals with subsensory stimulation either 'on' or 'off'<BR/>Setting: single centre, UK<BR/>Withdrawals: none<BR/>Intention-to-treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-11 09:54:04 +0000" MODIFIED_BY="[Empty name]">
<P>Enrolled: 2<BR/>Age: 65 and 61 years<BR/>Gender: female (2).<BR/>Duration of symptoms: 2.5 years and 3 years.<BR/>Inclusion criteria: passive faecal incontinence; intact external sphincter; informed consent given<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-11 09:54:10 +0000" MODIFIED_BY="[Empty name]">
<P>To implant the unilateral electrode (Medtronic InterStim model 3080), the sacral nerve root (usually S3) that produces the maximal anal response was identified via percutaneous needle stimulation. An incision over the sacrum allows access to the sacral foramen. The permanent electrode was inserted directly and secured to the sacral periosteum after checking its correct placement by stimulation. A connecting lead (model 7495) was then tunnelled to the anterior abdominal wall to be connected to the stimulator. The Implantable Pulse Generator (model 3023) is programmable using telemetry. The voltage required for stimulation was between 0.5 and 2 volts at a frequency of 15 pulses per second and a pulse width of 210 &#956;s.</P>
<P>A Intervention: stimulator 'on' for two weeks with subsensory stimulation</P>
<P>B Control: stimulator 'off' for two weeks</P>
<P>No treatment-free period between the weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Episodes of faecal incontinence for liquid or solid stool; anal manometry; psychological assessment; quality of life.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality of life was assessed with the SF-36 instrument, score 0 (poor) to 100 (excellent), reporting the domains of role-emotional, general health, mental health, bodily pain, physical functioning, role-physical, social function, and vitality.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-08-17 13:44:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-12-11 09:54:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dinning-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-11 09:54:11 +0000" MODIFIED_BY="[Empty name]">
<P>No comparator used and study is a trial of wave measurements during the temporary stimulation phase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-17 13:44:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dinning-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-17 13:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>Only reported proportion of participants who satisfied primary outcome measure. Secondary outcomes (pain, bloating, laxative-free days) and longer term responses of primary outcomes are not available. Author was contacted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-08 23:22:17 +0000" MODIFIED_BY="Amin A Abukar" STUDY_ID="STD-Knowles-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-08 23:22:17 +0000" MODIFIED_BY="Amin A Abukar">
<P>No report on results of permanent SNS stimulation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-08-17 13:45:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-08-17 13:44:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borjesson-2013">
<CHAR_STUDY_NAME MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Sacral nerve stimulation or anal bulking therapy for faecal incontinence - a comparative study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel groups<BR/>Blinding: unknown<BR/>Follow-up: 12-months.</P>
<P>Withdrawals: unknown<BR/>Setting: multi-centre, Sweden<BR/>Intention-to-treat analysis: unknown</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>100</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>SNS vs. anal bulking therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-17 13:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: proportion of participants responding with &gt; 50% reduction in the number of faecal incontinence episodes compared to baseline, one year after randomisation.</P>
<P>Secondary outcomes: change in number of faecal incontinence episodes, change in deferring time, change in incontinence score, change in quality of life, and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>01/03/2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Lars Börjesson </P>
<P>lars.g.borjesson@vgregion.se</P>
<P>Sahlgrenska University Hospital<BR/>Department of Surgery<BR/>Gothenburg<BR/>416 85<BR/>Sweden</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>Recruitment end date: 01/03/2015</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-08-17 13:45:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jayne-2014">
<CHAR_STUDY_NAME MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>SaFaRI: Sacral nerve stimulation versus the FENIX TM magnetic sphincter augmentation for adult faecal incontinence: a randomised Investigation</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-08-17 13:44:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel groups<BR/>Blinding: unknown<BR/>Follow-up: 2 weeks; 6, 12, and 18 months.</P>
<P>Withdrawals: unknown<BR/>Setting: multi-centre (at least 20 centres), UK<BR/>Intention-to-treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]">
<P>350</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>FENIXTM magnetic anal sphincter (MAS) vs. SNS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-17 13:45:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: proportion of patients with device in-situ at 18 months, and proportion of patients reporting &gt; 50% improvement in continence scores.</P>
<P>Secondary outcomes: complications, quality of life, and cost-effectiveness.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>01/01/2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-08-17 13:45:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary contact: Professor David Jayne.</P>
<P>Julie Croft: safari@leeds.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by NIHR HTA; co-ordinated by the Clinical Trials Research Unit, University of Leeds.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-08-17 13:45:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vallance-2014">
<CHAR_STUDY_NAME MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>Sacral nerve stimulation versus the FENIXTM magnetic anal sphincter for adult faecal incontinence: A randomised investigation (SaFaRI). </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-08-17 13:45:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, parallel groups<BR/>Blinding: unknown<BR/>Follow-up: 2 weeks; 6, 12, and 18 months.</P>
<P>Withdrawals: unknown<BR/>Setting: multi-centre (at least 20 centres), UK<BR/>Intention-to-treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>350</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>FENIXTM magnetic anal sphincter (MAS) vs. SNS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-17 13:45:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: proportion of patients with device in-situ at 18 months, and proportion of patients reporting &gt; 50% improvement in continence scores.</P>
<P>Secondary outcomes: complications, quality of life, and cost-effectiveness.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>01/01/2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-08-17 13:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary contact: Professor David Jayne.</P>
<P>Julie Croft: safari@leeds.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-05-19 12:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by NIHR HTA; co-ordinated by the Clinical Trials Research Unit, University of Leeds.</P>
<P>ISRCTN16077538</P>
<P>DOI 10.1186/ISRCTN16077538</P>
<P>http://www.isrctn.com/ISRCTN16077538</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-08-17 13:51:51 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-08-17 13:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>Utilised an off-site NHMRC clinical trials centre automated phone link.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>Random number table utilised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>Unclear: 'Randomised crossover trial'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>Random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 19:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>'shuffling envelopes'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Randomization sequence generated remotely by a statistician uninvolved in recruitment, and requests were made and actioned by e-mail. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-11 09:53:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>Randomisation was performed from the central registry by using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:44:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-08-17 13:51:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>Utilised an off-site NHMRC clinical trials centre automated phone link.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>Unclear 'Randomised crossover study'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>Unclear: 'Randomised crossover trial'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>Unclear 'Randomised crossover trial'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 20:00:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>'shuffling envelopes'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Randomization sequence generated remotely by a statistician uninvolved in recruitment, and requests were made and actioned by e-mail. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-11 09:53:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>Randomisation was performed from the central registry by using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:44:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-07-14 12:37:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-08-17 13:43:38 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-19 12:48:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>Participants and personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>Participants and key study personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-17 13:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>Participants blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>Participants were blinded to treatment allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>Participants and personnel blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-19 12:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Investigator blinded but unclear whether patients were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-07 10:16:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>Participants could not be not blinded and the control group did not have sham stimulation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-07 10:16:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Participants and outcome assessors were blinded to the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-08-17 13:43:39 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-19 12:48:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>Investigator blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>Personnel assessing outcome were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-08-17 13:43:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>Outcome assessor blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-10 19:55:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>Personnel assessing outcome were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-11 09:53:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>Examiners blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Investigator blinded but unclear whether patients were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-11 09:53:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>Unblinded assessment for both control and experimental group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-05-07 10:16:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Participants and outcome assessors were blinded to the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-08-17 13:44:51 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>Out of the 59 participants enrolled, 6 withdrew. The reasons for discontinuation were depression (n = 1), too far to travel (n = 2), could not commit (n = 1), pregnancy (n = 1) and severe wound infection (n = 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:43:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>Out of the 16 participants enrolled, 2 discontinued; the reasons cited were participant turned stimulator ON with handheld device because she had become completey incontinent (n = 1); participant fell on lower back leading to breakage of permanent lead (n = 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>Results were reported for everyone who entered the studies and the participants were analysed in the groups to which they were originally allocated, effectively resulting in an intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:43:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>Out of the 34 participants enrolled, 10 prematurely discontinued. The reasons for discontinuation were device-related adverse events (n = 4), protocol violation (n = 3), insufficient therapeutic response (n = 1), no return to follow-up (n = 1), and adverse event (stroke) not related to SNS (n = 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-10 20:01:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>No withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:44:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Out of 23 participants randomised to the SNS group, 4 withdrew prior to intervention (intercurrent disease n = 1; symptoms resolved n = 1; declined further participation n = 2). Then a further 3 participants failed temporary SNS. Another participant who passed the temporary SNS withdrew from treatment owing to urgent investigation for new pararectal cyst. Moreover, in the PTNS group 1 participant withdrew before intervention (symptoms resolved).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-10 20:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>7 participants in the SNS group stopped early but have been counted in the denominators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-17 13:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Results were reported for everyone who entered the studies and the participants were analysed in the groups to which they were originally allocated, effectively resulting in an intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-08-17 13:43:41 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>All outcomes reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>The results of the Short Form 36 quality of life questionnaire were not reported in results table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-04 13:17:05 +0000" MODIFIED_BY="Amin A Abukar" RESULT="YES" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 20:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-19 12:48:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>Pre-specified outcomes in study protocol reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 20:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>Data from all participants reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-04 14:17:55 +0000" MODIFIED_BY="Amin A Abukar" RESULT="UNKNOWN" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>Psychological assessment not reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-08-17 13:44:52 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-21 13:34:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinning-2015_x0023_">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahlke-2015_x0023_">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenefick-2002_x0023_">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 19:55:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leroi-2005_x0023_">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 20:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-21 13:34:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thin-2015">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 20:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tjandra-2008">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-17 13:44:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vaizey-2000_x0023_">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2015-08-17 13:45:32 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-08-17 13:45:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-12-11 09:54:21 +0000" MODIFIED_BY="[Empty name]">Episode of faecal incontinence per week (from Fraser 2004)</TITLE>
<TABLE COLS="8" ROWS="8">
<TR>
<TH>
<P>Study id</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>p-value</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Ganio 2002</P>
</TD>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>7.5 (1 to 11)</P>
</TD>
<TD>
<P>0.15 (0 to 2)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>&#8722;7.35 (&#8722;98%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jarrett 2004</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>7.5 (1 to 78)</P>
</TD>
<TD>
<P>1.00 (0 to 39)</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
<TD>
<P>&#8722;6.50 (&#8722;87%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leroi 2001</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>3.0 (2.7)</P>
</TD>
<TD>
<P>0.50 (0.6)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>&#8722;2.50 (&#8722;83%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Matzel 2003</P>
</TD>
<TD>
<P>Median</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>40%</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Matzel and colleagues reported the percentage of bowel movements that were faecally incontinent</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosen 2001</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>2.0 (1 to 5)</P>
</TD>
<TD>
<P>0.67 (0 to 1.67)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>&#8722;1.33 (&#8722;67%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Uludag 2002</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>8.66</P>
</TD>
<TD>
<P>0.67</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
<TD>
<P>&#8722;7.99 (&#8722;92%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MDT-301</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>37;33</P>
</TD>
<TD>
<P>16.4 (19.3)</P>
</TD>
<TD>
<P>2.7 (4.8)</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
<TD>
<P>&#8722;13.70 (&#8722;84%)</P>
</TD>
<TD>
<P>The number of participants was 37 at baseline and 33 at follow-up</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-08-12 21:17:19 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-07-21 13:36:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Faecal incontinence: parallel group data SNS vs medical therapy</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="13.837300323007986" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Episodes of faecal incontinence per week</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2014-07-09 16:46:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-1.2496305113845185" CI_START="-9.15036948861548" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="8.1" MODIFIED="2014-07-04 11:25:01 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="6.3" SD_2="14.1" SE="2.0155316729161816" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" MODIFIED="2014-07-09 16:47:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-2.2616257651045917" CI_START="-10.33837423489541" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="9.4" MODIFIED="2014-07-09 16:47:11 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="10.1" SD_2="11.8" SE="2.060432878741441" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.9578181562359473" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days using pads per week</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2014-07-09 16:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.2106815859325184" CI_START="-2.589318414067481" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.0" MODIFIED="2014-07-04 14:48:02 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="2.6" SD_2="3.8" SE="0.6068062594255167" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2014-07-09 16:49:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="0.1258760368774039" CI_START="-2.125876036877404" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.2" MODIFIED="2014-07-09 16:49:17 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="3.0" SD_2="3.1" SE="0.5744371048438494" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.724066078802442" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days with incontinence per week</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2014-11-25 19:31:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-1.1395736241771153" CI_START="-2.6604263758228845" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.9" MODIFIED="2014-07-04 17:17:16 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.7" SD_2="2.4" SE="0.38797976994528005" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" MODIFIED="2014-07-09 16:47:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-1.1918469948800845" CI_START="-3.0081530051199157" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.1" MODIFIED="2014-07-09 16:47:58 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.7" SD_2="3.1" SE="0.46335188415874506" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.010655363558759" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days with faecal staining per week</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2014-07-09 16:48:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-2.4987044491931316" CI_START="-3.9012955508068687" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="4.5" MODIFIED="2014-07-04 17:19:46 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.7" SD_2="2.1" SE="0.3578104273030517" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2014-07-09 16:48:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-2.307150682798042" CI_START="-3.892849317201958" EFFECT_SIZE="-3.1" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="4.5" MODIFIED="2014-07-09 16:48:41 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="2.0" SD_2="2.3" SE="0.4045223909499624" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.762713697726328" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cleveland Clinic Incontinence Score</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2014-07-09 16:49:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-10.404325946151374" CI_START="-11.595674053848626" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="12.1" MODIFIED="2014-07-04 15:01:13 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.0" SD_2="2.1" SE="0.3039209182144294" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2014-07-09 16:49:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-12.217384351976515" CI_START="-13.582615648023486" EFFECT_SIZE="-12.9" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="14.1" MODIFIED="2014-07-09 16:49:54 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="1.8" SD_2="1.9" SE="0.3482796895289256" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="13.837300323007986" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SF12 Physical</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2014-08-10 19:12:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="2.338743157821318" CI_START="-5.698743157821317" EFFECT_SIZE="-1.6799999999999997" ESTIMABLE="YES" MEAN_1="-43.18" MEAN_2="-41.5" MODIFIED="2014-08-10 19:12:12 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="11.68" SD_2="9.89" SE="2.0504168390443143" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2014-07-09 16:50:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="1.8664592537715583" CI_START="-5.306459253771556" EFFECT_SIZE="-1.7199999999999989" ESTIMABLE="YES" MEAN_1="-42.22" MEAN_2="-40.5" MODIFIED="2014-07-09 16:50:28 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="9.25" SD_2="10.2" SE="1.8298597739862008" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="13.837300323007986" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SF12 Mental</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2015-02-13 22:37:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.5497300253015878" CI_START="-6.22973002530158" EFFECT_SIZE="-2.3399999999999963" ESTIMABLE="YES" MEAN_1="-50.16" MEAN_2="-47.82" MODIFIED="2014-07-04 15:14:07 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="10.41" SD_2="10.66" SE="1.9845926027127427" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" MODIFIED="2015-02-13 22:37:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="2.890607949716598" CI_START="-4.890607949716598" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-49.22" MEAN_2="-48.22" MODIFIED="2014-07-09 16:51:05 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="10.88" SD_2="10.12" SE="1.9850405315634454" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.7718338423151676" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Lifestyle</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2014-08-10 19:21:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.9190143687073387" CI_START="-1.5209856312926608" EFFECT_SIZE="-1.2199999999999998" ESTIMABLE="YES" MEAN_1="-3.34" MEAN_2="-2.12" MODIFIED="2014-08-10 19:21:09 +0100" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="0.72" SD_2="0.91" SE="0.15356691942647793" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" MODIFIED="2014-08-10 19:21:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-0.7028679166562027" CI_START="-1.2971320833437971" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-3.31" MEAN_2="-2.31" MODIFIED="2014-08-10 19:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="0.72" SD_2="0.89" SE="0.15160078740606317" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.9755440046649144" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Coping/behaviour</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" MODIFIED="2014-08-10 19:26:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.7028602731192168" CI_START="-1.3371397268807832" EFFECT_SIZE="-1.02" ESTIMABLE="YES" MEAN_1="-2.87" MEAN_2="-1.85" MODIFIED="2014-08-10 19:26:10 +0100" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="0.8" SD_2="0.92" SE="0.16180895637998496" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.02" MODIFIED="2014-08-10 19:26:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-0.4968269669461202" CI_START="-1.1431730330538799" EFFECT_SIZE="-0.8200000000000001" ESTIMABLE="YES" MEAN_1="-2.68" MEAN_2="-1.86" MODIFIED="2014-08-10 19:26:22 +0100" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="0.87" SD_2="0.88" SE="0.16488723037924546" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.2670441893017523" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Depression/self perception</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2014-08-10 19:28:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.36537975309464027" CI_START="-0.8946202469053595" EFFECT_SIZE="-0.6299999999999999" ESTIMABLE="YES" MEAN_1="-3.31" MEAN_2="-2.68" MODIFIED="2014-08-10 19:28:10 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="0.77" SD_2="0.65" SE="0.13501281094583897" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" MODIFIED="2014-08-10 19:28:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-0.3074062409762517" CI_START="-0.9125937590237481" EFFECT_SIZE="-0.6099999999999999" ESTIMABLE="YES" MEAN_1="-3.25" MEAN_2="-2.64" MODIFIED="2014-08-10 19:28:17 +0100" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="0.8" SD_2="0.84" SE="0.15438740783533225" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2015-06-17 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.786345800277056" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Embarrassment</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control medical treatment
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>
Favours medical
</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" MODIFIED="2014-08-10 19:30:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.9052060903472784" CI_START="-1.474793909652722" EFFECT_SIZE="-1.1900000000000002" ESTIMABLE="YES" MEAN_1="-2.89" MEAN_2="-1.7" MODIFIED="2014-08-10 19:30:04 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="0.85" SD_2="0.67" SE="0.14530568515500272" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.02" MODIFIED="2014-08-10 19:30:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="-0.6835761667938924" CI_START="-1.276423833206107" EFFECT_SIZE="-0.9799999999999998" ESTIMABLE="YES" MEAN_1="-2.76" MEAN_2="-1.78" MODIFIED="2014-08-10 19:30:10 +0100" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="0.94" SD_2="0.61" SE="0.15123942865494505" STUDY_ID="STD-Tjandra-2008" TOTAL_1="53" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-07-21 13:40:43 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Faecal Incontinence: parallel group data SNS vs PTNS</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2015-07-21 13:37:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="32" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Episodes of faecal incontinence per week</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2015-07-21 13:37:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.6098959466006559" CI_START="-6.6098959466006555" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="5.8" MODIFIED="2015-02-13 22:49:07 +0000" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="2.5" SD_2="6.9" SE="1.8418174900534166" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2015-07-21 13:37:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.7405960182103208" CI_START="-7.140596018210321" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="6.3" MODIFIED="2015-02-13 22:50:03 +0000" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="4.0" SD_2="6.9" SE="2.010545116794614" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2015-07-21 13:37:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="32" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cleveland Clinic Incontinence Score</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2015-07-21 13:37:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.7412115683181169" CI_START="-5.141211568318115" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="11.7" MODIFIED="2015-02-13 22:57:21 +0000" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="5.3" SD_2="4.4" SE="1.7557524502806958" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2015-07-21 13:37:50 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.7362897845861012" CI_START="-6.736289784586101" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="12.1" MODIFIED="2015-02-13 22:58:49 +0000" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="5.4" SD_2="5.2" SE="1.9063053270659451" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2015-07-21 13:38:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="9.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Lifestyle</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2015-07-21 13:38:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.4243960353329179" CI_START="-0.8243960353329183" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-2.9" MODIFIED="2015-03-22 14:35:49 +0000" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="0.8" SD_2="1.0" SE="0.3185752596772565" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" MODIFIED="2015-07-21 13:38:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.4248783807392136" CI_START="-0.8248783807392139" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.8" MODIFIED="2015-03-22 14:35:54 +0000" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="0.9" SD_2="0.9" SE="0.3188213587944343" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2015-07-21 13:39:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Coping</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2015-07-21 13:38:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.3197184632088599" CI_START="-0.7197184632088602" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.3" MODIFIED="2015-03-22 14:36:32 +0000" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="0.7" SD_2="0.8" SE="0.265167353741361" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2015-07-21 13:39:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.08901312159752572" CI_START="-1.0890131215975258" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.0" MODIFIED="2015-03-22 14:36:34 +0000" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.8" SD_2="0.9" SE="0.30052242094425513" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2015-07-21 13:39:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Depression</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" MODIFIED="2015-07-21 13:39:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.6554474495459675" CI_START="-0.45544744954596816" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-2.8" MODIFIED="2015-03-22 14:36:55 +0000" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="0.8" SD_2="0.8" SE="0.28339676337283054" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" MODIFIED="2015-07-21 13:39:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.4554474495459676" CI_START="-0.6554474495459678" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-2.6" MODIFIED="2015-03-22 14:36:52 +0000" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="0.7" SD_2="0.9" SE="0.2833967633728305" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2015-07-21 13:40:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.71" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FIQL Embarrassment</NAME>
<GROUP_LABEL_1>SNS</GROUP_LABEL_1>
<GROUP_LABEL_2>PTNS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.01" MODIFIED="2015-07-21 13:40:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.21971846320886024" CI_START="-0.8197184632088599" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.2" MODIFIED="2015-03-22 14:37:09 +0000" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="0.7" SD_2="0.8" SE="0.265167353741361" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.02" MODIFIED="2015-07-21 13:40:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="-0.04455255045403228" CI_START="-1.155447449545968" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-2.0" MODIFIED="2015-03-22 14:37:11 +0000" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="0.8" SD_2="0.8" SE="0.28339676337283054" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2015-07-21 13:40:43 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>EQ-5D</NAME>
<GROUP_LABEL_1>
SN
S

</GROUP_LABEL_1>
<GROUP_LABEL_2>
PTNS

</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SNS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PTNS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" MODIFIED="2015-07-21 13:40:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.2895818545286243" CI_START="-0.1695818545286242" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="0.6" MODIFIED="2015-03-22 14:57:45 +0000" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="0.28" SD_2="0.38" SE="0.11713575164622239" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.02" MODIFIED="2015-07-21 13:40:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.3381589513880925" CI_START="-0.07815895138809248" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.76" MEAN_2="0.63" MODIFIED="2015-03-22 14:58:12 +0000" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="0.22" SD_2="0.37" SE="0.10620549817752965" STUDY_ID="STD-Thin-2015" TOTAL_1="15" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-08-12 21:17:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Faecal incontinence: crossover trials</NAME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.01" MODIFIED="2015-07-21 13:41:02 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Participants cured and improved on treatment</NAME>
<TR>
<TH>
<P>Cured</P>
</TH>
<TH>
<P>%</P>
</TH>
<TH>
<P>Improved</P>
</TH>
<TH>
<P>%</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-02-13 21:49:12 +0000" MODIFIED_BY="[Empty name]" ORDER="137" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>5/19</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>17/19</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-02-13 21:52:09 +0000" MODIFIED_BY="[Empty name]" ORDER="138" STUDY_ID="STD-Thin-2015">
<TR>
<TD>
<P>
3/15
</P>
</TD>
<TD>
<P>
20
</P>
</TD>
<TD>
<P>
10/15
</P>
</TD>
<TD>
<P>
67
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-02-13 21:49:12 +0000" MODIFIED_BY="[Empty name]" ORDER="139" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>22/53</P>
</TD>
<TD>
<P>41.5</P>
</TD>
<TD>
<P>53/53</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-02-13 21:49:13 +0000" MODIFIED_BY="[Empty name]" ORDER="140" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD>
<P>1/2</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>2/2</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.02" MODIFIED="2015-08-12 21:17:19 +0100" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO">
<NAME>Episodes of faecal incontinence per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-12 21:17:19 +0100" MODIFIED_BY="[Empty name]" ORDER="141" STUDY_ID="STD-Kahlke-2015_x0023_">
<TR>
<TD/>
<TD>
<P>
Mean (SD)
</P>
</TD>
<TD>
<P>
14
</P>
</TD>
<TD>
<P>
18 (19.6)
</P>
</TD>
<TD/>
<TD>
<P>
8.4 (8.7)
</P>
</TD>
<TD>
<P>
1
 (1.7)
</P>
</TD>
<TD>
<P>
-7.4 (
-
88%)
</P>
</TD>
<TD>
<P>
0.3 (0.5)
</P>
</TD>
<TD>
<P>
p&lt;0.05
</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 19:57:35 +0000" MODIFIED_BY="[Empty name]" ORDER="142" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 16<BR/>3 months: 16<BR/>'Off' period: 19<BR/>'On' period: 19<BR/>Follow-up: 18</P>
</TD>
<TD>
<P>3.5 (0 to 16)</P>
</TD>
<TD>
<P>0.3 (0 to 3)</P>
</TD>
<TD>
<P>1.7 (0 to 9)</P>
</TD>
<TD>
<P>0.7 (0 to 5)</P>
</TD>
<TD>
<P>-1 (-59%)</P>
</TD>
<TD>
<P>0.5 (0 to 11)</P>
</TD>
<TD>
<P>1. 
P &lt; 0.05: 'off' versus 'on' period; 3 months, 'off' period, 'on' period, follow-up period versus baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>3 months: 4<BR/>'Off' period: 5<BR/>'On' period: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>7 (0 to 11)</P>
</TD>
<TD>
<P>1.9 (1 to 10)</P>
</TD>
<TD>
<P>1.7 (0 to 11)</P>
</TD>
<TD>
<P>3.7 (0 to 11)</P>
</TD>
<TD>
<P>2 (118%)</P>
</TD>
<TD>
<P>3.5 (0 to 10)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-06-12 18:57:29 +0100" MODIFIED_BY="[Empty name]" ORDER="143" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD/>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-02-13 22:25:37 +0000" MODIFIED_BY="[Empty name]" ORDER="144" STUDY_ID="STD-Thin-2015">
<TR>
<TD>
<P>
PTNS group
</P>
</TD>
<TD>
<P>
Mean±SD
</P>
</TD>
<TD>
<P>
16
</P>
</TD>
<TD>
<P>
10.6
±
11.2
</P>
</TD>
<TD>
<P>
5.8
±
6.9
</P>
</TD>
<TD/>
<TD/>
<TD>
<P>
-4.3
 (-41%)
</P>
</TD>
<TD>
<P>
6.3
±
6.9
</P>
</TD>
<TD>
<P>
Follow up was at 6 months.
 
% change is reported as the difference between baseline and at 
6
 months.
</P>
</TD>
</TR>
<TR>
<TD>
<P>
SNS
 group
</P>
</TD>
<TD>
<P>
Mean±SD
</P>
</TD>
<TD>
<P>
15
</P>
</TD>
<TD>
<P>
12.1
±
13.7
</P>
</TD>
<TD>
<P>
2.8
±
2.5
</P>
</TD>
<TD/>
<TD/>
<TD>
<P>
-9
(-74%)
</P>
</TD>
<TD>
<P>
3.1
±
4.0
</P>
</TD>
<TD>
<P>
Follow up was at 6 months.
 
% change is reported as the difference between baseline and at 
6
 months.
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 19:57:50 +0000" MODIFIED_BY="[Empty name]" ORDER="145" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>9.2±13.4</P>
</TD>
<TD>
<P>8.1±14.1</P>
</TD>
<TD/>
<TD/>
<TD>
<P>0.2 (2%)</P>
</TD>
<TD>
<P>9.4±11.8</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline. Follow-up was at 12 months. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>9.5±12.8</P>
</TD>
<TD>
<P>2.9±6.3</P>
</TD>
<TD/>
<TD/>
<TD>
<P>-6.4 (-67%)</P>
</TD>
<TD>
<P>3.1±10.1</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at all time points compared with baseline. Follow-up was at 12 months. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-08-12 21:17:19 +0100" MODIFIED_BY="[Empty name]" ORDER="146" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>10 (5 and 15)</P>
</TD>
<TD/>
<TD>
<P>6 (2 and 10)</P>
</TD>
<TD>
<P>1 (0 and 1)</P>
</TD>
<TD>
<P>-5 (-83%)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.03" MODIFIED="2014-11-27 19:58:17 +0000" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Ability to defer defaecation (minutes)</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 19:58:17 +0000" MODIFIED_BY="[Empty name]" ORDER="147" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 13<BR/>3 months: 13<BR/>'Off' period: 17<BR/>'On' period: 14<BR/>Follow-up: 15</P>
</TD>
<TD>
<P>1 (1 to 2)</P>
</TD>
<TD>
<P>1.8 (1 to 3)</P>
</TD>
<TD>
<P>1.4 (1 to 3)</P>
</TD>
<TD>
<P>1.8 (1 to 3)</P>
</TD>
<TD>
<P>0.4 (29%)</P>
</TD>
<TD>
<P>1.9 (1 to 3)</P>
</TD>
<TD>
<P>1. P
 &lt; 0.05: 3 months, 'off' period, 'on' period, follow-up versus baseline</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 4<BR/>3 months: 4<BR/>'Off' period: 5<BR/>'On' period: 4<BR/>Follow-up: 4</P>
</TD>
<TD>
<P>1 (1)</P>
</TD>
<TD>
<P>1 (1 to 3)</P>
</TD>
<TD>
<P>1 (1 to 3)</P>
</TD>
<TD>
<P>1 (1 to 2)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1.2 (1 to 1.8)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.04" MODIFIED="2014-07-04 11:15:49 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Episodes of urgency per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="148" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 14<BR/>3 months: 14<BR/>'Off' period: 18<BR/>'On' period: 17<BR/>Follow-up: 17</P>
</TD>
<TD>
<P>2.3 (0 to 26)</P>
</TD>
<TD>
<P>1.4 (0 to 14)</P>
</TD>
<TD>
<P>1.4 (0 to 19)</P>
</TD>
<TD>
<P>1 (0 to 16)</P>
</TD>
<TD>
<P>-0.4 (-29%)</P>
</TD>
<TD>
<P>1 (0 to 24)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 4<BR/>3 months: 3<BR/>'Off' period: 4<BR/>'On' period: 4<BR/>Follow-up: 4</P>
</TD>
<TD>
<P>10.4 (0 to 17)</P>
</TD>
<TD>
<P>0.4 (0 to 9)</P>
</TD>
<TD>
<P>4.5 (3 to 10)</P>
</TD>
<TD>
<P>8.2 (2 to 19)</P>
</TD>
<TD>
<P>3.7 (82%)</P>
</TD>
<TD>
<P>5.2 (0 to 20)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-06-12 19:57:39 +0100" MODIFIED_BY="[Empty name]" ORDER="149" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD/>
<TD>
<P>4.14 (-0.16-8.44)</P>
</TD>
<TD>
<P>2.43 (-0.23-5.1)</P>
</TD>
<TD>
<P>-1.71 (-70%)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.05" MODIFIED="2014-11-27 19:59:05 +0000" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Days with pads per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>12 months</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 19:59:05 +0000" MODIFIED_BY="[Empty name]" ORDER="150" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>3.7±3.4</P>
</TD>
<TD>
<P>3±3.8</P>
</TD>
<TD>
<P>3.2±3.1</P>
</TD>
<TD>
<P>-0.5 (-14%)</P>
</TD>
<TD>
<P>
P
 &gt; 0.05 at 3 months and 12 months compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.8±3</P>
</TD>
<TD>
<P>1.6±2.6</P>
</TD>
<TD>
<P>2.2±3</P>
</TD>
<TD>
<P>-1.6 (-42%)</P>
</TD>
<TD>
<P>
P
 &lt; 0.0001 at all time points compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.06" MODIFIED="2015-03-27 21:52:09 +0000" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Cleveland Clinic Incontinence Score</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-03-27 21:52:09 +0000" MODIFIED_BY="[Empty name]" ORDER="151" STUDY_ID="STD-Kahlke-2015_x0023_">
<TR>
<TD/>
<TD>
<P>
Mean (SD)
</P>
</TD>
<TD>
<P>
14
</P>
</TD>
<TD>
<P>
16 (4.6)
</P>
</TD>
<TD/>
<TD>
<P>
14.6 (4.6)
</P>
</TD>
<TD>
<P>
8.7 (3.6)
</P>
</TD>
<TD>
<P>
-5.9 (-40%)
</P>
</TD>
<TD>
<P>
6.4 (3.3)
</P>
</TD>
<TD>
<P>
p&lt;0.05
</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:00:13 +0000" MODIFIED_BY="[Empty name]" ORDER="152" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Whole group</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 23<BR/>3 months: 16<BR/>'Off' period: 15<BR/>'On' period: 17</P>
</TD>
<TD>
<P>16 (8 to 20)</P>
</TD>
<TD>
<P>9 (0 to 19)</P>
</TD>
<TD>
<P>10.5 (4 to 17)</P>
</TD>
<TD>
<P>8.5 (3 to 18)</P>
</TD>
<TD>
<P>-2 (-19%)</P>
</TD>
<TD>
<P>Not reported for whole group</P>
</TD>
<TD>
<P>1. Cleveland Clinic scores are reported for whole group.<BR/>2. The score ranges from 0 (normal continence) to 20 (maximum incontinence)</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 18<BR/>3 months: 13<BR/>'Off' period: 12<BR/>'On' period: 14<BR/>Follow-up: 18</P>
</TD>
<TD>
<P>16 (8 to 20)</P>
</TD>
<TD>
<P>8 (0 to 15)</P>
</TD>
<TD>
<P>10 (4 to 17)</P>
</TD>
<TD>
<P>8 (3 to 15)</P>
</TD>
<TD>
<P>-2 (-20%)</P>
</TD>
<TD>
<P>10 (3 to 17)</P>
</TD>
<TD>
<P>1. 
P &lt; 0.05: 3 months, 'off' period, 'on' period, follow-up versus baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>3 months: 3<BR/>'Off' period: 3<BR/>'On' period: 3<BR/>Follow-up: 3</P>
</TD>
<TD>
<P>16 (12 to 20)</P>
</TD>
<TD>
<P>14 (9 to 19)</P>
</TD>
<TD>
<P>15 (11 to 15)</P>
</TD>
<TD>
<P>15 (14 to 18)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>13 (11 to 18)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-02-13 22:27:51 +0000" MODIFIED_BY="[Empty name]" ORDER="153" STUDY_ID="STD-Thin-2015">
<TR>
<TD>
<P>
PTNS group
</P>
</TD>
<TD>
<P>
Mean±SD
</P>
</TD>
<TD>
<P>
16
</P>
</TD>
<TD>
<P>
15.1
±
2.7
</P>
</TD>
<TD>
<P>
11.7
±
4.4
</P>
</TD>
<TD/>
<TD/>
<TD>
<P>
-3 (-
20%)
</P>
</TD>
<TD>
<P>
12.1
±
5.2
</P>
</TD>
<TD>
<P>
Follow-up was at 6 months. 
% change is reported as the difference between baseline and at 
6
 months.
</P>
</TD>
</TR>
<TR>
<TD>
<P>
SNS group
</P>
</TD>
<TD>
<P>
Mean±SD
</P>
</TD>
<TD>
<P>
15
</P>
</TD>
<TD>
<P>
16.3
±
3.3
</P>
</TD>
<TD>
<P>
10.0
±
5.3
</P>
</TD>
<TD/>
<TD/>
<TD>
<P>
-7.2(-44%)
</P>
</TD>
<TD>
<P>
9.1
±
5.4
</P>
</TD>
<TD>
<P>
Follow-up was at 6 months.
 
% change is reported as the difference between baseline and at 
6
 months.
</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:00:38 +0000" MODIFIED_BY="[Empty name]" ORDER="154" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>15.2±1.6</P>
</TD>
<TD>
<P>12.1±2.1</P>
</TD>
<TD>
<P>
14.1<U>+</U>1.9
</P>
</TD>
<TD/>
<TD>
<P>-1.1 (-7%)</P>
</TD>
<TD>
<P>14.1±1.9</P>
</TD>
<TD>
<P>p &gt; 0.05 at 3 months and 12 months compared with baseline. Follow-up was at 12 months. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>16±1.3</P>
</TD>
<TD>
<P>1.1±1</P>
</TD>
<TD>
<P>
1.2<U>+</U>

1.8 
</P>
</TD>
<TD/>
<TD>
<P>-14.8 (-93%)</P>
</TD>
<TD>
<P>1.2±1.8</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at all time points compared with baseline. Follow-up was at 12 months. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.07" MODIFIED="2015-03-22 16:02:01 +0000" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Quality of life - SF36</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Role-emotional</P>
</TH>
<TH>
<P>General health</P>
</TH>
<TH>
<P>Mental health</P>
</TH>
<TH>
<P>Bodily pain</P>
</TH>
<TH>
<P>Physical functioning</P>
</TH>
<TH>
<P>Role-physical</P>
</TH>
<TH>
<P>Social function</P>
</TH>
<TH>
<P>Vitality</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-03-22 16:00:55 +0000" MODIFIED_BY="[Empty name]" ORDER="155" STUDY_ID="STD-Thin-2015">
<TR>
<TD>
<P>
SNS
 (3 months)
: n=15
</P>
</TD>
<TD>
<P>
Mean
 (95% CI)
</P>
</TD>
<TD>
<P>
11.1 (-19.8 to 42.1)
</P>
</TD>
<TD>
<P>
-6.8 (-20.2 to 6.7)
</P>
</TD>
<TD>
<P>
-2.7 (-13.8 to 8.4)
</P>
</TD>
<TD>
<P>
2.7 (-15.7 to 21.0)
</P>
</TD>
<TD>
<P>
-9.8 (-24.2 to 4.7)
</P>
</TD>
<TD>
<P>
26.7 (3.6 to 49.8)
</P>
</TD>
<TD>
<P>
19.1 (3.7 to 34.6)
</P>
</TD>
<TD>
<P>
2.7 (-8.9 to 14.3)
</P>
</TD>
</TR>
<TR>
<TD>
<P>
PTNS
 (3 months)
 
n=1
6
</P>
</TD>
<TD>
<P>
Mean (95% CI)
</P>
</TD>
<TD>
<P>
20
.
0 (&#8722;15
.
4
 to
 55
.
4) 
</P>
</TD>
<TD>
<P>
-4.0 (-12.1 to 4.1)
</P>
</TD>
<TD>
<P>
8.3 (1.2 to 15.3)
</P>
</TD>
<TD>
<P>
-5.5 (-20.5 to 9.5)
</P>
</TD>
<TD>
<P>
9.1 (-3.4 to 21.7)
</P>
</TD>
<TD>
<P>
6.7 (-23.6 to 36.9)
</P>
</TD>
<TD>
<P>
13.3 (1.2 to 25.5)
</P>
</TD>
<TD>
<P>
2.0 (-3.7 to 7.7)
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-03-22 16:02:01 +0000" MODIFIED_BY="[Empty name]" ORDER="156" STUDY_ID="STD-Thin-2015">
<TR>
<TD>
<P>
SNS (
6
 months)
 
n=15
</P>
</TD>
<TD>
<P>
Mean (95% CI)
</P>
</TD>
<TD>
<P>
17.8 (-12.5 to 
48.1
)
</P>
</TD>
<TD>
<P>
-
4.8 (-15.4 to 5.8)
</P>
</TD>
<TD>
<P>
1
.7 (-12.2 to 15.5)
</P>
</TD>
<TD>
<P>
7.2 (-12.7 to 
27.0
)
</P>
</TD>
<TD>
<P>
-9.1 (-25.4 to 7.3)
</P>
</TD>
<TD>
<P>
25.0 (-5.5 to 55.5)
</P>
</TD>
<TD>
<P>
17.5 (-0.4 to 35.4)
</P>
</TD>
<TD>
<P>
8.7 (-4.3 to 21
.6
)
</P>
</TD>
</TR>
<TR>
<TD>
<P>
PTNS (
6
 months)
 
n=16
</P>
</TD>
<TD>
<P>
Mean (95% CI)
</P>
</TD>
<TD>
<P>
16.7 (-0.5 t
o 33.8
)
</P>
</TD>
<TD>
<P>
-7.5 (-14.7 to -0.3)
</P>
</TD>
<TD>
<P>
10.5 (5.1 to 15.9)
</P>
</TD>
<TD>
<P>
0.9 (
-8.8 to 10.6
)
</P>
</TD>
<TD>
<P>
9.1 (-3.3 to 21.4)
</P>
</TD>
<TD>
<P>
0.0 (-22.3 to 22.3)
</P>
</TD>
<TD>
<P>
10.9 (-0.7 to 22.6)
</P>
</TD>
<TD>
<P>
0.0 (-8.9 to 8.9)
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="157" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>33 (only recorded for one participant)</P>
</TD>
<TD>
<P>79 (72 to 86)</P>
</TD>
<TD>
<P>70 (64 to 76)</P>
</TD>
<TD>
<P>52 (30 to 74)</P>
</TD>
<TD>
<P>71 (70 to 72)</P>
</TD>
<TD>
<P>38 (0 to 75)</P>
</TD>
<TD>
<P>44 (12 to 75)</P>
</TD>
<TD>
<P>40 (10 to 70)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nine months</P>
</TD>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>83 (66 to 100)</P>
</TD>
<TD>
<P>92 (both 92)</P>
</TD>
<TD>
<P>80 (72 to 88)</P>
</TD>
<TD>
<P>92 (84 to 100)</P>
</TD>
<TD>
<P>83 (80 to 85)</P>
</TD>
<TD>
<P>100 (both 100)</P>
</TD>
<TD>
<P>88 (75 to 100)</P>
</TD>
<TD>
<P>75 (70 to 80)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.08" MODIFIED="2014-11-27 20:01:19 +0000" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life - SF12</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Scale</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>3 months</P>
</TH>
<TH>
<P>12 months</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 20:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="158" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Physical health</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>39.29±12.12</P>
</TD>
<TD>
<P>41.5±9.89</P>
</TD>
<TD>
<P>40.5±10.2</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Mental health</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>45.38±12.32</P>
</TD>
<TD>
<P>47.82±10.66</P>
</TD>
<TD>
<P>48.22±10.12</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS</P>
</TD>
<TD>
<P>Physical health</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>39.81±11.14</P>
</TD>
<TD>
<P>43.18±11.68</P>
</TD>
<TD>
<P>42.22±9.25</P>
</TD>
<TD>
<P>

P &gt; 0.025 at all time points.</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>Mental health</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>45.25±11.09</P>
</TD>
<TD>
<P>50.16±10.41</P>
</TD>
<TD>
<P>49.22±10.88</P>
</TD>
<TD>
<P>

P &gt; 0.025 at 12 months. However, p = 0.005 at 3 months.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.09" MODIFIED="2014-11-27 20:01:42 +0000" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life - modified ASCRS</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Lifestyle</P>
</TH>
<TH>
<P>Coping/behaviour</P>
</TH>
<TH>
<P>Depression/self-perc</P>
</TH>
<TH>
<P>Embarrassment</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 20:01:42 +0000" MODIFIED_BY="[Empty name]" ORDER="159" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>34?</P>
</TD>
<TD>
<P>1.7 (1 to 3.8)</P>
</TD>
<TD>
<P>1.5 (1 to 2.8)</P>
</TD>
<TD>
<P>2.2 (1 to 4.1)</P>
</TD>
<TD>
<P>1.3 (1 to 3)</P>
</TD>
<TD>
<P>The ASCRS ranges from a best score of 5 to a worst score of 1.</P>
</TD>
</TR>
<TR>
<TD>
<P>Follow-up</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>24?</P>
</TD>
<TD>
<P>3.2 (1.9 to 4)<BR/>

P = 0.001 versus baseline</P>
</TD>
<TD>
<P>2.7 (1 to 4)<BR/>

P = 0.002 versus baseline</P>
</TD>
<TD>
<P>3.6 (1.8 to 4.2)<BR/>

P = 0.009 versus baseline</P>
</TD>
<TD>
<P>2.3 (1 to 4)<BR/>

P = 0.002 versus baseline</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="9" ID="CMP-003.10" MODIFIED="2014-11-27 20:02:18 +0000" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life - ASCRS FIQL</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Period</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Lifestyle</P>
</TH>
<TH>
<P>Coping/behaviour</P>
</TH>
<TH>
<P>Depression/self-perception</P>
</TH>
<TH>
<P>Embarrassment</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 20:02:18 +0000" MODIFIED_BY="[Empty name]" ORDER="160" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>2.26±0.98</P>
</TD>
<TD>
<P>1.79±0.82</P>
</TD>
<TD>
<P>2.59±0.72</P>
</TD>
<TD>
<P>1.81±0.52</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>2.12±0.91</P>
</TD>
<TD>
<P>1.85±0.92</P>
</TD>
<TD>
<P>2.68±0.65</P>
</TD>
<TD>
<P>1.7±0.67</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>2.31±0.89</P>
</TD>
<TD>
<P>1.86±0.88</P>
</TD>
<TD>
<P>2.64±0.84</P>
</TD>
<TD>
<P>1.78±0.61</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS</P>
</TD>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>2.39±0.99</P>
</TD>
<TD>
<P>1.89±0.82</P>
</TD>
<TD>
<P>2.65±0.84</P>
</TD>
<TD>
<P>1.93±0.78</P>
</TD>
<TD/>
</TR>
<TR>
<TD/>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.34±0.72</P>
</TD>
<TD>
<P>2.87±0.8</P>
</TD>
<TD>
<P>3.31±0.77</P>
</TD>
<TD>
<P>2.89±0.85</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
<TR>
<TD/>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.31±0.72</P>
</TD>
<TD>
<P>2.68±0.87</P>
</TD>
<TD>
<P>3.25±0.8</P>
</TD>
<TD>
<P>2.76±0.94</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at 3 months and 12 months compared with baseline.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.11" MODIFIED="2014-11-27 20:04:45 +0000" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES">
<NAME>Anorectal manometry</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.11.01" MODIFIED="2014-11-27 20:02:31 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="4">
<NAME>Maximal resting pressure (cm H20)</NAME>
<OTHER_DATA MODIFIED="2014-11-27 20:02:27 +0000" MODIFIED_BY="[Empty name]" ORDER="161" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 19<BR/>'Off 'period: 13<BR/>'On' period: 17<BR/>Follow-up: 18</P>
</TD>
<TD>
<P>40 (12 to 109)</P>
</TD>
<TD>
<P>37 (26 to 100)</P>
</TD>
<TD>
<P>50 (27 to 155)</P>
</TD>
<TD>
<P>60 (30 to 96)</P>
</TD>
<TD>
<P>

P &lt; 0.05: 'on' period versus baseline; follow-up versus baseline; 'off' period versus follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>'Off' period: 5<BR/>'On' period: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>40 (20 to 90)</P>
</TD>
<TD>
<P>50 (39 to 98)</P>
</TD>
<TD>
<P>64 (37 to 98)</P>
</TD>
<TD>
<P>50 (31 to 100)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-06-12 20:42:06 +0100" MODIFIED_BY="[Empty name]" ORDER="162" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD>
<P>106.2 (71.1-141.4)</P>
</TD>
<TD>
<P>84.2 (70.4-98.3)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="163" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>42.4±15.2</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD>
<P>Only performed at baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>40.4±15.9</P>
</TD>
<TD/>
<TD/>
<TD>
<P>40.9±21.9</P>
</TD>
<TD>
<P>

P &gt; 0.05 at all time points compared with baseline. Follow-up was at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="164" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>38 (35 and 40)</P>
</TD>
<TD>
<P>43 (35 and 50)</P>
</TD>
<TD>
<P>58 (45 and 70)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.02" MODIFIED="2014-11-27 20:03:30 +0000" MODIFIED_BY="[Empty name]" NO="2" STUDIES="4">
<NAME>Maximal squeeze pressure (cm H20)</NAME>
<OTHER_DATA MODIFIED="2014-11-27 20:02:43 +0000" MODIFIED_BY="[Empty name]" ORDER="165" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 19 <BR/>'Off' period: 13<BR/>'On' period: 17<BR/>Follow-up: 19</P>
</TD>
<TD>
<P>30 (0 to 270)</P>
</TD>
<TD>
<P>49 (10 to 98)</P>
</TD>
<TD>
<P>53 (6 to 326)</P>
</TD>
<TD>
<P>50 (0 to 213)</P>
</TD>
<TD>
<P>

P &lt; 0.05: follow-up versus baseline</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>'Off' period: 5<BR/>'On' period: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>30 (23 to 90)</P>
</TD>
<TD>
<P>54 (37 to 110)</P>
</TD>
<TD>
<P>30 (21 to 90)</P>
</TD>
<TD>
<P>30 (20 to 140)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:03:30 +0000" MODIFIED_BY="[Empty name]" ORDER="166" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD>
<P>223.0 (153.7
 to 292.4)</P>
</TD>
<TD>
<P>223.0 (159.1
 to 287.0)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:02:54 +0000" MODIFIED_BY="[Empty name]" ORDER="167" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>88.5±42.6</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD>
<P>Only performed at baseline.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>83.2±39.6</P>
</TD>
<TD/>
<TD/>
<TD>
<P>90.2±54.9</P>
</TD>
<TD>
<P>

P &gt; 0.05 at all time points compared with baseline. Follow-up was at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="168" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>100 (80 and 120)</P>
</TD>
<TD>
<P>65 (60 and 70)</P>
</TD>
<TD>
<P>95 (90 and 100)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.03" NO="3" STUDIES="1">
<NAME>Squeeze pressure duration (seconds)</NAME>
<OTHER_DATA ORDER="169" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 19<BR/>'Off' period: 13<BR/>'On' period: 17<BR/>Follow-up: 19</P>
</TD>
<TD>
<P>15 (0 to 45)</P>
</TD>
<TD>
<P>21 (4 to 32)</P>
</TD>
<TD>
<P>18 (6 to 92)</P>
</TD>
<TD>
<P>22 (0 to 110)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>'Off' period: 5<BR/>'On' period: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>20 (5 to 28)</P>
</TD>
<TD>
<P>40 (5 to 40)</P>
</TD>
<TD>
<P>32 (23 to 38)</P>
</TD>
<TD>
<P>25 (4 to 40)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.04" MODIFIED="2014-11-27 20:04:14 +0000" MODIFIED_BY="[Empty name]" NO="4" STUDIES="3">
<NAME>Rectal volume sensation - threshold (ml)</NAME>
<OTHER_DATA ORDER="170" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 17<BR/>Follow-up: 18</P>
</TD>
<TD>
<P>25 (10 to 120)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>30 (10 to 120)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>10 (10 to 40)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>10 (10 to 50)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:04:14 +0000" MODIFIED_BY="[Empty name]" ORDER="171" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD>
<P>50.0 (34.6
 to 65.4)</P>
</TD>
<TD>
<P>27.1 (17.8
 to 36.4)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="172" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>45 (both 45)</P>
</TD>
<TD>
<P>38 (25 and 50)</P>
</TD>
<TD>
<P>68 (45 and 90)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.05" MODIFIED="2014-11-27 20:04:29 +0000" MODIFIED_BY="[Empty name]" NO="5" STUDIES="2">
<NAME>Rectal volume sensation - urge (ml)</NAME>
<OTHER_DATA MODIFIED="2014-11-27 20:04:29 +0000" MODIFIED_BY="[Empty name]" ORDER="173" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD>
<P>82.9 (64.8
 to 101)</P>
</TD>
<TD>
<P>60 (48.7
 to 71.3)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="174" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>68 (65 and 70)</P>
</TD>
<TD>
<P>85 (70 and 100)</P>
</TD>
<TD>
<P>103 (85 and 120)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.06" MODIFIED="2014-11-27 20:04:45 +0000" MODIFIED_BY="[Empty name]" NO="6" STUDIES="3">
<NAME>Rectal volume sensation - maximal tolerated (ml)</NAME>
<OTHER_DATA ORDER="175" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 17<BR/>Follow-up: 17</P>
</TD>
<TD>
<P>185 (80 to 350)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>170 (40 to 275)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>200 (80 to 300)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>195 (100 to 300)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:04:45 +0000" MODIFIED_BY="[Empty name]" ORDER="176" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD>
<P>124 (106
 to 142)</P>
</TD>
<TD>
<P>124 (82.4
 to 165.6)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="177" STUDY_ID="STD-Vaizey-2000_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>118 (95 and 140)</P>
</TD>
<TD>
<P>135 (120 and 150)</P>
</TD>
<TD>
<P>140 (130 and 150)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.11.07" NO="7" STUDIES="1">
<NAME>Rectal volume sensation - constant sensation volume (ml)</NAME>
<OTHER_DATA ORDER="178" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 17<BR/>Follow-up: 18</P>
</TD>
<TD>
<P>100 (40 to 230)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>85 (30 to 300)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>50 (20 to 90)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>50 (20 to 95)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-003.12" MODIFIED="2015-03-27 21:54:38 +0000" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Bowel movements per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-03-27 21:54:38 +0000" MODIFIED_BY="[Empty name]" ORDER="179" STUDY_ID="STD-Kahlke-2015_x0023_">
<TR>
<TD/>
<TD>
<P>
Me
an (SD)
</P>
</TD>
<TD>
<P>
14
</P>
</TD>
<TD/>
<TD/>
<TD>
<P>
18.2 (8.7)
</P>
</TD>
<TD>
<P>
10.9 (4.1)
</P>
</TD>
<TD>
<P>
-7.3 (-
40
%)
</P>
</TD>
<TD>
<P>
9.4 (2.6)
</P>
</TD>
<TD>
<P>
p
&lt;0.05
</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:05:19 +0000" MODIFIED_BY="[Empty name]" ORDER="180" STUDY_ID="STD-Leroi-2005_x0023_">
<TR>
<TD>
<P>Group of 19 who chose 'on' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 16<BR/>3 months: 15<BR/>'Off' period: 18<BR/>'On' period: 16<BR/>Follow-up: 16</P>
</TD>
<TD>
<P>11.5 (6 to 28)</P>
</TD>
<TD>
<P>12 (4 to 27)</P>
</TD>
<TD>
<P>10.6 (6 to 33)</P>
</TD>
<TD>
<P>10.2 (5 to 26)</P>
</TD>
<TD>
<P>-0.4 (-4%)</P>
</TD>
<TD>
<P>10.6 (7 to 37)</P>
</TD>
<TD>
<P>1. 
P &lt; 0.05: 'on' versus 'off' period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Group of 5 who chose 'off' following the crossover period</P>
</TD>
<TD>
<P>Median (range)</P>
</TD>
<TD>
<P>Baseline: 4<BR/>3 months: 4<BR/>'Off' period: 5<BR/>'On' period: 5<BR/>Follow-up: 5</P>
</TD>
<TD>
<P>13.7 (7 to 30)</P>
</TD>
<TD>
<P>10.6 (8 to 11)</P>
</TD>
<TD>
<P>12.7 (8 to 19)</P>
</TD>
<TD>
<P>11.2 (7 to 32)</P>
</TD>
<TD>
<P>-1.5 (-12%)</P>
</TD>
<TD>
<P>11.7 (7 to 32)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-11-27 20:05:41 +0000" MODIFIED_BY="[Empty name]" ORDER="181" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD/>
<TD>
<P>Mean (95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD/>
<TD/>
<TD>
<P>12.1 (6.32
 to 17.9)</P>
</TD>
<TD>
<P>8.86 (6.21
 to 11.5)</P>
</TD>
<TD>
<P>-3.24 (-27%)</P>
</TD>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-003.13" MODIFIED="2014-11-25 22:46:04 +0000" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Soiling/week</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-06-12 19:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="182" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD>
<P>(95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>1.86 (0.29-3.43)</P>
</TD>
<TD>
<P>0.71 (-0.69-2.11)</P>
</TD>
<TD>
<P>-1.15 (-62%)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.14" MODIFIED="2014-11-27 20:06:25 +0000" MODIFIED_BY="[Empty name]" NO="14" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Days with staining per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>12 months</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 20:06:25 +0000" MODIFIED_BY="[Empty name]" ORDER="183" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>4.3±1.9</P>
</TD>
<TD>
<P>4.5±2.1</P>
</TD>
<TD>
<P>4.5±2.3</P>
</TD>
<TD>
<P>0.2 (5%)</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>4±2.3</P>
</TD>
<TD>
<P>1.3±1.7</P>
</TD>
<TD>
<P>1.4±2</P>
</TD>
<TD>
<P>-2.6 (-65%)</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at all time points compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-003.15" MODIFIED="2014-11-27 20:06:56 +0000" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Days with incontinence per week</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Three months</P>
</TH>
<TH>
<P>12 months</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 20:06:56 +0000" MODIFIED_BY="[Empty name]" ORDER="184" STUDY_ID="STD-Tjandra-2008">
<TR>
<TD>
<P>Control group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>3.3±2.1</P>
</TD>
<TD>
<P>2.9±2.4</P>
</TD>
<TD>
<P>3.1±1.8</P>
</TD>
<TD>
<P>-0.2 (-6%)</P>
</TD>
<TD>
<P>

P &gt; 0.05 at 3 months and 12 months compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>SNS group</P>
</TD>
<TD>
<P>Mean±SD</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.3±2.4</P>
</TD>
<TD>
<P>1±1.7</P>
</TD>
<TD>
<P>1±1.7</P>
</TD>
<TD>
<P>-2.3 (-70%)</P>
</TD>
<TD>
<P>

P &lt; 0.0001 at all time points compared with baseline. % change is reported as the difference between baseline and at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-003.16" MODIFIED="2014-11-27 15:00:04 +0000" MODIFIED_BY="[Empty name]" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Passive leakage/week</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-11-27 15:00:04 +0000" MODIFIED_BY="[Empty name]" ORDER="185" STUDY_ID="STD-S_x00f8_rensen-2010_x0023_">
<TR>
<TD>
<P>(95% CI for mean)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>0.43 (-0.41
 to 1.27)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-0.43 (-100%)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-08-05 11:04:55 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Constipation</NAME>
<OTHER_OUTCOME COLS="8" ID="CMP-004.01" MODIFIED="2015-08-05 11:04:55 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Bowel movements per week</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:04:55 +0100" MODIFIED_BY="[Empty name]" ORDER="186" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>3.6 (2.0)</P>
</TD>
<TD/>
<TD>
<P>4.0 (1.9)</P>
</TD>
<TD>
<P>4.3 (1.8)</P>
</TD>
<TD>
<P>0.7 (19%)</P>
</TD>
<TD>
<P>Off period is sham, and on period is suprasensory stimulation</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-08-05 11:04:55 +0100" MODIFIED_BY="[Empty name]" ORDER="187" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2 (1 and 3)</P>
</TD>
<TD>
<P>8 (8 and 9)</P>
</TD>
<TD>
<P>2 (1 and 2)</P>
</TD>
<TD>
<P>5 (4 and 5)</P>
</TD>
<TD>
<P>3 (150%)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-004.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Time with abdominal pain and bloating (%)</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="188" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>98 (95 and 100)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>79 (65 and 93)</P>
</TD>
<TD>
<P>33 (0 and 65)</P>
</TD>
<TD>
<P>-46</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-004.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Wexner Constipation Score</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="189" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>21 (20 to 22)</P>
</TD>
<TD>
<P>5 (4 to 6)</P>
</TD>
<TD>
<P>14 (13 to 15)</P>
</TD>
<TD>
<P>9 (5 to 13)</P>
</TD>
<TD>
<P>-5 (-36%)</P>
</TD>
<TD>
<P>The score ranges from 0 (normal) to 30 (severe constipation)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-004.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Symptom Analogue Score</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA ORDER="190" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>30 (28 and 32)</P>
</TD>
<TD>
<P>89 (84 and 94)</P>
</TD>
<TD>
<P>32 (30 and 33)</P>
</TD>
<TD>
<P>74 (60 and 88)</P>
</TD>
<TD>
<P>42 (131%)</P>
</TD>
<TD>
<P>The score ranges from a best score of 100 to a worst score of 0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="7" ID="CMP-004.05" MODIFIED="2014-12-11 10:10:44 +0000" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Anorectal manometry</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>'Off' period</P>
</TH>
<TH>
<P>'On' period</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.05.01" MODIFIED="2014-12-11 10:10:33 +0000" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>Maximal resting pressure (cm H&#8322;0)</NAME>
<OTHER_DATA ORDER="191" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>75 (65 and 84)</P>
</TD>
<TD>
<P>85 (82 and 87)</P>
</TD>
<TD>
<P>51 (39 and 63)</P>
</TD>
<TD>
<P>76 (68 and 84)</P>
</TD>
<TD>
<P>Stationary pull-through technique</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.05.02" MODIFIED="2014-12-11 10:10:44 +0000" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>Maximal squeeze pressure (cm H&#8322;0)</NAME>
<OTHER_DATA ORDER="192" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>39 (32 and 46)</P>
</TD>
<TD>
<P>78 (52 and 104)</P>
</TD>
<TD>
<P>54 (51 and 57)</P>
</TD>
<TD>
<P>93 (41 and 145)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.05.03" NO="3" STUDIES="1">
<NAME>Rectal volume sensation - threshold (ml air)</NAME>
<OTHER_DATA ORDER="193" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>46 (45 and 47)</P>
</TD>
<TD>
<P>40 (20 and 60)</P>
</TD>
<TD>
<P>35 (30 and 40)</P>
</TD>
<TD>
<P>18 (15 and 20)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.05.04" NO="4" STUDIES="1">
<NAME>Rectal volume sensation - urge (ml air)</NAME>
<OTHER_DATA ORDER="194" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>130 (75 and 185)</P>
</TD>
<TD>
<P>55 (35 and 75)</P>
</TD>
<TD>
<P>70 (60 and 80)</P>
</TD>
<TD>
<P>34 (33 and 35)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.05.05" NO="5" STUDIES="1">
<NAME>Rectal volume sensation - maximal tolerated (ml air)</NAME>
<OTHER_DATA ORDER="195" STUDY_ID="STD-Kenefick-2002_x0023_">
<TR>
<TD>
<P>Mean (range)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>194 (143 and 245)</P>
</TD>
<TD>
<P>83 (65 and 100)</P>
</TD>
<TD>
<P>103 (85 and 120)</P>
</TD>
<TD>
<P>68 (65 and 70)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="7" ID="CMP-004.06" MODIFIED="2015-08-05 11:03:53 +0100" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Stool frequency (per week)</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Off period</P>
</TH>
<TH>
<P>On period</P>
</TH>
<TH>
<P>Change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:03:53 +0100" MODIFIED_BY="[Empty name]" ORDER="196" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>5.6 (3.7)</P>
</TD>
<TD>
<P>6.4 (3.7)</P>
</TD>
<TD>
<P>6.6 (3.9)</P>
</TD>
<TD>
<P>17.9%</P>
</TD>
<TD>
<P>Off period is sham, and on period is suprasensory stimulation</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="7" ID="CMP-004.07" MODIFIED="2015-08-05 11:04:07 +0100" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Pain score (weekly average)</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Off period</P>
</TH>
<TH>
<P>On period</P>
</TH>
<TH>
<P>Percentage change (%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:04:07 +0100" MODIFIED_BY="[Empty name]" ORDER="197" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>1.4 (0.6)</P>
</TD>
<TD>
<P>1.0 (0.8)</P>
</TD>
<TD>
<P>0.9 (1.3)</P>
</TD>
<TD>
<P>-35.7%</P>
</TD>
<TD>
<P>Off period is sham, and on period is suprasensory stimulation</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="7" ID="CMP-004.08" MODIFIED="2015-08-05 11:04:16 +0100" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Bloating score (weekly average)</NAME>
<TR>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Patient</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Off period</P>
</TH>
<TH>
<P>On period</P>
</TH>
<TH>
<P>hange(%)</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:04:16 +0100" MODIFIED_BY="[Empty name]" ORDER="198" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>1.6 (0.6)</P>
</TD>
<TD>
<P>1.2 (0.7)</P>
</TD>
<TD>
<P>1.2 (0.7)</P>
</TD>
<TD>
<P>-25%</P>
</TD>
<TD>
<P>Off period is sham, and on period is suprasensory stimulation</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="10" ID="CMP-004.09" MODIFIED="2015-08-05 11:04:31 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life - SF36</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Measure</P>
</TH>
<TH>
<P>Role - emotional</P>
</TH>
<TH>
<P>General health</P>
</TH>
<TH>
<P>Mental health</P>
</TH>
<TH>
<P>Bodily pain</P>
</TH>
<TH>
<P>Physical functioning</P>
</TH>
<TH>
<P>Role-physical</P>
</TH>
<TH>
<P>Social function</P>
</TH>
<TH>
<P>Vitality</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:04:31 +0100" MODIFIED_BY="[Empty name]" ORDER="199" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Baseline (n=59)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>44 (13)</P>
</TD>
<TD>
<P>42 (12)</P>
</TD>
<TD>
<P>46 (13)</P>
</TD>
<TD>
<P>43 (9)</P>
</TD>
<TD>
<P>49 (10)</P>
</TD>
<TD>
<P>44 (12)</P>
</TD>
<TD>
<P>42 (12)</P>
</TD>
<TD>
<P>44 (11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sham/Off (n=53)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>46 (13)</P>
</TD>
<TD>
<P>45 (11)</P>
</TD>
<TD>
<P>47 (11)</P>
</TD>
<TD>
<P>42 (11)</P>
</TD>
<TD>
<P>49 (9)</P>
</TD>
<TD>
<P>43 (11)</P>
</TD>
<TD>
<P>42 (12)</P>
</TD>
<TD>
<P>45 (12)</P>
</TD>
</TR>
<TR>
<TD>
<P>Suprasensory/On (n=53)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>49 (8)</P>
</TD>
<TD>
<P>46 (10)</P>
</TD>
<TD>
<P>48 (10)</P>
</TD>
<TD>
<P>45 (9)</P>
</TD>
<TD>
<P>51 (8)</P>
</TD>
<TD>
<P>48 (10)</P>
</TD>
<TD>
<P>46 (11)</P>
</TD>
<TD>
<P>46 (10)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.10" MODIFIED="2015-08-05 11:04:38 +0100" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="8" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse events</NAME>
<TR>
<TH>
<P>Type</P>
</TH>
<TH>
<P>Number of adverse events</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-08-05 11:04:38 +0100" MODIFIED_BY="[Empty name]" ORDER="200" STUDY_ID="STD-Dinning-2015_x0023_">
<TR>
<TD>
<P>Implanted pulse generator site (IPG) related pain</P>
</TD>
<TD>
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>Wound infection</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
<TR>
<TD>
<P>Leg pain/discomfort</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pain/discomfort</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>Urological</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Tachycardia</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>Altered mood</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-08-17 13:51:52 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-06-24 14:39:24 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAAQSCAYAAADaG/PMAABlNUlEQVR42u2dD4RV2QPHlyRJEkmS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-08-17 13:51:52 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUcAAAJFCAIAAADBC6KqAAAauElEQVR42u3dv44dSRXH8ZGQEIED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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-08-17 13:51:52 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-08-25 13:04:39 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2015-06-24 12:49:56 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-06-24 12:28:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-06-24 12:28:08 +0100" MODIFIED_BY="[Empty name]">Search strategy for the Incontinence Group Specialised Register</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-24 12:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>The Incontinence Group Specialised Register was searched using the Group's own keyword system; the search terms used were:</P>
<P>topic.faecal*<BR/>AND<BR/>({design.cct*} OR {design.rct*})<BR/>AND<BR/>({intvent.surg.SNS} OR {intvent.phys.electstim.implanted})<BR/>(All searches were of the keyword field of <LINK REF="REF-Reference-Manager-2012" TYPE="REFERENCE">Reference Manager 2012</LINK>).</P>
<P>Date of the most recent search of the register for this review: 5 February 2015.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-06-24 12:49:56 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-06-24 12:47:58 +0100" MODIFIED_BY="[Empty name]">Search strategy for Embase</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-24 12:49:56 +0100" MODIFIED_BY="[Empty name]">
<P>Embase on OvidSP (1 January 1947 to 2015 Week 5) was searched on 5 February 2015 using the search strategy given in below. Only the years 2010 to 2015 (inclusive) were searched as these years were not covered by the Cochrane Collaboration's centralised search of Embase for CENTRAL at this time .</P>
<P>1. Randomized Controlled Trial/</P>
<P>2. crossover procedure/ or double blind procedure/ or parallel design/ or single blind procedure/</P>
<P>3. Placebo/</P>
<P>4. placebo$.tw,ot.</P>
<P>5. random$.tw,ot.</P>
<P>6. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw,ot.</P>
<P>7. crossover.tw,ot.</P>
<P>8. cross over$.tw,ot.</P>
<P>9. allocat$.tw,ot.</P>
<P>10. trial.ti.</P>
<P>11. parallel design/</P>
<P>12. triple blind procedure/</P>
<P>13. or/1-12</P>
<P>14. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/</P>
<P>15. exp human/ or exp "human tissue, cells or cell components"/</P>
<P>16. 14 and 15</P>
<P>17. 14 not 16</P>
<P>18. 13 not 17</P>
<P>19. continence/</P>
<P>20. (incontinen$ or continen$).tw.</P>
<P>21. incontinence/</P>
<P>22. feces incontinence device/</P>
<P>23. feces incontinence/</P>
<P>24. constipation/</P>
<P>25. constipat*.tw,ot.</P>
<P>26. dyschezia.tw,ot.</P>
<P>27. obstipat*.tw,ot.</P>
<P>28. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27</P>
<P>29. sacral nerve stimulation/</P>
<P>30. (sacral adj3 stimul*).tw,ot.</P>
<P>31. (sacral adj3 neuromodul*).tw,ot.</P>
<P>32. sns.tw,ot.</P>
<P>33. snm.tw,ot.</P>
<P>34. 29 or 30 or 31 or 32 or 33</P>
<P>35. (2010* or 2011* or 2012* or 2013* or 2014*).em.</P>
<P>36. 18 and 28 and 34</P>
<P>37. 35 and 36</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2014-08-25 13:04:39 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies were included in the quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 reports of 8 studies were included in the qualitative synthesis, additionally there were 3 reports of 3 ongoing studies with details given in the &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_ONGOING_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of ongoing studies&lt;/a&gt; table&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;197 records identified through database searching: 58 from Specialised Register and 139 from Embase searches&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;181 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3 reports of 3 full-text articles excluded, with reasons given in the &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>